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Résumé grand public 
Les milieux aquatiques sont exposé continuellement à de plus en plus de substances chimiques qui 
sont émises par les activités humaines. Les médicaments, par exemple, sont connus pour atteindre 
l’environnement et provoquer des effets chez les organismes aquatiques. Une fois consommés, ces 
molécules sont éliminées par l’intermédiaire des urines ou des fèces sous forme originale ou 
transformée. Ces résidus de médicaments se retrouvent dans les eaux usées et sont dirigés vers une 
station d’épuration afin d’y être traité. Les stations d’épuration ne sont pas toutes dotées de procédés 
complexes permettant d’éliminer toutes les substances synthétiques comme les médicaments. Ces 
molécules sont alors rejetées dans les eaux de surfaces, avec les effluents de la station d’épuration. 
Une fois dans l’environnement, les effets de ces molécules sont peu connus sur la faune et la flore 
aquatique. 
Les anticancéreux font partie des médicaments qui peuvent être rejetés par les effluents des stations 
d’épuration et se retrouver dans les eaux naturelles. Parmi ceux-ci, le tamoxifen est utilisée en 
oncologie pour prévenir et traiter certains cancers du sein. Il est largement prescrit à travers le monde 
et il a la capacité d’être transformé par le foie en d’autres sous-molécules qui sont également très 
actives pour lutter contre les cellules cancéreuses. Deux de celles-ci sont le 4-hydroxy-tamoxifen 
(4OHTam) et l’endoxifen. Tout comme le tamoxifen, le 4OHTam et l’endoxifen sont principalement 
éliminés par l’intermédiaire des fèces et le tamoxifen a été retrouvé dans des échantillons d’eaux 
naturelles, à travers le monde. Enfin, un autre anticancéreux qui est éliminé principalement par voie 
biliaire et qui pourrait potentiellement se retrouver dans les eaux de surface est l’imatinib. Cette 
molécule cible des cellules tumorales spécifiques et cette spécificité a révolutionné le traitement et la 
survie des patients souffrant de certains cancers comme la leucémie myéloïde chronique. 
Les objectifs de cette thèse ont été d’évaluer les effets du tamoxifen, 4OHTam, endoxifen et imatinib 
sur organismes aquatiques. Les daphnies ont été choisies car elles représentent des organismes clés de 
la chaîne alimentaire et leur disparition pourrait entraîner des répercussions importantes sur l’équilibre 
de l’écosystème. Ces petits crustacés d’environ 3 mm ont été élevés en laboratoire afin d’être exposés 
à une des quatre molécules anticancéreuse ci-dessus. Ce sont principalement des expériences sur 
plusieurs générations et à faibles concentrations qui ont été conduites dans notre laboratoire. Une 
expérience basée sur la modification des protéines a également été entreprise, car il est possible que 
des protéines soient modifiées alors qu’aucun effet n’a encore été observé chez l’organisme entier. Ce 
type d’essais permettrait d’identifier de potentiel effets indésirable chez des organismes aquatiques 
avant que ceux-ci soient affaiblis. 
Les résultats obtenus dans cette thèse montrent que le tamoxifen, le 4OHTam et l’endoxifen sont 
capables de modifier la taille, la reproduction et la viabilité des daphnies à des concentrations qui sont 
proches de celles pouvant se retrouver dans l’environnement. Ces molécules ont également provoqués 
des daphnies anormales, avec des antennes et des queues déformées, des prématurés et des œufs 
avortés. Le tamoxifen fut la molécule la plus toxique pour les daphnies, suivie du 4OHTam, de 
l’endoxifen et enfin de l’imatinib. Ce sont donc les effets du tamoxifen, du 4OHTam et de l’endoxifen 
qui posent le plus de questions quant à l’impact potentiel su la faune et la flore aquatique. Le 
tamoxifen semble ainsi une molécule à considérer lors des procédures d’évaluation du risque d’une 
substance pour l’environnement. Nos résultats montrent également que les expériences qui considèrent 
plusieurs générations de daphnies offrent un meilleur reflet de la réalité environnementale que des 
essais de courte durée où les générations sont généralement plus élevées. Finalement, nous avons 
également remarqué qu’il est important de discuter de l’opportunité de mesurer les concentrations qui 
sont testées lors d’essais en laboratoire afin de ne pas sous-estimer le risque pour la faune et la flore 
aquatique. 
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Summary 
The aquatic environment is exposed continuously and increasingly to chemical substances such as 
pharmaceuticals. These medical compounds are released into the environment after having being 
consumed and body-excreted by patients. Pharmaceutical residues are synthetic molecules that are not 
always removed by traditional sewage treatment processes and thus escape degradation. Among 
pharmaceuticals that escape sewage treatment plants (STPs), the anticancer drugs were measured in 
STP effluents and natural waters. In the aquatic environment, their long-term effects at low 
concentrations are sparsely known on non-target species. 
Tamoxifen is an anticancer drug that is widely prescribed worldwide for the prevention and treatment 
of hormone receptor-positive breast cancers. Two of its metabolites, i.e., endoxifen and 4-hydroxy-
tamoxifen (4OHTam), have high pharmacological potency in vivo and such as tamoxifen, they are 
excreted via faeces by patients. Tamoxifen was measured in STP effluents and natural waters but, to 
the best of our knowledge, its metabolites concentrations in waters have never been reported. Imatinib 
is another and recent anticancer compound that targets specific tumour cells. This pharmaceutical is 
also body excreted and because of its increasing use in cancer treatment, imatinib may reach the 
natural water. The effects of tamoxifen and imatinib are unknown upon more than one generation of 
aquatic species. And the effects of 4OHTam, endoxifen have never been studied in ecotoxicology so 
far. 
The aims of this thesis were threefold. First, the sensitivity of D. pulex exposed to tamoxifen, 
4OHTam, endoxifen or imatinib was assessed using ecotoxicological experiments. Ecotoxicology is 
the science that considers the toxic effects of natural or synthetic substances, such as pharmaceuticals, 
on organisms, populations, community and ecosystem. Acute and multigenerational (2-4 generations) 
tests were performed on daphnids considering several studied endpoints, such as immobilisation, size, 
reproduction, viability and intrinsic rate of natural increase. Additional prospective assays were 
designed to evaluate whether 1) low concentrations of tamoxifen and 4OHTam were able to induce 
toxic effects when used in combination, and 2) daphnids were able to recover when offspring were 
withdrawn from solutions carrying the pharmaceutical. Second, the stability of tamoxifen, 4OHTam 
and endoxifen in incubation medium was evaluated in solution exempted from daphnids. Because the 
nominal concentrations of tamoxifen, 4OHTam and endoxifen did not correspond to the measured, we 
provide a predictive method to estimate the concentrations of these chemicals during long-term 
ecotoxicological tests. Finally, changes in protein expressions were analysed in D. pulex exposed 2 or 
7 seven days to tamoxifen using ecotoxicoproteomic experiments with a shot-gun approach inducing a 
peptide fractionation step. 
Our results show that tamoxifen, 4OHTam and endoxifen induced adverse effects in D. pulex at 
environmentally relevant concentrations. At very low concentrations, these molecules displayed 
 V  
unusual and teratogenic effects because morphological abnormalities were observed in offspring, such 
as thick and short antennas, curved spines, premature neonates and aborted eggs. Tamoxifen was the 
most toxic compound among the test chemicals, followed by 4OHTam, endoxifen and imatinib. 
Tamoxifen no-observed effect concentrations (NOECs) that were calculated for size, reproduction and 
intrinsic rate were below or in the range of the concentrations measured in natural waters, i.e., between 
0.12 µg/L and 0.67 µg/L. For instance, the tamoxifen NOECs that were calculated for reproduction 
were between 0.67 and 0.72 µg/L, whereas the NOEC was < 0.15 µg/L when based on morphological 
abnormalities. The NOECs of 4OHTam were higher but still in the same order of magnitude as 
tamoxifen environmental concentrations, with a value of 1.48 µg/L. Endoxifen NOEC for the intrinsic 
rate of natural increase (r) and the reproduction were 0.4 and 4.3 µg/L, respectively. Daphnids that 
were withdrawn from tamoxifen and 4OHTam were not able to recover. Also, the reproduction of D. 
pulex was reduced when the treated animals were exposed to the combination of tamoxifen and 
4OHTam while no effects were observed when these chemicals were tested individually at the same 
concentration. Among the anticancer drugs that were tested during this thesis, imatinib was the less 
toxic molecule towards D. pulex. No effects on size and reproduction were observed within two 
generations, except for the first whose reproduction decreased at the highest test concentration, i.e., 
626 µg/L. 
Our results also underline the need to use measured or predicted concentrations instead of the nominal 
during aquatic experiments, particularly when lipophilic molecules are tested. Indeed, notable 
differences between nominal (i.e., theoretical) and measured concentrations were found with 
tamoxifen, 4OHTam and endoxifen at all test concentrations. A cost and time sustainable method was 
proposed to predict the test exposure levels of these chemicals during long-term experiments. This 
predictive method was efficient particularly for low concentrations, which corresponded to the test 
concentrations in multigenerational tests. 
In the ecotoxicoproteomic experiments a total of 3940 proteins were identified and quantified in D. 
pulex exposed to tamoxifen. These results are currently the largest dataset from D. pulex that is 
published and the results of proteomic analyses are available for the scientific community. Among 
these 3940 proteins, 189 were significantly different from controls. After protein annotation, we 
assumed that treated daphnids with tamoxifen had shifted cost-energy functions, such as reproduction, 
to maintain their basic metabolism necessary to survive. This metabolic cost hypothesis was supported 
by the presence of proteins involved in oxidative stress. Biomarkers for early detection of tamoxifen 
harmful effects on D. pulex were not discovered but the proteins of the vitellogenin-2 family 
(E9H8K5) and the ryanodine receptor (E9FTU9) are promising potential biomarkers because their 
expression was already modified after 2 days of treatment. 
In this thesis, the effects of tamoxifen, 4OHTam and endoxifen on daphnids raise questions about the 
potential impact of tamoxifen and 4OHTam in other aquatic ecosystems, and therefore, about 
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metabolites in ecotoxicology. Because the NOECs were environmentally relevant, these results 
suggest that tamoxifen and 4OHTam may be interesting pharmaceuticals to consider in risk 
assessment. Our findings also emphasize the importance of performing long-term experiments and of 
considering multi-endpoints instead of the standard reproductive endpoint. Finally, we open the 
discussion about the importance to measure test exposures or not, during ecotoxicological studies.  
  
 VII  
Résumé 
Les milieux aquatiques sont exposés continuellement à un nombre croissant de substances chimiques, 
notamment les médicaments issus de la médecine vétérinaire et humaine. Chez les patients, les 
substances administrées sont utilisées par le corps avant d’être éliminées par l’intermédiaire des 
excrétas dans le système d’eaux usées de la ville. Ces eaux rejoignent ensuite une station de traitement 
afin d’y éliminer les déchets. Dans le cas des molécules chimiques, il arrive que les processus de 
traitement d’eaux usées ne soient pas suffisamment efficaces et que ces molécules ne soient pas 
dégradées. Elles sont alors libérées dans le milieu aquatique avec les effluents de la station 
d’épuration. Une fois dans l’environnement, ces résidus de médicaments sont susceptibles d’induire 
des effets sur la faune et la flore aquatique, dont les conséquences à long terme et à faibles 
concentrations sont peu connues. 
Les anticancéreux sont une famille de médicaments qui peuvent échapper aux traitements des stations 
d’épuration et qui sont retrouvées dans le milieu aquatique naturel. Parmi ces substances, le tamoxifen 
est une molécule utilisée dans le monde entier pour prévenir et traiter les cancers hormonaux 
dépendant du sein, notamment. Une fois ingéré, le tamoxifen est transformé par le foie en métabolites 
dont deux d’entre eux, le 4-hydroxy-tamoxifen (4OHTam) et l’endoxifen, possèdent un affinité pour 
les récepteurs aux estrogènes et une efficacité sur les cellules tumorales supérieure au tamoxifen lui-
même. Tout comme la molécule mère, ces métabolites sont principalement éliminés par 
l’intermédiaire des fèces. Le tamoxifen a déjà été mesuré dans les effluents de stations d’épuration et 
dans les eaux naturelles, mais aucune valeur n’a été reportée pour ses métabolites jusqu’à présent. Un 
autre anticancéreux, également éliminé par voie biliaire et susceptible d’atteindre l’environnement, est 
l’imatinib. Cette récente molécule a révolutionné le traitement et la survie des patients souffrant de 
leucémie myéloïde chronique et de tumeur stromales gastrointestinales. Les effets du tamoxifen et de 
l’imatinib sur plusieurs générations d’organismes aquatiques, tels que les microcrustacés Daphnia, 
sont inconnus et le 4OHTam et l’endoxifen n’ont même jamais été testés en écotoxicologie. 
Cette thèse s’est articulée autour de trois objectifs principaux. Premièrement, la sensibilité des D. 
pulex exposés au tamoxifen, 4OHTam, endoxifen et imatinib a été évaluée par l’intermédiaire de tests 
aigus et de tests sur deux à quatre générations. La mobilité, la taille, la reproduction, la viabilité et la 
croissance potentielle de la population ont été relevées au cours de ces expériences. Des tests 
supplémentaires, à but prospectifs, ont également été réalisés afin d’évaluer 1) la capacité de 
récupération des daphnies, lorsque leurs descendants ont été placés dans un milieu exempté de 
tamoxifen ou de 4OHTam, 2) les effets chez les daphnies exposées à une solution contenant de faibles 
concentration de tamoxifen et de 4OHTam mélangés. Le deuxième objectif a été d’évaluer la stabilité 
du tamoxifen, 4OHTam et endoxifen dilué dans le milieu des daphnies. Après analyses, les 
concentrations mesurées ne correspondaient pas aux concentrations nominales (c.-à-d., théoriques) et 
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il a été nécessaire de développer une méthode efficace de prédiction des niveaux d’exposition lors de 
tests de longue durée réalisés avec ces trois molécules. Finalement, des changements dans l’expression 
des protéines chez des daphnies exposées au tamoxifen ont été investigués par l’intermédiaire 
d’expériences écotoxicoprotéomiques avec une approche dite de shot-gun avec une étape de 
fractionnement des protéines. 
Les résultats obtenus dans cette thèse montrent que le tamoxifen, le 4OHTam et l’endoxifen induisent 
des effets indésirables chez les daphnies à des niveaux d’exposition proches ou identiques aux 
concentrations du tamoxifen mesurées dans l’environnement, c’est-à-dire 0.12 et 0.67 µg/L de 
tamoxifen. Ces molécules ont induit des effets inhabituels tels que la production de : nouveau-nés 
anormaux, avec des antennes et des queues déformées, des prématurés et des œufs avortés. Le 
tamoxifen fut la molécule la plus toxique pour les D. pulex suivie du 4OHTam, de l’endoxifen et enfin 
de l’imatinib. Lors des expériences sur plusieurs générations, les concentrations n’ayant 
statistiquement pas d’effet (c.à.d. NOEC en anglais) sur la taille, la reproduction et la croissance 
intrinsèque de la population étaient du même ordre de grandeur que les concentrations 
environnementales du tamoxifen. Par exemple, les NOECs du tamoxifen calculées pour la 
reproduction étaient de 0.67 et 0.72 µg/L, tandis que celle calculée sur la base des anomalies chez les 
nouveau-nés était < 0.15 µg/L. Les NOECs du 4OHTam se situaient entre 0.16 et 1.48 µg/L et celles 
de l’endoxifen pour la croissance intrinsèque de la population, ainsi que pour la reproduction, étaient 
de 0.4 et 4.3 µg/L, respectivement. Dans l’expérience basée sur la récupération des daphnies, la taille 
et la reproduction ont diminué bien que la descendance fût placée dans un milieu sans substances 
chimiques. Les daphnies exposées au mélange de tamoxifen et de 4OHTam ont produit moins de 
nouveau-nés que les contrôles, alors que ces concentrations n’ont pas induit d’effets lorsque testées 
individuellement. Finalement, l’imatinib n’a pas montré d’effets sur les deux générations testées. 
Seule la première génération exposée à la plus haute concentration (626 µg/L) a montré une 
diminution de la reproduction. 
Les résultats obtenus lors de l’évaluation de la stabilité du tamoxifen, 4OHTam et endoxifen dans le 
milieu des daphnies ont souligné l’importance d’utiliser des concentrations mesurées ou prédites en 
écotoxicologie. En effet, des différences notables entre concentrations nominales et mesurées ont été 
observées à toutes les concentrations et l’hypothèse d’un phénomène d’adsorption sur le verre des 
récipients a été posée. De ce fait, il a été nécessaire d’élaborer une méthode prédictive efficace et 
acceptable, en terme de temps et de coûts. Une régression polynomiale basée sur des concentrations 
mesurées et nominales a permis de prédire avec efficacité les faibles niveaux d’exposition utilisés lors 
d’expériences écotoxicologiques à long terme, sur plusieurs générations. 
Suite aux expériences d’écotoxicoprotéomiques, un total de 3940 protéines ont été identifiées et 
quantifiées chez des daphnies exposées au tamoxifen. Ce nombre est actuellement la plus large série 
de données publiées et mises à disposition pour la communauté scientifique. Parmi ces protéines, 189 
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sont significatives et possiblement reliées à des processus de reproduction et de stress. Sur cette base, 
nous avons émis l’hypothèse que les individus subissant un stress, lié à l’exposition au tamoxifen, ont 
utilisé leur énergie de base pour favoriser leur survie plutôt que la reproduction. Enfin, la 
détermination de bio-marqueurs exprimant des dommages précoces des daphnies exposées au 
tamoxifen n’a pas abouti en tant que telle, mais des protéines prometteuses, telle que la famille de 
viellogenin-2 (E9H8K5) et le récepteur à la ryanodine  (E9FTU9), ont été exprimées après deux jours 
d’exposition déjà. Ces protéines pourraient faire l’objet d’investigations écotoxicoprotéomiques 
futures. 
Les résultats de cette thèse posent certaines questions quant au risque du tamoxifen, du 4OHTam et de 
l’endoxifen sur la faune et la flore aquatique et plus particulièrement sur les anticancéreux présents 
dans l’environnement. Les effets toxiques de ces molécules ont été observés à des concentrations 
environnementales et sur plusieurs générations. La question de considérer les métabolites, et ainsi les 
pro-médicaments, en écotoxicologie est soulevée, notamment parce que ces molécules peuvent être 
plus actives et efficaces que la molécule mère. Les expériences chroniques, sur plusieurs générations 
sont également à favoriser car elles offrent un meilleur reflet de la réalité environnementale que des 
essais aigus ou d’une génération. L’utilisation de la protéomique permet d’agrandir les connaissances 
sur les effets des médicaments à un niveau inférieur de l’organisation biologique et ainsi, de mieux 
comprendre de potentiels mécanismes d’action ou de déterminer de potentiels biomarqueurs. 
Finalement, il semble important de discuter de l’opportunité de mesurer les concentrations qui sont 
testées en écotoxicologie afin de ne pas sous-estimer le risque pour la faune et la flore aquatique. 
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Glossary and Abbreviation 
4OHTam 4-hydroxyl-tamoxifen 
5-FU 5-Fluorouracil 
Antagonism A class of interactive joint action between compounds where the potency 
effects of the mixture are lower than expected, i.e., where the joint action is 
interactive 
Antimetabolite (cancer 
treatment) 
Class of anticancer drugs that interact with DNA synthesis and thus cell 
division. 
CML Chronic myeloid leukemia 
CYP450 Cytochrome P450 
dappu-ERR Daphnia estrogen-related receptor 
DMSO Organosulfur (CH3)2SO dimethyl sulfoxide  
Dose-response curve The dose-response curve is a statistical curve determined for a given 
organism and a given substance. It is established based on laboratory data 
that express different concentration-effect relationships for the substance. 
For a species, the curve predicts the intensity effect (usually expressed in a 
percentage between 0 and 100) of a substance concentration 
EC50 The 50% effect concentration refers to the concentration of a substance 
where 50% of its maximal effect is observed for a specified endpoint (e.g. 
immobilisation, death, etc) in a population. This value is statically 
determined based on the dose-response curve for a given species and a given 
substance. 
Ecdyseroid & 
Ecdysone 
Ecdysteroids are polyhdroxylated ketosteroids that are present in whole 
arthropod groups. They are major endocrine signaling molecules in 
crustaceans and other arthropods and are involved in important processes 
such as molting regulation, embryo development, covering organism 
formation (cuticle), vitellogenin production, ovulation, etc. 
Endoxifen 4-hydroxy-N-desmethyl-tamoxifen 
Endpoint Parameter measured on a given organism during a test exposure, for 
example, mortality or reproduction. A measurement endpoint designates 
calculated values such as NOEC or EC50. 
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EPA (U.S.) U.S. environmental protection agency 
Epigenetic Gene regulation by factors not coded in the DNA sequence 
ERR Estrogen-related receptors 
ERα Alpha estrogen receptors 
ERβ Beta estrogen receptors  
F0, F1, F2, F3 Daphnia generation that are treated with one or several substances. The first 
generation exposed to a chemical is F0 
FDA Food and Drug Administration  
Hsp Heat shock proteins 
LOEC Lowest observed effect concentration is an experimental value that is 
determined for a substance. It refers to the lowest test concentration, whose 
the average response in organism is not statistically different from controls 
LogP Logarithm of the partition coefficient between n-octanol and water 
log(coctanol/cwater) 
Mode of action General term used to characterize the action of a molecule on organism. 
This molecule can have a specific mode of action because a receptor binds 
to it. In toxicology, the non receptor-mediated mechanisms are the most 
frequently observed. Most toxic agents act through binding sites in a non-
specific manner, i.e. by targeting molecules that are not considered as 
“receptors” in the pharmacological sense. In addition, toxicants may act 
indirectly by inducing a change in the immediate biological environment of 
the target 
NOEC The No-observed effect concentration is an experimental value that is 
determined for a substance. It refers to the highest test concentration, whose 
the average response in organism is not statistically different from controls 
Nominal concentration Theoretical concentration is deduced from dilution procedure (stock 
solutions, prediluted solutions, test solutions), which are applied during 
experimental work.  
OECD Organisation for economic co-operation and development  
Phenotype Observable traits or characteristics of an organism (e.g., size, behaviour, 
morphology, etc.) 
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Pseudopersistent A continual introduction of pharmaceuticals in the environment by treated 
and untreated sewage effluents makes these chemicals "pseudopersistent" 
(Daughton et al. 2002) 
SERM Selective estrogen-response modulator 
Signal transduction  The passage of inter- or intra-cellular information (biological 
activation/inhibition of a function) 
STP Sewage treatment plant 
Synergism Class of interactive joint action between compounds, where the potency 
effects of the mixture are greater than expected. Synergism can be observed 
in certain formulations of substances involved in plant protection or biocidal 
or pharmaceutical products. Synergism was often observed in binary 
mixture toxicity experiments 
Teratogen Molecules that induce growth retardation or functional abnormalities 
resulting from nongenetic causes, in fetus and embryo 
TKI Tyrosine kinase inhibitor 
Xenobiotic Unnatural molecule that are found within an organism or a natural 
compartment (e.g., water, soil, etc.). Usually a xenobiotic is not expected to 
be present within living-organisms but in the case of pharmaceuticals, it can 
be intentionally administrated. 
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General introduction  
The aquatic environment is exposed continuously and increasingly to chemical substances, such as 
pesticides, personal care products, antifouling paint, plasticizers, cosmetics, etc., which are emitted 
daily by anthropic activities (e.g., manufacturing processes, fishing, agriculture, traffic, industries, 
leisure, medicine, etc., [1–7]). These substances are not considered as natural and they are called 
xenobiotics. The potential effects of xenobiotics are of growing concern because living organisms, 
including humans, are chronically exposed to several of them via food or waters [7–18]. 
Pharmaceuticals are chemicals among these thousand of xenobiotics that invade the aquatic 
environment (for reviews see [19,20]). They are present in STP effluents, surface water, groundwater 
and drinking water (for recent review see [21]). Since the 1990s, several studies have focused on the 
occurrence of these pharmacologically active compounds because once in the aquatic environment, 
some of them can induce effects in organisms ([22,23], for recent review on pharmaceuticals see 
Brausch et al. [20]). These effects were death or physiological dysfunctions in individual organisms 
(e.g., reproduction, body-length, molte, etc.), but also decline in population growth and alterations in 
structure and functions of ecosystems [3,5,24,25]. 
Industries, consumers and prescribers are considered as the three sources of pharmaceuticals release in 
waters [26–28]. The pharmaceutical industries are the producers of synthetic molecules that are 
dedicated to prevent, cure, substitute or diagnose physiological dysfunctions. Prescribers are primarily 
the professional teams (e.g., pharmacists, physicians, etc.) that are entitled to give pharmaceuticals to 
patients or animals in hospitals, in physician/veterinary offices, in medical services, in pharmacies, etc 
[29–31]. Consumers are people and animals that receive prescribed or non-prescribed 
pharmaceuticals. Except from accidentally discharges in the environment, consumers are considered 
as the main environmental entrance pathway for pharmaceuticals [26]. Once absorbed, the body uses, 
transforms and eliminates these molecules. Less or more active forms of the pharmaceutical are 
primarily body-excreted with faeces and urine in soil (animals) or wastewaters (human). These drug 
residues reach the aquatic environment by runoff or sewage treatment plant (STP) effluents, for 
instance. Although new STP technologies are effective at removing some pharmaceutical products 
[32], traditional STP processes are primarily efficient for organic mater. Therefore, some synthetic 
molecules, such as pharmaceuticals, escape STP processes and are measured in STP effluents and 
surface waters (e.g., rivers, lakes, estuaries, groundwater [21,22,33–45]). 
Among pharmaceuticals that escape STP processes, different anticancer drugs were measured in 
wastewaters and natural waters. Most of these chemicals induce side effects in treated patients because 
they do not target abnormal cells only. They are able to disturb physiological function of normal cells, 
which cause adverse reactions such as mutagenic, carcinogenic, teratogenic or embryotoxic effects 
[46,47]. Although recent generations of anticancer drugs, such as signal transduction inhibitors, have a 
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low mutagenic potential, they may interfere with important cell cycle-related functions in exposed 
organisms (e.g., nucleic acids synthesis, DNA replication, mitosis). For instance, STP poorly 
biodegraded methotrexate, ifosfamide and cyclophosphamide, and these compounds were often found 
in STP effluents and natural waters [43,45,47–53]. Anticancer residues may still be active in waters 
and their specific or general action on tumours and normal cells could induce effects in non-target 
eukaryote organisms, i.e., in organisms with complex cells that contain a nucleus with genetic 
material. Consequently, their prolonged presence in surface water may also adversely modulate 
physiological functions of eukaryotic organisms that compose the flora and fauna [54]. In other words, 
active anticancer residues may induce genetic and cell cycle changes in aquatic organisms such as 
algae, invertebrates and vertebrates, which constitute the biodiversity of the environment. Biodiversity 
is a key factor for humans and environment health and well-being. It ensures the supply of ecosystem 
services and facilitates ecosystem stability, which is the basis of sustainable development [55,56]. For 
instance, invertebrates are key species in the food chain and their ability to filter waters improves 
water quality. Among invertebrates, the freshwater microcrustacean Daphnia is primary food supply 
for most aquatic animals, and it is also involved in the food chain to sustain fish that is consumed by 
human. Its ability to transform phytoplankton and decaying matter into more usable form represent a 
vital step for almost any freshwater ecosystem. Daphnids can also be used as sensitive model 
organism in ecotoxicology to assess the effect of xenobiotics on the aquatic fauna [57,58]. 
Ecotoxicology is the science that considers the toxic effects of natural or synthetic substances, such as 
pharmaceuticals, on organisms, populations, community and ecosystem, including the transport, 
transformation and degradation processes of these compounds [59]. Ecotoxicological experiments can 
be performed in laboratories with aquatic invertebrates but also with vertebrates and algae. Compared 
to the number of studies that are performed yearly in rodents and other vertebrates to improve 
scientific knowledge in pharmaceuticals, which are already on the market or in pre-clinical studies, 
ecotoxicological experiments are sparse [60], particularly with algae and invertebrates. Invertebrate is, 
however, an abundant species family that comprises about 95% of all species [61], and crustaceans 
cover at least 30,000 species [62]. Therefore, invertebrates need to be considered when the effects of 
chemicals are assessed in the environment.  
In ecotoxicology, treated organisms such as daphnids are exposed to one or more substances during a 
certain period of time that can be acute or chronic when the period is short  (e.g., 2 days) or long (e.g., 
21 days), respectively. Acute ecotoxicological experiments are usually performed with higher 
concentrations than those used in long-term experiments. Although recent efforts, ecotoxicological 
studies with pharmaceuticals are performed primarily in short-term exposure rather than in chronic 
exposure [20,63–65]. In 2006, Buerge and al. [47] warned researchers about the serious lack of 
chronic exposure studies of drug residues on aquatic biocenosis. The same year Brennan and al. [66] 
drew attention to the paucity of multigenerational testing with oestrogen-mimicking compounds, while 
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alarming effects were observed even in humans; the classical case of diethylstilbestrol still remains the 
most illustrative example of an endocrine disruptive compounds that induced side effects on offspring 
[16]. Acute toxicological assays neglect possible chronic actions of the chemical [67] and these 
experiments have little relevance concerning the “true” exposure of the organisms in the environment. 
Indeed, pharmaceutical residues are considered as pseudopersistent in the aquatic environment, 
because of their continuous release by STP effluents [27], and therefore organisms are exposed to 
these molecules during long periods. International organisations and agencies such as the Organisation 
for economic co-operation and development (OECD) and the U.S. environmental protection agency 
(EPA), recommend standard exposure period depending on the test species [68–72], which includes 
whole life cycle of the organisms or several generations (i.e., multigenerational exposure) [65,66,73]. 
In risk assessment, ecotoxicological experiments with pharmaceuticals are therefore preferred at low 
concentration and during long-term exposure, although the impacts of anticancer drugs on the aquatic 
fauna and flora at these conditions are sparsely evaluated [63]. 
A complementary approach could be used to observe effects at lower level of the biological 
organisation and earlier in time, before these effects are observed at the individual level [74–76]. In 
ecotoxicology, pollutants are primarily interpreted in terms of ecotoxicological threat when they are 
linked to phenotype effects. Elucidating the effects of xenobiotics at the cell level allows subtle 
understanding of the mechanisms that are activated by chemical exposure. Proteins carry out or 
regulate most biological processes, and analysis that consider proteomes, i.e. all proteins that are 
expressed by a cell or tissue, seems to be relevant to assess the functional state of an organism [77]. 
Indeed, a proteomics approache may be able to detect changes in protein expression before these 
changes affect the homeostasis of the organisms [74,78,79]. In association with metabolic, 
transcriptional and histopathological data, proteomics represents therefore an appealing strategy in 
ecotoxicology. 
In this introduction, the following subsections contain more details on why anticancer drugs are 
important to consider in environment and why they may induce effect on non-target species. Three 
anticancer families are presented: the traditional, the recent and the hormonal anticancer drug families. 
Four molecules belonging to these families are described in this section, including two potent 
metabolites. The science of proteomics is introduced as well as its usefulness in ecotoxicology. 
Finally, the reasons of using the freshwater microcrustacean Daphnia pulex are described in the last 
section of this chapter. 
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Anticancer drugs 
Why and which anticancer drugs? 
The incidence of cancers is increasing worldwide related to levels of human development, longer 
average life expectancy, efficiency of new treatments, etc. The number of new cancer cases is 
expected to grow to 23.6 million each year by 2030, which would be 68% more cases than in 2012 
[80]. This prediction takes in consideration the recent trends in incidence of major cancers as well as 
the global population growth in the future. An accurate evaluation of anticancer drugs consumption is 
difficult to obtain in Switzerland. In 2002, Buerge et al. [47] reported a consumption of 55 kg 
cyclophosphamide and 12 kg ifosfamide in Switzerland. In 2004 in France, other authors calculated a 
yearly administration of about 5.8 tons of hydroxycarbamide, 1.7 tons of 5-fluorouracile, 580 kg of 
imatinib, 120 kg of ifosfamide [81]. The Canadian Ministers of the Environment and of Health 
estimated that 320 Kg/year of tamoxifen was used in Canada in year 2012 [82]. Furthermore, demands 
for chemotherapy treatment may increase with increasing number of cases, and with the recent 
treatment improvements, the number of deaths may decrease because patients spend progressively 
longer periods of their lifetime under treatment. 
Oncology represents currently one of the most active fields of pharmaceutical innovation and 
progress. The increasing use of signal transduction inhibitors provides a typical example illustrating 
the recent evolution of cancer treatments [83,84]. Agents belonging to this class of anticancer drugs 
are able to disrupt signalling pathways that maintain cellular proliferation. For instance, imatinib and 
the next generations of tyrosine kinase inhibitors (TKIs) are recent family of anticancer drugs that 
target specific mechanisms of tumour cell biology. These TKIs prolong life of patients with chronic 
myeloid leukaemia compared to other traditional treatment used against this disease [85]. They target 
the mechanisms that are involved in pathological deregulations of a normal cell proliferation, i.e., key 
biological pathways responsible per se or implicated in cancer development [86]. As TKIs, other 
anticancer drugs from the recent generation have specific mechanisms of action and a high specificity 
for key biological pathways. These properties increase their antitumour efficiency and limit their 
overall toxicity. Numbers of these recent anticancer agents are small molecules that interact with 
membrane-bound receptor kinases, intracellular signalling kinases, epigenetic mechanisms such as 
DNA methylation and histone acetylation, and/or the tumour microenvironment. The traditional 
anticancer drugs are less specific and they can be cytotoxic. Cytotoxic anticancer drugs are systemic 
anti-proliferative agents that target dividing cells and not specific cells [87]. They include 
antimetabolites, alkylating agents, DNA-complexing agents, mitosis inhibitors or hormones, such as 
cyclophosphamide, ifosfamide, busulfan, methotrexate, tamoxifen, etc. [88]. Usually, they interfere 
with cell divisions, DNA synthesis and/or repair mechanisms [86]. Among the traditional class of 
anticancer compounds some have also endocrine disruptive activities. This class of drug is often used 
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in cancers associated with endocrine disorder, and they include aromatase inhibitors (letrozole, 
anastrozole, exemestane), selective estrogen-response modulator SERM (tamoxifen), progesterone-
like drugs (megestrol acetate), antiandrogens (flutamide, bicalutamide), etc. These anticancer drugs 
are prescribed in medicine therapies, but they are also used in sport and veterinary fields to enhance 
performance or growth [89–91]. Once in the environment, these pharmaco-active molecules could be 
considered as potential endocrine disruptors, according to the WHO definition [92] : “A potential 
endocrine disruptor is an exogenous substance or mixture that possesses properties that might be 
expected to lead to endocrine disruption in an intact organism, or its progeny, or (sub)populations”. 
More precisely, endocrine disruptive substances, such as certain anticancer drugs, may act at the pre-
receptor, the receptor and the post-receptor levels of the endocrine system in non-target organisms (for 
details see Annexe 1). When a xenobiotic interferes with this endocrine system, the physiology and 
thus the normal development of the organism can be disrupted, which is considered as an adverse 
effect that would not have occurred in absence of this compound [93]. For instance, some industrial 
compound residues, such as pesticides (atrazine, DDT, endosulfan, dieldrin, etc), antifouling 
compounds (tributyltin “TBT”), fungicides (vinclozolin), phtalates, PCBs and its congeners, phenolic 
chemicals (bisphenol-A) are known to induce endocrine responses in aquatic organisms. In mollusks, 
alligators and fish, some of these chemicals influence sexual determination, differentiation, and 
development, which cause adverse effects such as feminization, imposex (simultaneous presence of 
male and female reproductive organs), decrease in fecundity and embryos production, or 
morphological abnormalities [17,94–99]. Due to these evidences, hormone-like industrial compounds 
have received more attention than hormonal drugs [7], although these pharmaceutical were found in 
the aquatic environment under active forms [100,101]. In general however, anticancer drugs are body 
excreted and are found in wastewaters and in natural waters, like cyclophosphamide and ifosfamide 
for instance [47–49,102]. These traditional anticancer drugs have enzymatic targets that are present in 
numerous living organisms, and once in the aquatic environment, they may pose a risk to the aquatic 
flora and fauna, and also to human [103].  
 
The chosen anticancer drugs 
In this study, tamoxifen and two of its potent metabolites were chosen among the traditional 
anticancer family that have hormone disruptive effects in vertebrates. Conversely, the anticancer drug 
imatinib was chosen because it is a new anticancer molecule that has no endocrine disruptive activities 
in vertebrates. The properties of these four molecules and their pharmacological effects are explained 
in the next subsections. 
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Tamoxifen and its potent metabolites 4-hydroxy-tamoxifen and endoxifen 
Tamoxifen is a synthetic non-steroidal anticancer drug that is prescribed to slow down growth of 
hormone-dependent tumours. It was the first hormonal agent approved by the US Food and Drug 
Administration (FDA) for the prevention of breast cancer, for the treatment of ductal carcinoma in 
situ, and for the treatment of pre-menopausal breast cancer. It is also the main hormonal treatment 
prescribed for early and advanced male breast cancers [104]. In 1970, tamoxifen was available for the 
treatment of advanced breast cancer in postmeopausal women [105] but its approval has differed 
depending on the countries. In 1978, tamoxifen was accepted as endocrine therapy for postmenopausal 
women with advanced cancers and became the drug of choice for these cancers in 1980. Tamoxifen 
approval was mainly due to its similar efficiency, but less toxic, than diethylstilbestrol [105]. 
 
Figure 1.1: Molecular structure of tamoxifen, 4OHTam and endoxifen. Tamoxifen is extensively 
metabolized (predominantly by the cytochrome P450 system) into several primary and secondary 
metabolites 
 
Tamoxifen is considered as a selective estrogen receptor modulator (SERM) because it exerts agonist 
and antagonist estrogenic effects depending on the targeted tissue [16]. When the effects are mediated 
by alpha estrogen receptors (ERα), tamoxifen acts as a partial agonist or a partial antagonist. When the 
effects are mediated by beta estrogen receptors (ERβ), this drug behaves as a partial agonist. 
Tamoxifen anti-estrogenic effect (inhibiting agent) is predominant on breast, vagina and central 
nervous system tissues while its estrogenic-like effects (stimulating agent) are reported to be mostly 
present in cholesterol metabolism and other tissues including the endometrium, bone and liver. In 
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stroma breast cells, its main action is cytostatic since it blocks cell cycle in G1 phase and then induces 
a decrease of tumour cellular proportion and proliferation [106]. Tamoxifen also controls cell 
replication through nuclear interaction or growth factors mechanisms (increases the production of 
transforming growth factor β (TBFβ) or decreases IGF1, TGFα and EGF growth factor expression). 
Also, tamoxifen is often used in laboratory experimentation with Cre genetically modified animals. It 
is an inducing agent that trigs the gene expression of specific tissue, usually from mouse mutants. It is 
administrated at a specific time point in the embryonic development or adult life [107].  
 
Pharmacology of tamoxifen  
Patients orally take 20-40 mg of tamoxifen citrate per day [108], which corresponds to 0.4-0.8 mg/kg 
for an average 50 kg woman, sometimes after loading doses of 80 to 200 mg during 1 to 7 days [109]. 
The treatment is usually taken for 5 years or according to its efficacy and safety, in the case of 
metastatic hormone-dependent breast cancer. Longer durations might even become recommended 
[110]. Following a single oral dose of 20 mg tamoxifen citrate, the peak concentration in plasma is 
about 40 µg/L (range 35 to 45 µg/L) and occurred 4 - 7 hours after dosing [111]. The native substance 
half-life is about 7 days [112]. Tamoxifen is more than 99% bound to plasma proteins, predominantly 
to albumin [113]. A steady-state plasma concentration of 140 and 160 µg/L is reached after a chronic 
administration of 20 and 30 mg of tamoxifen citrate twice daily, respectively [113,114]. This steady-
state is achieved after 4 weeks [112] but it can be reached faster when high loading doses are 
administrated [109]. The volume of distribution is high, i.e., 50-60 l/kg, which indicates that 
tamoxifen accumulates in organs either by active transport or by specific binding to tissue molecules. 
In patients with breast cancer, the concentrations of tamoxifen were 10 to 60 times higher in liver, 
lung, pancreas, brain and adipose, than in serum [115]. 
Tamoxifen is metabolized by hepatic P450 cytochromes into several metabolites [116]. Its main 
metabolites are: N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen (4OHTam), tamoxifen N-oxide, and 
alpha-hydroxy-tamoxifen. Finally, 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) results as a 
secondary metabolite of tamoxifen that is primarily formed from N-desmethyl-tamoxifen by the 
cytochrome CYP2D6. The molecular structures of tamoxifen, 4OHTam and endoxifen are shown in 
Figure 1.1. Note that mutations in CYP2D6 prevent the formation of endoxifen and thus may reduce 
tamoxifen response in patients [117]. Endoxifen serum level is 6 to 12 fold higher than 4OHTam, but 
pharmacological activity of both metabolites is 30 to 100 fold more potent than the parent molecule 
[104,118–120]. More specifically, 4OHTam and endoxifen express an affinity to ERs 100 fold higher 
than the original molecule and than other metabolites. Their potency to suppress cell proliferation in 
breast cancer is also 30 to 100 fold greater than the latters. In vitro, both metabolites have equivalent 
potency to bind ERα and ERβ, and to suppress ER-dependent human breast cancer cell line.  
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Tamoxifen anticancer action in breast tumour may also be explained by antagonist properties on the 
estrogen-related receptors (ERRs) [121]. In mammals, the ERRs belongs to the nuclear receptors 
superfamily (ERRα, ERRβ and ERRγ in mammals), which regulate transcription via estrogen response 
elements and estrogen-related response elements [121]. The amino acid sequence of human ERRs is 
over 60% identical to the human ERα and ERβ [122]. Although they share common transcriptional 
target genes, their function are different [123–125]. For instance, ERRs are unable to bind natural 
estrogenic ligands such as 17β-estradiol [126]. Its metabolite 4OHTam has a higher potency and 
affinity to ERs than tamoxifen [118–120], and also a higher affinity to ERRα and ERRγ. Tamoxifen 
and 4OHTam are considered as antagonist of ERRα and ERRγ [121] and none of them bind ERRβ 
[124,127]. 
Tamoxifen and its metabolites ultimately undergo fecal excretion (i.e. biliary route [109]). To be better 
excreted within the bile, tamoxifen and 4OHTam are mainly conjugated into glucuronide acids. 
Deglucuronidated tamoxifen and metabolites undergo enterohepatic cycle [128], which prolongs their 
half-life in patients. Kisanga et al. [129] analyzed the excretion of tamoxifen and its metabolites in 
human urine and bile after a per os dose of 14C-tamoxfien. 4OHTam and endoxifen were both found in 
urine and feces. The 4OHTam was first detected followed by endoxifen (three days later than 
4OHTam). However, 4OHTam was the dominant metabolite excreted in the bile and might result from 
a first-pass, contrary to endoxifen that only appeared when tamoxifen had reached the central 
compartment. 
 
Physical-chemical properties of tamoxifen, 4OHTam and endoxifen 
Tamoxifen is a tripheylethylene drug. It is a white crystalline solid from petroleum ether that is easily 
soluble in methanol but very slightly soluble in water [130]. Tamoxifen is not readily biodegradable 
[131] and it has a high bioaccumulation potential with an experimental logP of 7.1 [132]. The physical 
state of tamoxifen as human pharmaceutical is tablets. In pharmaceutical formulations, tamoxifen is 
invariably present as its citrate salt. Each tablet contains 15.2 mg of tamoxifen citrate, which is 
equivalent to 10 mg of tamoxifen [82]. The metabolites 4-hydroxy-tamoxifen (4OHTam) and 
endoxifen are formed in liver cells. Physical and chemical properties of tamoxifen, 4OHTam and 
endoxifen are summarised in Table 1.1. 
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Table 1.1: Physical and chemical properties of tamoxifen, 4OHTam and endoxifen 
 
CEREP, 2010 [130], DrugBank, 2013 [132], Government Canada, 2014 [82] 
 
Toxicity of tamoxifen in terrestrial organisms 
During acute exposure experiments, it was observed that a single oral dose of 2.5 and 3 g/kg of 
tamoxifen was lethal on 50% (LD50) of the treated rats and mice, respectively [133]. There is no 
available data on acute over dosage in humans by ingestion, inhalation, skin exposure, eye contact, 
parenteral exposure or other. In 1992 however, Trump et al. [134] run a study where high doses were 
given in advanced metastatic cancer women. In this study, patients took an initial dose of > 400 mg 
per body surface area in m2 (mg/m2) followed by a treatment of 150 mg/m2 twice a day. These doses 
induced acute neurotoxicity symptoms, such as tremor, over-reflexes, unsteady gait and/or dizziness, 3 
to 5 days after the loading dose. The neurotoxic symptoms were not permanent and decreased 2 to 5 
days after the treatment was stopped. Cardiac symptoms, i.e., prolongation of the QT interval on the 
electrocardiogram, were also observed in patients who received loading dose > 250 mg/m2, followed 
by maintenance doses of 80 mg/m2 twice a day. The maximum tolerated dose determined in that study 
was 300 mg/m2/day tamoxifen. 
Property Type Data Reference
CAS 10540-29-1 Government Canada, 2014
Molecular formula C26H29NO Government Canada, 2014
Molecular weight (g/mol) 371.51 Government Canada, 2014
Boiling point (°C) Modelled 468.2 Government Canada, 2014
Density (kg/m3) Experimental N/A Government Canada, 2014
Vapour pressure (Pa) Modelled 4.62 × 10−6 Government Canada, 2014
Log P experimental 7.1 (experimental) DrugBank 2013
Water solubility (mg/L) Experimental < 0.5 CEREP, 2010
CAS 68047-06-3 Government Canada, 2014
Molecular formula C26H29NO2 Government Canada, 2014
Molecular weight (g/mol) 387.51 Government Canada, 2014
Boiling point (°C) Modelled 503.04 Government Canada, 2014
Density (kg/m3) Experimental N/A Government Canada, 2014
Vapour pressure (Pa) Modelled 4.14 × 10−9 Government Canada, 2014
Log P experimental 6.3 (calculated) Pubchem.ncbi.nlm.nih.gov
Water solubility (mg/L) Experimental < 0.5 CEREP, 2010
CAS 110025-28-0 Government Canada, 2014
Molecular formula C25H27NO2 Government Canada, 2014
Molecular weight (g/mol) 373.49 Government Canada, 2014
Boiling point (°C) Modelled 501.85 Government Canada, 2014
Density (kg/m3) Experimental Not available Government Canada, 2014
Vapour pressure (Pa) Modelled 4.32 × 10−9 Government Canada, 2014
Log P experimental 6.3 (calculated) Pubchem.ncbi.nlm.nih.gov
Water solubility (mg/L) Modelled < 1.5 CEREP, 2010
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Table 1.2: Tamoxifen toxicity in vertebrates including human 
 
Buckley and Goa, [135], Decensi et al., [136], Hard et al., [137], IARC, [105], Ravindranath et al., [138]Schild et al. 
[139], Sousa et al., [140]. 
 
Table 1.2 summarised the chronic effects assessed during laboratory experiments or clinical studies. 
The international agency for research on cancer (IARC, [105]) also reviewed the long-term toxicity of 
tamoxifen in vertebrates. It is know for instance that approximately 4 % of the patients stop tamoxifen 
therapy due to side effects, mainly such as hot flushes, tachycardia, nausea and vomiting. A chronic 
exposure to about 0.1 mg/kg is well tolerated by mice, rats and dogs [105]. In rats, repeated doses of 
higher doses of tamoxifen induced endometrial epithelium hypertrophy, while endometrial hyperplasia 
was observed in mice. Chronic exposure to tamoxifen also induced different types of ocular toxicity 
[105,135]. 
 
Compound Species Dose Unit Endpoint Effect(s) Duration References/cited in
Tamoxifen citrate Women/men ≤ 180 mg sides effects Eyes  (retinal damage and keratitiss) > 1 year Buckley and Goa. 1989
Tamoxifen citrate Women 20 mg/day pregnancy Fetal, neonatal disorder months IARC, 1996
Tamoxifen citrate Women 1 and 5 mg/day
cell proliferation, serum 
biomarkers
Suppressing breast cell proliferation, 
decreasing activity in modulating serum 
biomarkers
Decensi et al., 2003
Tamoxifen citrate Women 1 mg/day blood proteins and markers IGF-I declined, antithrombin III, CRP 12 months Decensi et al., 2007
Tamoxifen citrate Women 10 mg/day
Ki-67, Estrogen receptor 
(1D5), progesterone receptor 
positivity in breast epithelium
Reduced: monoclonal antibody Ki-67 
(MIB-1), estrogen receptor (1D5) and 
progesterone receptor positivity (PgR 
636) in the breast epithelium of carcinoma
14 days Sousa et al. 2006
Tamoxifen citrate Women 5 mg/day biomarker, mammographic 
density
Insulin-like growth factor I (IGF-I), 
uterine effects, breast neoplastic events
2 years Decensi et al., 2009
Tamoxifen citrate Women 1 and 5 mg/day biomarkers
Marker (Ki-67 expression), cancer blood 
biomarkers (insulin-like growth factor-I,
sex hormone-binding globulin), 
cardiovascular disease, bone fracture risk
4 weeks Decensi et al., 2003
Tamoxifen Monkey 2 mg/kg BW DNA DNA-adducts in multiple tissues 30 days Schild et al. 2003
Tamoxifen Monkey 3 mg/kg-day Reproduction Inhibition of pregnancy establishment 3 to 12 days Ravindranath et al., 1986
Tamoxifen Citrate Dog 0.1 mg/kg tolerance Well tolerated chronic IARC, 1996
Tamoxifen Citrate Mice 0.1 mg/kg tolerance Well tolerated chronic IARC, 1996
Tamoxifen Citrate Mice > 0.1 mg/kg sides effects Endometrium (hyperplasia) chronic IARC, 1996
Tamoxifen Citrate Mice 5 mg/kg/day LOAEL Benign tumors, reproductive system 13-15 months [a]
Tamoxifen Citrate Rabbit 0.5 mg/kg/day LOAEL Fetotoxicity chronic [a]
Tamoxifen Citrate Rabbit 2 mg/kg/day LOAEL Not Teratogenic chronic [a]
Tamoxifen Citrate Rat 0.1 mg/kg tolerance Well tolerated chronic IARC, 1996
Tamoxifen Citrate Rat > 0.1 mg/kg sides effects Endometrium (epithelium hypertrophy) chronic IARC, 1996
Tamoxifen Citrate Rat 147 mg/kg LOAEL Female reproductive system 7 weeks [a]
Tamoxifen Citrate Rat 0.04 mg/kg BW reproduction Oocyte implantation 2 weeks IARC, 1996
Tamoxifen Citrate Rat 0.025 mg/kg BW highest dose Successful pregnancy IARC, 1996
Tamoxifen Citrate Rat 0.04 mg/kg/day LOAEL Fertility, Fetotoxicity chronic [a]
Tamoxifen Citrate Rat 0.16 mg/kg/day LOAEL Fertility, Fetotoxicity chronic [a]
Tamoxifen Citrate Rat 5 mg/kg/day incidence of tumour Tumors, liver 2 years [b] 
Tamoxifen Citrate Rat 45 mg/kg/day LOAEL Tumors, liver 6 months [a]
Tamoxifen Citrate Rat 5 mg/kg/day LOAEL Tumors, liver 24 months [a]
Tamoxifen Rat 22.6 mg/kg-day Carcinomas incidence
100% incidence of cancer (hepatocellular 
carcionomas), first carcinoma observed at 
6 month already
12 monts Hard et al., 1993
Tamoxifen Rat 11.3 mg/kg                
twice a day
incidence of carcinomas 67% incidenc of carcinomas 12 montrs Hard et al., 1993
[a]   Pfizer pharmaceutical company: www.pfizer.com/products
[b]   www.druginfonet.com/tamoxfen.htm
LOAEC: lowest-observed-adverse-effect concentration
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Toxicity of tamoxifen in aquatic organisms 
Tamoxifen is known to escape degradation process by STPs [48,49,141,142] and this pharmaceutical 
was found in the aquatic environment, including groundwater [50,53,143]. The concentrations of 
tamoxifen in sewage and natural waters are summarised in Table 1.3. We hypothesis its metabolites 
undergo the same scenario because they are also body-excreted in faeces and because they have 
similar properties as tamoxifen. Therefore, tamoxifen and its metabolites may enter continuously in 
surface waters, being considered as pseudopersistent compounds in the environment. To the best of 
our knowledge, no literature reports aquatic concentration levels or effects of its metabolites in aquatic 
species (e.g., endoxifen and 4OHTam). 
 
Table 1.3: Tamoxifen concentrations in waters 
 
Ashton et al., [51]; Langford and Thomas,[52]; López-Serna et al., [50], 
Roberts and Thomas, [53], Reh et al., [143] 
 
Some aquatic species are known to be sensitive to tamoxifen, such as fish and crustacean. Table 1.4 
summarises the concentrations that induced adverse effect on aquatic species. Various morphological 
and developmental effects were induced in sea urchin embryos after exposure to 3.715 to 3715 µg/L of 
tamoxifen but other adverse outcomes were observed in crustaceans and algae [82,144–146].  
Location Concentration (µg/L) Reference
STP effluents 0.02 - 0.37 
Ashton et al., 2004;                             
Langford and Thomas, 2009;            
Roberts and Thomas, 2006
Surface waters 0.01 - 0.21 Roberts and Thomas, 2006;                   López-Serna et al., 2012
Groundwater 0.01 - 0.02 López-Serna et al., 2012,                                       Reh et al., 2013
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Table 1.4: tamoxifen toxicity in aquatic species (algae, invertebrates and vertebrates)  
 
Andersen et al. [144], DellaGreca et al. [145], Pagano et al. [146], Unpublished AsraZeneca study, in [82] 
 
 
Imatinib 
Imatinib (Gleevec®) was the fourth pharmacologically active molecule that was chosen in this thesis. 
Imatinib was the first tyrosine kinase inhibitor (TKI) that reached the market. This molecule belongs 
to the recent class of anticancer drug, with specific properties in tumour cells. This specificity has 
revolutionized the treatment and the survival of patients suffering from chronic myeloid leukaemia or 
gastrointestinal stromal tumour [147,148]. While the number of people susceptible to receive this 
pharmaceutical was initially restricted to about 60 per year in Switzerland, it has been increasing by 
tenfold over the last decade (personal communication, Thierry Buclin) and this number of treated 
patient may continue to grow. The reason of this increase is precisely due to survival of patients who 
would otherwise died. Following imatinib several other TKIs were marketed, such as gefitinib, 
sunitinib, nilotinib, dasatinib, sorafenib and lapatinib. These new generations of molecules are used 
against various cancers but with a broad prevalence for chronic myelogenous leukemia and 
gastrointestinal stromal tumours. Because these molecules demonstrated a definite efficacy on survival 
of advanced cancer patients - however less impressive than for imatinib in its specific indications - a 
progressive increase in their use and in their release in the environment may also be expected to occur.  
 
Species Effect(s) Endpoint
Exposure 
(µg/L) Duration References
M. aeruginosa growth rate LOEC 130 21 days Unpublished AstraZeneca study
S. capricornutum growth rate LOEC 8 21 days Unpublished AstraZeneca study
B. calyciflorus population growth inhibition EC50 250 48 hours DellaGreca et al. 2007
T.s platyurus lethal LC50 400 24 hours DellaGreca et al. 2007
C. dubia population growth inhibition EC50 0.81 7 days DellaGreca et al. 2007
D. magna lethal LC50 1530 24 hours DellaGreca et al. 2007
D. magna reproduction LOEC 90 21 days Unpublished AstraZeneca study
D. magna length NOEC 30 21 days Unpublished AstraZeneca study
D. magna reproduction NOEC 50 21 days Unpublished AstraZeneca study
A. tonsa inhibition of naupliar development EC10 8.7 5 days Andersen et al. 2001
A. tonsa inhibition of naupliar development EC50 49 5 days Andersen et al. 2001
P. lividus, S. granularis fertilization, malformations - 3715 - Pagano et al., 2001
P. lividus, S. granularis fertilization - 3.715 - Pagano et al., 2001
L.#macrochirus ? (acute) LC50 150 96 hours Unpublished AstraZeneca study
S.#gairdneri ? (acute) NOEC 180 96 hours Unpublished AstraZeneca study
EC10: the concentration of a substance that induced effect on 10% of the test organisms 
EC50: the concentration of a substancethat induced effec effect on 50% of the test organisms
LC50: the concentration of a substance that is lethal to 50% of the test organisms
LOEC: lowest-observed-effect concentration
NOEC: no-observed-effect concentration
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Pharmacology of imatinib  
Imatinib mesylate is mainly used to treat Philadelphia chromosome positive chronic myeloid leukemia 
(MCL) and gastrointestinal stromal tumours (GIT) with KIT mutations [147,149]. Imatinib mesylate is 
an oral anticancer drug precisely designed to selectively inhibit certain protein tyrosine kinase that are 
involved in oncogenesis. These protein tyrosine kinases control the activation of transduction 
pathways, which regulates cellular processes, such as growth, differentiation and apoptosis [150]. 
Dysregulated tyrosine kinases can display adverse molecular responses. In the chronic myeloid 
leukemia (CML) with Philadelphia chromosome aberration, the translocation of this chromosome 
leads to the fusion of ABL gene and BCR gene [151]. This fused tyrosine kinase Bcr-Abl induced 
unusual cell activity and thus the disease. Imatinib acts on cells that express the Bcr-Abl and inhibits 
the activity of this fused tyrosine kinase, which prevents tumours proliferation and growth [147]. In 
the case of GIT, imatinib inhibits KIT (and thus signal transduction) in a similar manner to its 
inhibition of Bcr-Abl [152,153]. Besides, imatinib targets other tyrosine kinases, such as platelet-
derived growth factor receptor (PDGF-R). Therefore, imatinib is a specific molecule that act on 
definite tyrosine kinase domains and not on normal healthy cells [149]. This specificity has 
revolutionized the treatment of patients, primarily for the CML. 
In patients treated with 400 mg/day of imatinib, its steady-state in plasma is about 979 µg/L after 29 
days [148]. Cytochrome P450 system metabolises imatinib in different metabolites. The N-
demethylated piperizine derivative, also named CGP 74588, is an active metabolite of imatinib, which 
has a similar potency to its parent compound [152,154]. Imatinib is the predominant component in 
plasma, followed by CGP 74588 [154]. Imatinib dose is predominately excreted in faeces (68%) and 
in urine (13%). Approximately 25% of the dose is excreted in unchanged form and < 13% was found 
in the form of CGP 74588 [154,155].  
 
Physical-chemical properties of imatinib 
Imatinib is a benzamide drug classified as protein kinase inhibitors and antineoplastic agent [155]. The 
molecular structure of imatinib is shown in Figure 1.2. This molecule is very soluble in water [155]. 
Table 1.5 summarises the physical and chemical properties of imatinib and imatinib mesylate. The 
physical state of imatinib is tablets and its pharmaceutical formulation is imatinib mesylate. The daily 
dose of imatinib mesylate is between 400 and 800 mg, which corresponds to between 478 and 956 mg 
of imatinib (factor of conversion: 1.2) [108]. 
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Figure 1.2: Molecular structure of imatinib mesylate, C29H31N70. Thick and thin arrows are the primary 
and the minor routes of metabolite formation, respectively 
 
Table 1.5: physical and chemical properties of imatinib and imatinib mesylate 
 
Drugbank, 2013 [155], Peng et al., [152] 
 
Toxicity of imatinib in aquatic organisms and environmental concentrations 
To the best of knowledge, the concentrations of imatinib in the aquatic environment have never been 
monitored up to now, and a single study assessed the effects of this chemical in non-target species. 
Parrella et al. [156] predicted a concentration of 0.005 µg/L, based on patients excretion rate. Then, 
they exposed four aquatic invertebrates to imatinib and shown that D. magna and C. dubia were the 
most sensitive species among the test animals, with NOECs of 3 and 0.3 µg/L, respectively [156]. The 
results of this study are summarised in Table 1.6. 
CGP 74588
Inactive metabolites
Imatinib
N
N
H
N
N
HN
N
O
CH3
CH3
Property Type Data Reference
CAS 152459-95-5
Molecular formula C26H31N7O
Molecular weight (g/mol) 493.6 Drugbank imatinib
Log P Experimental 3
Water solubility (mg/L) Predicted 14.2 (pH not indicated)
CAS 220127-57-1
Molecular formula C26H31N7O • CH4SO3
Molecular weight (g/mol) 589.7 Bin Peng et al. 2005
Log P Experimental 1.99
Water solubility (mg/L) Experimental 50 (at pH 1.99)
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Table 1.6 Imatinib acute and chronic ecotoxicity in aquatic invertebrates. 
The results come from the study of Parrella et al. [156] 
 
 
 
Ecotoxicoproteomics 
The aim of toxicoproteomics is to understand changes that occur at the protein level of a cells or an 
organism in response to toxin exposures, such as pollutants or drugs. Nowadays, toxicoproteomics is 
used in environmental toxicology to find early ecotoxicological markers at the protein level. This field 
of science is called ecotoxicoproteomics. 
Proteome refers to the techniques used to study proteins, which are encoded by a given genome, on a 
large scale. Contrary to genome, the proteome is highly dynamic and changes continuously as a 
response to numerous intra and extracellular signalling [157]. Proteomics can be more broadly defined 
as “the effort to establish the identities, quantities, structures, and biochemical and cellular functions of 
all proteins in an organism, organ, or organelle, and how these properties vary in space, time, and 
physiological state” [158]. Proteomics is closer to physiology than genomics because post-translational 
regulation of proteins can reduce the correlation between mRNA abundance and protein activity [157]. 
Proteomics has the ability to characterize a wide number of proteins in biological samples, and it is 
increasingly used to search for novel biomarkers of human disease [159]. Also, this method allows 
human studies that otherwise could have not been carried out at overtly toxic exposures.  
 
Species Effect(s) Endpoint
Exposure 
(µg/L) Duration
Acute
C. dubia mortality LD50 32 24 hours
B. calyciflorus mortality LD50 3.8 24 hours
T. platyurus mortality LD50 43.3 24 hours
D. magna imobilisation EC50 12 48 hours
C. dubia reproduction EC50 115 7 days
B. calyciflorus population growth inhibition EC50 740 48 hours
D. magna reproduction EC50 308 21 days
C. dubia reproduction NOEC 0.3 7 days
B. calyciflorus population growth inhibition NOEC 70 48 hours
D. magna reproduction NOEC 3 21 days
EC50: the concentration of a substance that induced effec effect on 50% of the test organisms
LD50: the concentration of a substance that is lethal to 50% of the test organisms
NOEC: no-observed-effect concentration
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Toxicoproteomics is the field of science that focuses on changes at the protein level, in cells or in 
organisms that are exposed to toxic compounds. The purpose of this science is to better understand the 
toxicological mechanisms and the potential effects of a compound on living organisms. 
Toxicoproteomics can be used in environmental toxicology to find early markers at the protein level 
resulting from chemical exposure [74,160]. With omic- technologies, different levels of the biological 
organization (from cell to the organism for example) could be considered in ecotoxicology to increase 
understanding of the environmental effects of micropollutants. Ecotoxicoproteomics may link toxicant 
responses that were observed at the protein level with the responses at the organism level, i.e., a higher 
level of the biological organization. While standard ecotoxicological tests commonly focus on survival 
and reproduction, omic- studies try to give faster responses to environmental changes. Indeed, protein 
responses may appear earlier in time than the response at the organism level, and at lower 
(environmental) stressor concentrations than those used in chronic ecotoxicology experiments. 
Ecotoxicoproteomic studies were already performed on microorganisms (bacteria, fungi), plants, 
invertebrates (molluscs, microcrustaceans, worms, insects) and vertebrates (freshwater and seawater 
fishes). For instance, specific proteomics signatures were associated with the exposure to sublethal 
concentrations of various marine pollutants (diallyl phthalate, PBDE-47, and bisphenol-A) in the blue 
mussel (Mytilus edulis) [75]. The authors also used identified proteins to better understand the possible 
mechanisms of toxicity in the blue mussel. They concluded that the main cause of the observed changes 
in protein expression was adaptive responses from oxidative stress. Heckmann and al. [161] also 
provided an interesting example of the application of “omics” technology to drug in ecotoxicology. The 
authors used a biology approach to link acute transcriptomic responses with chronic phenotypic stress 
responses, which occurred on Daphnia magna exposed to ibuprofen, a nonsteroidal anti-inflammatory 
drug. Similarities in the mode of ibuprofen action were shown in eicosanoid metabolism between 
vertebrates and invertebrates. In their study, they found that the reduced fecundity of daphnids resulted 
from disruption of the juvenile hormone metabolism. This study demonstrated that it is possible to use 
acute molecular responses to investigate the mode of action of xenobiotics and to assess their chronic 
impact on non-target organisms. 
However, for an efficient application of proteomics in organisms commonly used as model in 
ecotoxicology, a comprehensive protein sequence database of these organisms is required. 
Fortunately, a draft genome sequence of D. pulex was recently released (see the website: 
wfleabase.org). Froehlich et al. [74] showed that LC-MS/MS proteomics analyses were an efficient 
tool for D. pulex and D, longicephala studies. Their data demonstrated proteomics to be very 
promising for ecotoxicological investigations into Daphnia species, although few publications have 
inquired the proteome of daphnids up to know. In this study, we decided to use D. pulex as aquatic 
model to perform ecotoxicological and ecotoxicoproteomic experiments 
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Ecotoxicology 
Daphnids in general 
Daphnids are crustacean from the Branchiopoda class, suborder Cladocera, and more communally 
named water fleas because of their fast and spastic movements that look like small jumps.  During 
their life, these organisms have the particularity to use two reproductive strategies 
(http://animaldiversity.ummz.umich.edu/site/accounts/information/Daphnia_pulex.html). 
1. The parthenogenesis reproduction (i.e. asexual reproduction) is used during periods that are not 
stressful for the organisms, i.e., when the environmental parameters do not change and allow 
species to survive without negative pressure, such as resource decreases or temperature and 
photoperiod changes. During these periods, eggs undergo a single maturation division in the 
ovary [162]. The females produce broods of genetically identical diploid offspring (i.e. clones) 
[163] and only females are produced. 
2. The sexual reproduction is induced when environmental conditions are stressing for the 
daphnids, e.g., decrease in food resources or temperature. The females produce broods of male 
offspring. Once adult, males will mate “females that have produced a limited number of haploid 
eggs” [163]. The fertilized eggs, also called ephippium [164] or ephippia, will pass through the 
stressing period and hatch when favorable conditions come back. 
 
Daphnids are aquatic arthropods whereas respiration occurs through gills or upon the surface of the 
whole body [162]. The thoraco-abdominal part is almost fused with the head. A large compound eye 
with small hyaline lenses is located in the frontal part of the head (Figure 1.3). Two pairs of antennae 
and two mandibles that are followed by two pairs of maxillae emerge from the head. The first pair of 
antennae (antennules) looks like small stiff and play a role in olfactory. The second pair of antennae is 
much larger and visible and allows jerky swimming (Figure 1.4). Muscles from the neck can move the 
antennae. The carapace has a bivalve appearance because it covers the body, except the ventral part 
that is open. Eggs are released through this opening abdominal part. The posterior extremity ends by a 
spine [162]. 
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Figure 1.3 Daphnia pulex head. Photos were taken using an Olympus polarisation microscope BX51 with a 
digital imaging system (Colorview) 
 
 
Figure 1.4 Daphnia pulex. A = second pair of antennae, B = head, C = heart, D = brood chamber with 
eggs, E = shell, F = apical spine, G = abdominal setae, H = intestine; I = thoracic appendages with filter 
setae from the filter apparatus. Photos were taken using an Olympus polarisation microscope BX51 with a 
digital imaging system (Colorview) 
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Daphnia pulex  
The Daphnia pulex is a common species that is spread mainly over the entire North American 
continent and found in various habitats [165]. The average life span of D. pulex reared in our 
laboratory conditions is approximately 45 days (annexe 2). Molting (ecdysis, shedding) is an 
important process that allows daphnids to grow. Growth occurs immediately after each shedding while 
the new carapace is still flexible. Molting is strongly linked to reproduction and this process is active 
over the entire daphnids life. When sexual maturity is reached, i.e., about 6.5 days after birth (± 1 day) 
in our laboratory, the exoskeleton shedding comes with the passage of eggs from ovaries to the brood 
chamber [163,166]. When the first clutch of eggs is fully developed in the ovary, the first offspring (= 
single instar) is produced. The released young are similar in form to the adults. During each adult 
instar, daphnids undergo four distinct periods that occur in few minutes: the birth of young, molting, 
growth, and the release of new eggs into the brood chamber where they will hatch [162]. Indeed, eggs 
are dismissed into the brood chamber within minutes after molting and the juveniles are released just 
before the next female molt. D. pulex commonly produces 3 to 9 eggs and usually has 18-25 adult 
instars. 
In our laboratory, D. pulex from the arenata strain was reared in conditions that maintained 
parthenogenetic reproduction: total hardness 90 ± 5 mg/l as CaCO3; pH 7.9 ± 0.2; conductivity 
adjusted to 25°C, 286 ± 14 µS/cm; dissolved oxygen > 5 mg/L (annexe 3). Stock daphnids as well as 
individuals exposed to chemicals were reared in glass beakers placed in a Coolstore® environmental 
chamber (16: 8 h light: dark photoperiods at 21 ± 1°C). D. pulex was fed with the unicellular algae 
Pseudokirchneriella subcapitata (annexe 4). To ensure lipid need, suspension of Tetramin® tropical 
fish food was also given daily to daphnids [72,167]. 
 
D. pulex estrogen-related receptor (ERR) and tyrosine kinase proteins 
D. pulex is the first crustacean to have its complete genome sequenced (see the website: 
wfleabase.org) and since, Thomson et al. [168] identified twenty-five nuclear receptor genes. A single 
copy of the estrogen-related receptor (dappu-ERR, NR3 subfamily) gene was found, which was close 
structurally to their human homologs ERRα, ERRβ and ERRγ, and close also to human ERα and ERβ 
[168]. In D. pulex, the endogenous ligands and the functions of the ERR family are unknown [168], 
but they may be involved in estrogen signalling and metabolism pathway [122,169]. In drosophile for 
instance, this gene is expressed in embryo’s development [170]. The presence of dappu-ERR may 
explain why daphnids could be sensitive to tamoxifen and its metabolites. Imatinib may also induce 
physiological disruptions in D. pulex during long-term exposure because tyrosine kinase family is 
present in this species, such as insulin-like peptides and insulin receptor, which belongs to an ancient 
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transmembrane receptor tyrosine kinase superfamily [171–173]. A variety of related tyrosine kinases 
are also present in eukaryote cells [171], such as in cells of aquatic or terrestrial invertebrates [173–
175], but the tyrosine signaling pathway has been extensively characterized in the fruitfly Drosophila 
melanogaster and less in other invertebrates. For instance, Brogiolo et al. [172] reported that insulin 
receptor plays a role in growth control that was conserved from insects to humans. 
 
Long-term and multigenerational ecotoxicity experiments 
Daphnids are key organisms in the food chain and they produce clones by parthenogenesis 
reproduction. Clones are very attractive in ecotoxicology and in proteomics because confounding 
genetic differences are avoided [176], which eases the observation and the comparison of phenotype 
modifications between treated individuals of any strain. Daphnids are an attractive model for 
multigenerational testing as they have a short time of reproduction. Furthermore, daphnids have a long 
history as model organisms in ecology, in evolution and in environmental studies (see the website: 
www.wfleabase.org). In ecotoxicology, they are also classically used [72,177] because of their high 
sensitivity to a large number of chemicals, their key place in the trophic chain (primary consumer) and 
their ease of handling [178–180]. Daphnids are suitable organisms for ecotoxicological tests [177] and 
their relatively short life and amenability to laboratory culture ease long-term tests. In the last few 
years, daphnids were already used successfully to highlight the negative effects of drugs on aquatic 
organisms. However, few results are available in the literature about the chronic toxicity (i.e., ≥ 1 
generation) of xenobiotics on daphnids. For instance, Brennan et al. [66] performed a 
multigenerational study on D. magna with the endocrine disruptors diethylstilbestrol and 17 β-
estradiol, a synthetic and a natural estrogen, respectively. The authors revealed a significant decrease 
in fertility over consecutive generations exposed to diethylstilbestrol, and an increase in adult 
daphnids mortality in the second generation (F2) that was exposed to 17 β-estradiol, compared with 
the first (F1). This difference in mortality between F1 and F2 may suggest that sensitivity increased in 
the second generation and that potential genetic or epigenetic damages were induced. Sanchez et al. 
[181] showed that the F1 generation of treated animals did not recover completely after having being 
transiently exposed to a pesticide. Finally, Campiche et al. [182] also reported transgenerational 
effects on springtails exposed to pesticides. 
Regarding anticancer drugs, their long-term effects on aquatic species are also rarely assessed. Hensel 
and al. [183] reported a higher sensitivity of daphnids during chronic exposure to methotrexate than in 
acute. In this experiment, the NOEC of methotrexate was indeed > 330 times lower than the acute 
EC50. A two-generational study was performed on the freshwater microcrustacean D. magna exposed 
to falsodex, a selective estrogen receptor modulator (SERM) that is prescribed in breast cancer. In this 
study Clubbs and Brook [184] reported NOEC values of 10 and 100 µg/L (nominal concentrations) in 
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the first and second generation, respectively. In a seven days experiment on the cladoceran crustaceans 
C. dubia exposed to the SERM tamoxifen, the concentration that induced effect on 50% of the test 
organisms (EC50) was 0.81 µg/L (nominal concentration). Five anticancer drugs (5-fluorouracil, 
capecitabin, cisplatin, etoposide and imatinib) were tested in a 21 days experiment that was performed 
on the rotifer B. calyciflorus and the crustaceans D. magna and C. dubia [156]. The toxicity of the 
chemicals was: cisplatin < 5-fluorouracil < imatinib < etoposide < capecitabin with EC10 that range 
from 0.25 µg/L for cisplatin to 2800 µg/L for capecitabin. 
These few examples show the importance of investigating multigenerational effects of chemical 
compounds. And this is particularly true in the case of pseudopersistent chemicals that may 
chronically interact with the physiological functions of aquatic species. Therefore, the prolonged 
presence of anticancer compound exposes the fauna and flora to potential long-term effects, which can 
adversely modulate eukaryotic organisms homeostasis [20,54] and also being magnified over 
generations. 
 
 
Thesis objectives and hypotheses 
The general objective of this thesis was to assess multigenerational effects of anticancer drug 
compounds on aquatic key species. This thesis is a multidisciplinary study, which involves 
ecotoxicity, toxicology and proteomic fields. Four objectives were met to increase knowledge on 
ecotoxicoproteomics with pharmaceuticals: 
 
1. Is D. pulex sensitive to anticancer drugs or to some of their metabolites? The first goal was to 
determine which relevant anticancer compounds would be used in ecotoxicology, among the 
recent and the traditional anticancer families. Imatinib belongs to the recent family, while 
tamoxifen belongs to the traditional and also to the hormonal anticancer classes. 
 
2. Which effects are induced by anticancer drug exposure on daphnids, and are the effective 
concentrations environmentally relevant? Ecotoxicological experiments were performed to 
determine the effective concentrations of the chosen anticancer drugs. Acute and long-term 
experiments, over generations, were performed to observe the effects of these chemicals on D. 
pulex. The experiments were carried out with imatinib, tamoxifen, 4-hydroxytamoxifen and 
endoxifen in controlled environmental conditions. 
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3. Are the effects observed at the organism level associated with sub-organism changes in the 
expression of certain proteins? Protein changes in daphnids exposed to tamoxifen were 
analysed and described using short and mid-term test exposure. These protein changes were 
compared to phenotype effects on treated daphnids. The biological levels studied in this thesis 
are summarised in Figure 1.5. 
 
4. Do protein changes provide suitable biomarkers for an early detection of drug-related stress of 
daphnids? This question links ecotoxicological experiments with proteomic analyses to find 
early evidence of chronic stress in daphnids.  
 
 
 
Figure 1.5: Consequences of pharmaceutical toxic effect at different level of the biological organisation, 
and relationship with the temporal scales of the response. Adapted from Lemos and al. [157] 
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Outlines of the thesis 
This thesis comprises results of different laboratory experiments that are presented in independent 
chapters.  
 
Chapter 2: Is D. pulex sensitive to tamoxifen? 
The aim of the first experimental study was to investigate whether D. pulex was sensitive to 
tamoxifen, using non-standardised acute and chronic experiments. The viability, the reproductive 
performance and the morphology of offspring were considered in quantitative or qualitative 
assessment. While the acute test has already shown unusual effects in treated daphnids, such as erratic 
swim or evisceration, the chronic assay shown embryo abnormalities on offspring, in particular, 
aborted eggs, premature neonate and body-malformations. The chronic effects of a solvent, the 
DMSO, that were used in ecotoxicological experiments to dilute tamoxifen and its metabolites are also 
presented in the first part of this chapter. 
In this chapter, the need to consider measured test concentrations rather than nominal was also 
underlined, particularly in ecotoxicological experiment with lipophilic molecules, such as tamoxifen. 
Tamoxifen stability in incubation media was assessed at different concentrations and times. Due to 
large differences between nominal and measured concentrations, and because sampling and analyses 
in long-term ecotoxicological experiments are time consuming and costly to be performed, a good 
prediction method was developed and proposed. This cost-effective method allowed us to predict test 
exposure levels that were calculated from measured concentrations. 
 
Chapter 3: Is D. pulex sensitive to tamoxifen metabolites (4OHTam and endoxifen)? 
In this chapter, two metabolites of tamoxifen, i.e., 4-hydroxy-tamoxifen (4OHTam) and endoxifen, 
were considered because these metabolites are potent anticancer molecules in humans and because 
their effects in aquatic organisms were unknown. Therefore, the main objective of this study was to 
assess the sensitivity of D. pulex towards 4OHTam and endoxifen in a two-generational experiment in 
which each generation was exposed to the chemical during 21 days. The reproduction, the size, the 
viability and the estimated population growth (r) were impaired in treated daphnids. The toxicity was 
higher with 4OHTam than with endoxifen. The stability of the chemical in the incubation medium was 
also assessed because the measured concentrations in test solutions did not correspond to the nominal. 
A predictive method, such as the method proposed with tamoxifen, was developed and used to predict 
the exposure level in the ecotoxicological experiment with 4OHTam and endoxifen. This predictive 
method was efficient and easier to apply than a regular follow up of the test solutions during long-term 
ecotoxicity studies. 
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Chapter 4: Multigenerational effects of tamoxifen and 4OHTam. Are the toxic effects magnified 
over four generations of D. pulex? 
The chapter four reports the design and the results of a multigenerational experiment that was 
performed with the anticancer drug tamoxifen and its metabolite 4OHTam. Multigenerational studies 
are sparse in ecotoxicology and it was necessary to design the experimental framework prior to 
starting the experiment. The experimental design was based on the previous two-generational 
experiments that were performed with 4OHTam and endoxifen (see chapter 2 and 3). Tamoxifen and 
4OHTam were chosen because they were more toxic than endoxifen in acute and long-term studies 
and because magnified effects over generations were suspected in these previous experiments. The 
aim of this study was to assess whether the sensitivity of daphnids increased over generations. The 
size, the reproduction, the viability and the intrinsic rate of natural increase (r) were followed within 
four generations of D. pulex exposed 14 days each to tamoxifen or 4OHTam. These studied end points 
were also observed in two prospective experiments. First, offspring from treated mothers were 
withdrawn from chemical to determine whether these descendants were able to recover. Second, 
neonates from treated and untreated parents were exposed to tamoxifen and 4OHTam used in 
combination. The results showed that tamoxifen and 4OHTam induced several effects in treated 
organisms. The effects on the four generations exposed to 4OHTam were not magnified, while they 
were over the successive generations exposed to tamoxifen. Also, the descendants withdrawn from the 
chemical solution were not able to recover because their size and reproduction performance were 
decreased at the end of the experiment. The reproductive performance of daphnids exposed to mixture 
of tamoxifen and 4OHTam was reduced, whilst no effect was observed when chemical test 
concentrations were tested individually. 
 
 
Chapter 5: Is D. pulex sensitive to imatinib? 
Imatinib is the fourth anticancer drug that was tested in this thesis. This pharmaceutical belongs to the 
recent generation of anticancer compound that has very specific mode of action in tumour cells. This 
drug was mainly chosen in prediction to its increased consumption worldwide. The aim of this study 
was to observe the sensitivity of two generations of D. pulex towards imatinib. The range of test 
concentration was chosen using a preliminary chronic experiment on a single generation exposed 21 
days to this chemical. The viability, the size, the reproduction and the intrinsic rate of natural increase 
were not impaired in D. pulex at the concentrations that were chosen in this experiment, except at the 
highest concentrations where the reproductive performance was decrease in the first treated 
generation. 
 26  
Chapter 6: Ecotoxicoproteomics with tamoxifen  
The aim of this ecotoxicoproteomic study was to identify and quantify proteins that were differentially 
expressed in daphnids exposed to tamoxifen. Because little were published on the extraction of 
daphnia proteins [74], it was necessary to design and to test an extraction procedure, prior to starting 
ecotoxicoproteomic experiments. The objective of this preliminary part was to determine an easy and 
efficient technic procedure to obtain sufficient qualitative and quantitative biological material. 
Therefore, this chapter presents the extraction procedure in daphnids as well as the protein analysis 
results after daphnids exposure to tamoxifen. 
 
Chapter 7: general discussion and conclusion 
The different results that were found during the ecotoxicological and proteomic experiments are 
summarised and discussed in this last chapter. The significance of these results in the aquatic system is 
considered and possible additional laboratory experiments are proposed to improve knowledge on the 
anticancer drugs and their metabolites in aquatic species. Four levels of action are reported to prevent 
pharmaceutical releases in the aquatic environment. Also, the potential impact of pharmaceutical on 
the ecosystem, including human, is briefly discussed. 
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Figure 1.6: Conceptual approach and outline of the thesis 
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Chapter 2  
 
 
Is D. pulex sensitive to tamoxifen? 
In this chapter the effects of the anticancer drug tamoxifen were assessed on D. pulex during acute and 
long-term experiments. Prior to these experiments, the effects of the solvent (i.e., DMSO) that was 
used to dissolve tamoxifen in water were evaluated in a two-generational study. No effects were 
observed in the DMSO at the percentage that would have been used during ecotoxicological 
experiments with tamoxifen. Therefore, experiments with this chemical and also with its metabolites 
were also conducted. The sensitivity of daphnids toward tamoxifen was observed using a non-standard 
ecotoxicological method. More precisely, quantitative or qualitative assessments were undertaken 
based on the following endpoints: size, viability, reproductive performance and morphology of the 
treated organisms and their offspring. Unusual effects in treated daphnids, such as erratic swim-pattern 
or evisceration, were observed in the acute experiments. In the chronic assay, tamoxifen induced 
morphological abnormalities on offspring, such as aborted eggs, premature neonates and body-
malformations. 
An additional experiment was carried out to assess tamoxifen stability in test solutions and at different 
times. Large differences were observed between nominal and measured concentrations. These 
differences lowered tamoxifen exposure during ecotoxicological experiments, and we assumed that 
adsorption phenomenon of tamoxifen on glass flasks was one of the reasons of the chemical loss. A 
regular follow up of the concentrations would have been required to ascertain tamoxifen exposure 
during ecotoxicological experiments, but because this follow up were cost and time consuming, it was 
necessary to develop a sustainable method to predict tamoxifen exposure during multigenerational 
experiments. Therefore, subsamples of some test solutions were analysed and the measured 
concentrations were plotted against their nominal levels. This polynomial regression was used to 
establish the so-called predicted concentrations. 
The first part of this chapter presents the two-generational experiment that was performed with 
DMSO. This preliminary steps was required to determine DMSO concentrations to be used in the two-
generational assay with tamoxifen. The second part of this chapter reports the toxic effects of 
tamoxifen in the two-generational study, the stability of tamoxifen in daphnia medium over times and 
the method to predict tamoxifen exposure in ecotoxicological experiments. 
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Long-term toxicity of DMSO as a solvent carrier in D. pulex experiments 
(addendum) 
 
Introduction 
Tamoxifen and its metabolites are molecules practically insoluble in water and they need to be 
dissolved initially in solvent carrier to prepare stock solutions. These stock solutions would later be 
diluted in daphnia medium to prepare the test solutions that would be used in ecotoxicological 
experiments. The organosulfur (CH3)2SO dimethyl sulfoxide (DMSO) is a solvent that is 
recommended to dissolve tamoxifen and its metabolites [1]. To the best of our knowledge, long-term 
effects on D. pulex exposed to DMSO have never been reported. Therefore, the reproductive effects of 
this solvent were assessed before ecotoxicological experiments were carried out with tamoxifen and its 
metabolites. The aim of this experiment was to ensure that no reproductive effects would be induced 
in treated organisms exposed ≥ 10-d to DMSO. 
 
Materials & Method 
Test organisms 
D. pulex from the arenata strain was mass-cultured in conditions that maintain parthenogenetic 
reproduction (total hardness 90 ± 5 mg/l as CaCO3; pH 7.9 ± 0.2; conductivity adjusted to 25°C, 286 ± 
14 µS/cm; dissolved oxygen > 5 mg/L). Stock daphnids and treated individuals were reared in glass 
beakers placed in a Coolstore® environmental chamber (16: 8 h light: dark photoperiods at 21 ± 1°C). 
Daphnids were fed daily with both 0.2 mgC/daphnia of Pseudokirchneriella subcapitata algae and 
suspension of Tetramin®[2,3]. The treated and untreated medium was renewed every two days.  
A potassium dichromate (K2Cr2O7) assay was performed at the beginning and at the end of the 
exposure period of each generation. The mean concentration that immobilised 50% of the treated 
individuals (EC50) were consistent with those regularly obtained in our laboratory (i.e., mean EC50 ± 
standard deviation: 0.75 ± 0.25 µg/mL). The position of the test tubes in the environmental chamber 
was randomised to minimise systematic errors. 
 
Two-generation testing procedure 
Two generations of D. pulex (i.e., F0 and F1) were exposed to the following percentage of DMOS: 0, 
0.0003, 0.0008, 0.002, 0.03, 0.12%. Eighteen neonates (< 24-h, > 3rd brood) were randomly selected 
from a single stock of mothers to form F0. These neonates were pipetted and placed in separate glass 
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beakers with 50 mL of medium (three replicates per concentration). On the twenty-first day of 
maternal exposure, eighteen neonates (< 24-h) were collected to form the generation F1. One neonate 
per beaker (three replicates) was transferred to 50 mL of corresponding maternal concentration 
medium. They were reared during eleven days. Every day since treated animals started to reproduce, 
neonates were removed from glass beakers and counted. Then, they were discarded except on day 21. 
 
Statistics 
The reproductive performance of the daphnids was expressed as the average number of neonates per 
adult at the end of the exposure period. The results were compared using a one-way ANOVA test 
followed by the Bonferroni correction  (α < 0.05). Calculations were carried out with GraphPad Prism 
(version 4.00 for Mac OS X, GraphPad Software, San Diego California USA, www.graphpad.com). 
 
Results and discussion 
Figure 2.1 summarised the reproductive performances of D. pulex when they were exposed to DMSO 
during 21st and 11th days. In each experiment, the average number of neonates was statistically not 
different from the blank (p < 0.05). During the multigenerational experiment that was performed with 
tamoxifen and its metabolite 4OHTam (see chapter 4), two DMSO-controls were carried out at the 
DMSO percentages of 0.002% and 0.01%. The reproductive performance of the two first generations 
is summarised in Figure 2.2.  In both experiments, the reproduction of treated daphnids was 
comparable with the controls. These results are in accordance to Barbosa et al. [4], who reported low 
chronic toxicity of DMSO on D. magna. Therefore, DMSO was considered as a solvent of choice for 
long-term assays and was used in all ecotoxicological experiments.  
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Figure 2.1: Reproduction of two generations (F0 and F1) of D. pulex exposed 21 and 11 days to different 
percentages of DMSO (mean ± SD, n = 18 for F0 and for F1). The reproduction is the mean number of 
neonates that were produced during the exposure period. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Reproduction of two generations (F0 and F1) of D. pulex exposed 14 days each to DMSO 
(mean ± SD, n = 48 for F0 and for F1). 
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Tamoxifen preliminary test to determine the long-term test concentrations 
The concentrations that were chosen for the two-generational study with tamoxifen, which is 
presented next, were determined based on previous ecotoxicological experiments. These preliminary 
tests were performed in accordance with the experiments that are presented in this thesis. Briefly, 
acute pre-tests (48 hours of exposure, no replicates, n = 86) had preceded the acute experiment (48 
hours of exposure, 3 replicates, n = 167). The studied end points were death and viability after 2 days 
of exposure. In the chronic pre-test, daphnids were exposed 21 days to tamoxifen (no replicate, n = 
10), and the studied end points were death and the total neonates produced per individual. Figure 2.3 
summarised two points: 1) the predicted and the nominal concentrations that were used during each 
test (for more information on predicted concentrations see subsection “Predicted tamoxifen 
concentrations in ecotoxicity tests”), 2) the occurrence of adverse effects in D. pulex. The dotted zones 
are uncertainty areas in which toxic effect may be possible. In this figure, the so -called chronic test 
represents the two-generational experiment that is presented in the next section (see: “Tamoxifen, a 
molecule to consider in ecotoxicology?”). In this two-generational experiment, the range of test 
concentrations was determined based on the acute and the pre-chronic test results that are summarised 
in Figure 2.3.  
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Figure 2.3: Nominal vs predicted concentrations of tamoxifen used in ecotoxicological experiments (acute 
and chronic tests and pre-tests), and occurence of effects on D. pulex exposed to this chemical. In the acute 
pre-test (n = 86) and the acute test (n = 167), the studied end points were death and viability after 2 days 
of exposure. In the pre-chronic (21 days, n = 10) and chronic experiments (21 and 12 days for F0 and F1, 
respectively), the studied end points were death and the total neonates produced per individual (n = 18 
and 17 for F0 and F1, respectively). The dotted zones are uncertainty areas in which toxic effect may be 
possible. 
Nominal 
(µg/L)
Predicted 
(µg/L)
Acute 
pre-test
Acute 
test
Chronic 
pre-test
F0 F0 F1
2 0.15 x x x
4 0.23 x x x
8 0.37
17 0.64 x
20 0.72 x x x
33 1.08
66 1.91 x
102 2.79 x
132 3.51 x
142 3.76 x
199 5.12 x
200 5.15 x
220 5.63 x
264 6.69 x x
279 7.05 x
317 7.97 x
381 9.54 x
390 9.76 x
457 11.41 x
547 13.66 x
548 13.68 x no effect
658 16.47 x effects
765 19.22 x uncertity
789 19.84 x
947 23.99 x
1070 27.27 x
1500 39.12 x
x x x x xControl (DMSO)
Tamoxifen
Death & viability 
(%)
Reproduction (mean)
Chronic test
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Tamoxifen, a molecule to consider in ecotoxicology? 
 
 
Abstract 
Tamoxifen is widely prescribed worldwide for the prevention and treatment of hormone receptor-
positive breast cancer. Tamoxifen undergoes faecal excretion and is poorly removed by sewage 
treatment plants (STPs). It has been found in STP effluents and in natural waters in concentrations up 
to 0.3 µg/L and 0.2 µg/L, respectively. The aim of this study was to assess the acute and long-term 
(i.e., over two generations) toxicity of tamoxifen on Daphnia pulex, a freshwater microcrustacean 
crucial for the aquatic food chain. While the acute effect concentration 50% (EC50) was 13 µg/L, in 
chronic exposure tamoxifen decreased reproduction in daphnids already at a concentration of 5.15 
µg/L. These EC50 estimates were obtained through measurement of actual exposure concentrations, 
shown to significantly deviate from calculated levels for such a hydrophobic molecule. In addition, 
tamoxifen induced teratogenic effects on the offspring, such as miscarriages and morphological 
abnormalities. The latter occurred at lower concentrations than those effects that disrupted 
reproduction. The no observed effect concentration (NOEC) that was calculated for reproduction was 
0.72 µg/L, whereas the NOEC was < 0.15 µg/L when based on morphological abnormalities. These 
effects raise questions regarding the potential impact of tamoxifen and related anticancer drugs on 
aquatic ecosystems, in particular with respect of their growing therapeutic use. 
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Introduction 
Unprecedented amounts and varieties of pharmaceuticals are released continuously into the aquatic 
environment (for review, see [5,6]). The daily human consumption of pharmaceuticals to treat or 
prevent medical ailments amounts to thousands of tons of active substances worldwide [7]. After 
metabolism, these pharmaceuticals are excreted from the body in their intact or metabolised forms into 
sewage water networks and are transported to a sewage treatment plant (STP). Because conventional 
STPs are less efficient for chemicals than for organic matter [8], several pharmaceuticals escape STP 
degradation processes and are discharged into the aquatic environment with STP effluents [9–13]. 
These chemical residues often carry specific pharmacological activities that are susceptible to 
interacting with biological processes, which cause growing concerns regarding their potential adverse 
effects on the health and integrity of our living environment [14,15]. 
Among other pharmaceuticals, the presence of anticancer agents in aquatic systems is of special 
concern primarily because of their potential mutagenic, carcinogenic, teratogenic and/or embyotoxic 
properties [16,17]. These agents indeed do not exclusively target abnormal cells but interact as well 
with normal cells in the body. For instance, cytostatic agents that are used to treat malignant neoplastic 
diseases have the potential to increase the incidence of secondary tumours in animals and humans 
[18]. Moreover, demands for chemotherapy treatment have grown by 10% per year in industrial 
countries [19], which also indicates that the total amount of chemotherapy pharmaceuticals that are 
discharged in the environment is constantly increasing. For many years, researchers have highlighted 
the requirement to assess the risk of these chemicals to the aquatic environment [5,8,9,11,20,21]. 
Similarly, Dang et al. [22] overviewed the scientific efforts that have been devoted to hormone 
analogues that are found in surface water because these compounds induce endocrine-disrupting 
effects primarily in the reproductive system of living organisms, such as daphnids and fish. This group 
of molecules includes pharmaceuticals that are used in oral contraception, hormone replacement 
therapy, bone disorders and cancer treatments.  
Tamoxifen is a chemotherapeutic anti-oestrogen drug compound that is widely prescribed worldwide 
for the prevention and treatment of hormone receptor-positive breast cancer [18,23,24]. Basically, 
tamoxifen is considered a selective oestrogen receptor modulator that behaves not only as both a 
partial agonist and antagonist on alpha oestrogen receptors (ERα) but also as a partial agonist on beta 
oestrogen receptors (ERβ). Its action on breast cancer cells might also be explained by its ability to 
bind one of the three estrogen-related receptors (ERRs) described in humans [25]. In stromal breast 
cells, tamoxifen’s primary action is cytostatic [26]; however, tamoxifen is also able to control cell 
replication through nuclear interactions or through mechanisms involving growth factors. This 
pharmaceutical might also relieve Duchenne muscular dystrophy, which is a striated muscle disease 
that currently has no treatment [27]. In animals, tamoxifen is sometimes given in poultry as a growth 
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promoter or to laboratory rodents to trigger gene expression in specific tissues [28,29]. Tamoxifen has 
been recognised to cause various side effects, such as DNA-adducts formation, epigenetic 
dysregulation, genotoxicity and carcinogenicity, as recently acknowledged by the International 
Agency for Research on Cancer [30–37]. 
Regarding tamoxifen use in humans, patients are orally administered 20-40 mg of tamoxifen per day 
[31] sometimes after loading doses of 80 to 200 mg for 1 to 7 days [38]. The treatment is usually taken 
for 5 years or according to its efficacy and safety in the case of metastatic hormone-dependent breast 
cancer. Longer durations might even become advised [39]. Tamoxifen is partly metabolised in the 
organism and ultimately undergoes faecal excretion through the biliary route with an enterohepatic 
cycle [38,40]. Studies reported that approximately 30% of the dose was excreted in its unconjugated 
form in faeces, of which tamoxifen and its 4-hydroxy-tamoxifen metabolite were the predominant 
compounds [40,41]. Tamoxifen is not readily biodegradable [42] and has a high bioaccumulation 
potential with an experimental logP of 7.1 [43]. Similar to other anticancer agents, tamoxifen escapes 
STP degradation processes [44–46] and was measured in STP effluents in concentrations ranging from 
0.02 to 0.37 µg/L [47–49]. Tamoxifen was also found in the natural aquatic environment with 
concentrations ranging from 0.01 to 0.21 µg/L [49,50]. Due to its bioaccumulation potential and its 
toxicity to non-human organisms, tamoxifen was recently identified as requiring priority assessment 
[51].  
The aim of this study was thus to assess the acute and long-term (i.e., over two generations) toxicity of 
tamoxifen on Daphnia pulex. Daphnids are aquatic organism extensively used as test animals in 
ecotoxicology because of their sensitivity to xenobiotics, their key role in the trophic chain, and their 
short life cycle that allows experiments on several generations. Although daphnids lack ERs, a single 
copy of the ERR gene (dappu-ERR, 3 subfamily) was recently found in D. pulex [52], which may 
result in sensitivity to tamoxifen. To assess this sensitivity, non-standard endpoints, beyond 
reproduction, were considered in the acute and two-generation experiments. Indeed, Kim et al. 
recently highlighted the importance of studying the effects of pharmaceuticals on non-target species 
based on non-traditional endpoints [53]. Some of these endpoints are qualitative but they may be 
considered as relevant for risk assessment. Furthermore, because tamoxifen has low solubility in water 
(< 0.5 mg/L [54]) and tends to be adsorbed on surfaces of the glass flasks, we were confronted to the 
challenge of estimating its actual water concentration during our experiments. Therefore, we proposed 
a cost-effective method to predict real exposure levels from nominal concentrations. 
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Materials & Methods 
Chemicals  
Tamoxifen was purchased from Sigma/Fluka (>99%, lot: 011M1682V). For the ecotoxicological 
experiments, two stock solutions were prepared in pure DMSO 
(www.gaylordchemical.com/index.php?page=102b-dmso-solubility-data) at nominal concentrations of 
10 g/L and 2.5 g/L for acute and two-generational tests, respectively. Another stock solution was 
prepared at a nominal concentration of 1.6 E+07 µg/L for the experiment that was dedicated to assess 
the stability of tamoxifen in daphnia medium (see subsection “Tamoxifen stability in medium”). The 
three stock solutions were prepared in glass flasks with plastic caps a day before tests were performed 
and were stored in the dark at -80°C for no longer than the test duration. These stock solutions were 
thawed at room temperature before each use. 
 
Tamoxifen experiments 
Test organisms 
Individuals from the arenata strain of D. pulex were kindly provided by the Eawag Department of 
Aquatic Ecology (www.eawag.ch/forschung/eco/index_EN). These organisms were fed daily with 
both 0.2 mgC/daphnia of Pseudokirchneriella subcapitata algae and a suspension of the tropical fish 
food Tetramin® [55,3]. Individuals were mass-cultured in conditions that maintained parthenogenetic 
reproduction as follows: Elendt M4 [3] with a total water hardness of 93 ± 3 mg/L CaCO3 [56]; pH 7.8 
± 0.3; conductivity adjusted to 25°C, 285 ± 15 µS/cm; and dissolved oxygen, >5 mg/L. These 
chemical parameters were measured regularly, and also at the beginning and end of the experiments to 
ascertain the quality of the medium. Stock daphnids, as well as individuals that were exposed to 
tamoxifen, were reared in a Coolstore® environmental chamber, with 16 : 8 h light : dark 
photoperiods, at 21 ± 1°C. A potassium dichromate (K2Cr2O7) assay was performed at the beginning 
and end of each test to verify daphnia sensitivity, and the mean concentration that induced 50% effects 
(EC50) were consistent with our previous laboratory results (mean EC50 ± standard deviation: 0.75 ± 
0.25 µg/mL). The position of the test tubes in the environmental chamber was randomised to minimise 
systematic errors. 
 
Acute toxicity experiment 
The tamoxifen acute toxicity assay was performed over 48 hours exposure. One hundred and sixty-
seven neonates (< 24 h, > 3rd brood) were randomly placed in glass tubes at the following tamoxifen 
concentrations: 5.63, 6.69, 7.97, 9.54, 11.41, 13.68, 16.47, 19.84 and 23.99 µg/L (five individuals per 
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vessel, 3 replicates). These levels of exposure were predicted from measured concentrations (see 
subsection “Predicted tamoxifen concentrations in ecotoxicity tests”) and they correspond to the 
following nominal concentrations: 220, 264, 317, 381, 457, 548, 658, 789, 947 µg/L. Two controls 
were performed in parallel: a blank (i.e., with no drug or solvent) and a solvent control that contained 
DMSO 0.009%, which corresponded to the maximum solvent percentage that was used for the test 
concentrations. 
The studied endpoints were death and viability. Daphnids were counted as nonviable when the 
organisms showed evident signs of damage that could be observed by the naked eye, such as tissue 
deterioration (even if the organisms were able to swim), or by the immobilisation of living daphnids > 
20 seconds in the middle of the tube, despite gentle agitation. These endpoints were observed after 24 
and 48 h of exposure. 
 
Two-generation toxicity experiment 
The experimental design of the tamoxifen chronic test is shown in Figure 2.4. Twenty-one neonates (< 
24 h, > 3rd brood) were randomly isolated from a single stock of mothers to form the first generation 
(F0) that was exposed to tamoxifen. One individual per glass beaker (three replicates per 
concentration) was placed in 50 ml of the following predicted concentrations of tamoxifen: 0.15, 0.23, 
0.72, or 5.15 µg/L, which corresponded to the nominal concentrations of 2, 4, 20, 200 µg/L, 
respectively (see subsection “Predicted tamoxifen concentrations in ecotoxicity tests”). Daphnids were 
exposed continuously to the same concentration for 21 days. At the 6th laying (i.e., approximately the 
17.5th day), eighteen neonates were randomly selected to form the second generation (F1). Because a 
significant decrease in reproduction was already recorded for the F0 parents, the 5.15 µg/L 
concentration was not tested on the F1 generation. The neonates were individually placed in 50 mL of 
the corresponding maternal concentration for 12 days (three replicates per concentration). Indeed, 
preliminary chronic experiments showed that a 12-d exposure period was sufficient for highlighting 
the reproductive tendency. For F0 and F1 experiments, two controls were performed in parallel: a 
solvent control with 0.0008% of DMSO and a blank; both controls were composed of one individual 
per glass beaker (three and six replicates, respectively). Daphnids were fed daily with 0.2 
mgC/daphnia of P. subcapitata algae and Tetramin® [55,3]. 
The mortality (i.e., the number of dead parents) and the number of neonates in each incubation beaker 
were recorded daily. Then, the neonates were discarded, except those of the 6th laying. At each 
concentration, the reproductive performance of daphnids was expressed as the average number of 
neonates per adult that was released during the entire exposure period. Morphological abnormalities of 
offspring (e.g., body-deformed individuals) from the F0 generation were discovered during the 
experiment. Thus, randomly chosen neonates from each beaker were examined using an Olympus 
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polarisation microscope BX51 with a digital imaging system (Colorview). When morphological 
abnormalities were found, the day and the type of abnormalities were recorded. In addition to this 
qualitative assessment, small and incompletely developed neonates, which are designated here as 
“premature neonates”, were isolated and exposed to the same maternal concentration to assess their 
viability and reproductive ability (one premature neonate at 0.15 µg/L and two at 0.72 µg/L of 
tamoxifen). Because only one or two premature neonates per brood were released, no replicates were 
performed. 
 
 
Figure 2.4: Design of a two-generation toxicity study on D. pulex. A single organism per beaker was 
exposed to increasing concentrations of tamoxifen. The exposure is expressed in predicted concentrations 
and their corresponding nominal concentrations are given once in brackets. On the 6th laying, normal and 
premature neonates were kept to form the second generation. The concentration at 5.15 µg/L was not 
tested because significant reproductive effects were already observed in F0.  * three replicates ** six 
replicates, *** one and **** two premature neonates were exposed to 0.15 and 0.72 µg/L, respectively 
 
 
Predicted tamoxifen concentrations in ecotoxicity tests 
One hundred and forty-six aliquots of tamoxifen solutions (without daphnia and food) were collected 
and analysed during ecotoxicological experiments that were performed on daphnids over a period of 
18-months in our lab. Aliquots of the tamoxifen solutions were collected in PP microtubes 
immediately after preparation (t0) or after 48 h (t48) of exposure to the environmental chamber 
conditions. The aliquots were immediately frozen at –80°C until analyses. Tamoxifen concentrations 
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were determined using liquid chromatography which was coupled to a triple stage tandem mass 
spectrometry system (LC-MS/MS) using an adaptation of a method that was developed and validated 
at the Laboratory of Clinical Pharmacology at CHUV (University Hospital Center Lausanne, 
Switzerland) [57]. The limit of quantification (LOQ) of the LC-MS/MS assay for tamoxifen is 0.5 
ng/mL. This multiplex method also allows the assay of the metabolites E/Z- endoxifen, N-
demethyltamoxifen and 4-hydroxy-tamoxifen with LOQs of 0.5, 1.0 and 0.2 ng/mL, respectively. 
 
Tamoxifen stability in medium 
Due to the large differences that were observed between the nominal and measured concentrations of 
tamoxifen in the incubation medium, we performed an additional experiment to assess its 
concentration changes over time. Two methods were performed in parallel in the absence of daphnids, 
with the experimental design shown in Figure 2.5. Two final solutions (50 mL each) were prepared in 
duplicate with both methods, which were either supplemented with or without daphnia food. The 
dilutions were prepared using the incubation medium M4 [3] in laboratory glassware. 
In method 1, the nominal tamoxifen concentrations in final solutions were 3.2 and 320 µg/L with 
DMSO percentages of 0.00002 and 0.002%, respectively. These solvent percentages were kept as low 
as possible to avoid any influence of DMSO if ecotoxicity tests would have been run on the 
organisms. However, in this case, the concentrations of tamoxifen were above its reported solubility 
level in water (< 0.5 mg/L [54]). In method 2, the nominal tamoxifen concentrations were 1.6 and 160 
µg/L. The DMSO percentage was maintained at 0.1% in the final solutions to ensure a sufficient 
solubility for tamoxifen. For the final solutions that were supplemented with food, the quantity of 
proteins and lipids corresponded to the diet of a single daphnia that would have been reared in 50 mL 
of medium volume (i.e., 25 µl of the tropical fish food Tetramin® and 0.2 mgC/daphnia of P. 
subcapitata [58]). All final solutions were stored for 48 h in a Coolstore® environmental chamber, 
with 16:8 h light:dark photoperiods, at 21 ± 1°C. These conditions correspond to those conditions that 
were used in our ecotoxicological tests. 
Finally, the final test solutions were collected in PP microtubes (400 µg/L, 3 replicates) immediately 
after preparation (t0), and after 12 h (t12), 24 h (t24) and 48 h (t48) of exposure to the environmental 
chamber conditions. These solutions were then frozen and eventually analysed as described in 
subsection “Predicted tamoxifen concentrations in ecotoxicity tests”. 
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Figure 2.5: Experimental design of the analytical experiment that was performed with tamoxifen (nominal 
concentrations). Each step was performed using laboratory glassware. The volume of final concentrations 
was 50 ml. Sampling was performed at four different times. Food refers to the algae and lipids diet for a 
single daphnia 
 
 
Statistics  
Ecotoxicity experiments  
For the acute toxicity test, dose-response curves were plotted using nonlinear regression (sigmoidal 
dose-response), from which the acute effect concentration 50% (EC50) and its confidence intervals 
were calculated. For the two-generation test, reproduction was first compared between the blank and 
solvent controls using a one-way ANOVA with Bonferroni correction (α < 0.05). Because no 
significant differences were observed, the solvent control was used as a unique control for each 
ANOVA comparison with the Bonferroni correction (α < 0.05). Calculations were performed using 
the software GraphPad Prism (version 4.00 for Mac OS X, GraphPad Software, San Diego California 
USA, www.graphpad.com).  
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Tamoxifen stability 
Regarding tamoxifen stability in daphnia medium, the mean of the measured concentrations was 
compared either over time or between solutions that were supplemented with or without daphnia food. 
Statistically significant differences in means between times or solutions were calculated at the 95.0% 
confidence level using Fisher's least significant difference procedure (Statgraphics Centurion software, 
version 16.07 for Windows, Virginia USA, www.statgraphics.com). 
 
Results 
Predicted tamoxifen concentrations in ecotoxicity tests 
Tamoxifen is poorly soluble in water and tends to be adsorbed on surfaces of the glass flasks. 
Therefore, tamoxifen concentration was measured in some of the incubation media (without daphnia 
and food) to ascertain the actual drug exposure of daphnids during the acute and two-generation 
experiments. All measured concentrations were plotted against their respective nominal concentration 
and were fitted using a nonlinear regression analysis (Figure 2.6). The equation of the fitted model 
was: 
Ln(cP) = -3.67305 + 1.0503*Ln(nC) + 0.0363642*Ln(nC)2    (2.1) 
Where cP = predicted concentration; nC = nominal concentration; and unit = µg/mL (r2 = 0.93, 
residual plots were used to check that the assumptions for regression analysis were met). This 
regression can be used to extrapolate the actual tamoxifen exposure concentration from nominal 
concentrations. In the absence of evidence for systematic effects of time or daphnia food, the results of 
both acute and two-generation toxicity experiments are expressed as a function of the predicted 
concentrations that were calculated using Equation 2.1. 
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Figure 2.6: Relation between measured and nominal concentrations of tamoxifen (natural log). One 
hundred and forty-six samples were taken in solutions without daphnia and food. The graph shows the 
95.0% prediction intervals for new examination (i.e. predicted concentration) and 95.0% confidence 
intervals for the mean of observations. The prediction and confidence intervals correspond to the inner 
and outer bounds, respectively, on the graph of the fitted model. Unit = µg/mL 
 
 
Tamoxifen stability in medium 
Comparison between nominal and measured concentrations 
Major differences were highlighted between the nominal and measured concentrations of tamoxifen, 
following either dilution method 1 or 2 (Table 2.1). With method 1 (solvent < 0.1%), all mean 
measured concentrations were at least 90% lower than the nominal, excepted for the pre-dilution 
solution (solvent = 0.02%), whose concentration decreased only by 81.7%. With method 2 (solvent = 
0.1%), the solutions with 1.6 and 160 µg/L had measured concentrations between 74.4 and 99.5% 
lower than the nominal. In solutions of 1.6 µg/L, the discrepancy increased with time, and the 
concentrations that were measured after 24 h were 90% lower than the nominal. With methods 1 and 
2, intra-concentration variability was found primarily in solutions that were freshly prepared (t0). 
Conversely, the solutions with 100% of solvent, i.e., the stock and pre-diluted solutions of method 2, 
had mean measured concentrations 9.1% and 5.8% higher than the nominal, respectively. 
 
 54 
 
Table 2.1: Nominal and measured concentrations of tamoxifen using two different methods. Method 1 was 
performed with a low DMSO percentage that did not increase significantly tamoxifen solubility, whereas 
method 2 maintained both tamoxifen solubility and a high DMSO percentage. The final concentrations 
were prepared with (regular characters) or without (bold characters) the addition of daphnia food. Δ is 
the difference between nominal and measured concentrations in % 
 
 
Comparison between the measured concentrations 
The mean measured concentrations were not significantly different in five of the eight final solutions, 
when compared with the initial concentration at t0 (Table 2.1). Only for the solutions of 1.6 µg/L (with 
food), 160 µg/L (with food) and 320 µg/L (without food) did the mean measured concentrations 
decrease by up to 67%, 93% and 77% at t12, t24, and t48, respectively.  
At t12, t24 and t48, no significant differences in concentrations were observed between most solutions 
supplemented with or without daphnia food. Only two solutions that were supplemented with food 
showed significantly higher concentrations than the corresponding solutions without food, namely the 
solutions of 1.6 and 160 µg/L at t0 (by 56% and 75%, p < 0.05, respectively), while an opposite trend 
was found at 3.2 µg/L (mean measured concentration 45% lower on supplementation with food).  
Time 
(h)
DMSO   
(%)
Nominal 
(μg/L)
Stock solution 0 100 1.60E+07
pre-diluted solution 0 0.02 3200
concentration 1 0 0.002 320 8.023 8.738 3.615 2.697 97.5 97.3
concentration 1 12 0.002 320 3.665 * 3.366 0.850 0.510 98.9 98.9
concentration 1 24 0.002 320 2.559 * 6.551 1.252 6.914 99.2 98.0
concentration 1 48 0.002 320 1.808 * 2.049 0.168 0.459 99.4 99.4
concentration 2 0 0.00002 3.2 0.309 0.169 ★ 0.132 0.065 90.3 94.7
concentration 2 12 0.00002 3.2 0.142 0.149 0.035 0.018 95.6 95.3
concentration 2 24 0.00002 3.2 0.227 0.148 0.100 0.048 92.9 95.4
concentration 2 48 0.00002 3.2 0.198 0.145 0.038 0.052 93.8 95.5
pre-diluted solution 0 100 1.60E+05
concentration 1 0 0.1 160 2.004 8.135 ★ 0.729 3.383 98.7 94.9
concentratios 1 12 0.1 160 1.367 1.957 * 0.082 0.521 99.1 98.8
concentration 1 24 0.1 160 2.502 1.473 * 0.907 0.427 98.4 99.1
concentration 1 48 0.1 160 0.726 0.547 * 0.049 0.156 99.5 99.7
concentration 2 0 0.1 1.6 0.179 0.410 ★ 0.070 0.188 88.8 74.4
concentration 2 12 0.1 1.6 0.186 0.219 * 0.017 0.027 88.4 86.3
concentration 2 24 0.1 1.6 0.138 0.135 * 0.036 0.020 91.4 91.5
concentration 2 48 0.1 1.6 0.165 0.155 * 0.080 0.047 89.7 90.3
*  p < 0.05 when compared to t0
★ p < 0.05 when compared to solution without food addition
M
eth
od
 1
585.608 82.245 81.7
M
eth
od
 2
1.45E+05 9.39E+03 9.1
5.8
Δ concentration 
(%)TAMOXIFEN
Measured mean 
(μg/L) SD
1.51E+07 1.65E+06
 55 
 
Acute toxicity experiments 
Daphnid viability was assessed using two parameters: the immobilisation of the organisms for >20 
seconds and visual signs of tissue damage. The concentration that impaired the viability in 50% of the 
daphnids was 13 µg/L (CI 95%: 12.1 to 13.8, Figure 2.7). At concentrations of 19.8 µg/L and higher, 
organisms with internal tissues hanging from abdomen were observed. The tissues appeared as long 
fibres or as cluster of cells. Surprisingly, daphnids with these severe signs of damage were still able to 
swim. However, we hypothesised that daphnids whose organs were hanging were animals that could 
not escape predators in the environment and were counted as nonviable. Already at the lowest 
concentration, few daphnids swam with low energy or stopped moving for 15-20 seconds before 
suddenly resuming normal, energetic swimming. 
 
 
Figure 2.7: Tamoxifen acute experiment in D. pulex. The effects are death and viability (mean ± SEM, n = 
167). The EC50 is 13 µg/L. The exposure levels are expressed in predicted concentrations and their 
corresponding nominal concentrations are given on the right. 
 
 
Two-generation toxicity experiments 
Figure 2.8 shows the reproductive performance of both generations after 12 days of exposure to 
tamoxifen. The F0 and F1 generations began to release offspring approximately on the 6th day after 
birth, as expected. For the F0 organisms that were exposed to 5.15 µg/L of tamoxifen, the total number 
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of neonates decreased significantly (p < 0.05) compared with the solvent controls, namely by 58.2 and 
40.0% after 12-d and 21-d of exposure, respectively (Table 2.2). No significant difference was found 
for other concentrations. In addition to reproductive impairment, aborted eggs and/or morphological 
abnormalities were observed in offspring from the F0 parents that were exposed to lower 
concentrations, i.e., 0.15, 0.23 and 0.72 µg/L of tamoxifen. The occurrence of these abnormal events 
and a qualitative example of abnormalities are provided in Table 2.2 and Figure 2.9, respectively. The 
first embryonic developmental abnormalities appeared on the 7th day of exposure at 0.23 and 0.72 
µg/L, as well as after 13 days at 0.15 µg/L. Dead neonates were recorded at 0.72 µg/L but not at the 
other concentrations. Aborted eggs were observed in a single beaker of solvent control on the 7th day, 
whereas a single premature neonate was pipetted in a blank on the 15th day. Interestingly, no 
abnormalities were observed at 5.15 µg/L (with the exception of the significant drop on reproduction) 
in the F1 generation either. 
 
Table 2.2: Reproduction and occurrence of abnormal events in the D. pulex generation F0. The 
reproduction is the total number of neonates produced after 21-d of exposure. The number of living 
individuals are compared to the total of tested individuals, * occurrence of abnormal events, such as 
aborted eggs or morphological abnormalities. 
 
 
 
The reproduction of the F1 generation that was exposed to 0.15 µg/L was statistically higher than both 
solvent controls and the F0 generation, by 17.6 and 43.1%, respectively. At 0.23 µg/L, an individual 
died on the 8th and 10th days of the experiment, and the third individual was lost on the 3rd day. The 
reproduction of premature neonates (F1) that were exposed for 12-d to tamoxifen was also assessed. 
At 0.15 and 0.72 µg/L, their reproductive capacity was reduced by 39 and 35.6%, respectively, when 
compared with their mature sisters exposed to the same concentrations, and by 2.3 and 3.3%, 
respectively, when compared with solvent controls (Figure 2.8). 
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
0.15 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3a 3/3a 3/3a 3/3a 3/3 3/3 3/3 3/3 3/3 125
0.23 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3a 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3a 3/3 3/3a 3/3 3/3 3/3 117
0.72 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3a 3/3a 3/3a 3/3 3/3 3/3 2/3 2/3 2/3a 2/3 2/3a 2/3 2/3a 2/3 2/3 110
5.15 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 2/3 2/3 2/3 2/3 2/3 2/3 46
Blank 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 5/6 5/6 5/6a 5/6 5/6 5/6 5/6 5/6 5/6 113
Solvent 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3a 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 110
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Figure 2.8: Reproduction of F0 and F1 generation of D. pulex in the two-generation study. F0 was exposed 
21 days to the chemical, while F1 was exposed 13 days (mean ±  SD, n = 21 for F0, and n = 18 and 3 for F1 
normal and F1 premature neonates, respectively). The concentrations are predicted from measured 
concentrations. Reproduction is the total number of neonates per female. The grey squares are the 
reproduction effects on F1 premature neonates * p < 0.05 
 
 
 
 
Figure 2.9: Reproductive and developmental toxicity effects of tamoxifen on D. pulex offspring. (a) 
Neonate < 24 h from control (blank); (b) premature neonate with temporary abnormal development: 2-
fold smaller than a 24 h neonate from controls, able to swim; (c-d-e) neonates with abnormal morphology: 
2 to 3-fold smaller than blank, aged < 24 h, dead or not able to swim, body-deformed, found on the bottom 
of the beakers; (f) spontaneous aborted egg found on the bottom of the beaker 
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Discussion 
The results of our experiments show that tamoxifen induces acute toxic effects on D. pulex at the µg/L 
order of exposure. In the literature, a single study reported the acute effects of this pharmaceutical on 
D. magna but at higher concentrations [59]. The authors estimated an EC50 of 1530 µg/L, which is 
approximately 118-fold the EC50 that was observed in our experiment. Although differences in 
sensitivity may be observed in species that belong to the same Daphnia genus, no major differences in 
overall sensitivity towards several chemicals were found between D. pulex and D. magna [60]. 
Therefore, this discrepancy might be rather due to the use of nominal instead of measured 
concentrations. In our study indeed, the acute EC50 based on nominal concentrations would have been 
516 µg/L instead of 13 µg/L, which is, therefore, much closer to the EC50 that was found in the 
DellaGreca study. This comparison highlights the importance of controlling the tested concentrations 
with analytical measurements, whenever possible. If a difference exist between measured and nominal 
exposure, it is crucial to express the results in terms of measured concentrations or of concentrations 
predicted from analytical results, rather than in terms of nominal levels (i.e. theoretical concentrations 
that were deduced from dilution procedures). In this study, we decided not to use nominal 
concentrations and we question the use of these values in ecotoxicology. Indeed, we raise the issue of 
assessing actual test exposure, as already advocated here and there in the toxicological literature, 
including for human trials [61], or purely in vitro assays, when physicochemical properties of 
chemicals, such as lipophilicity, volatility, stability, etc., may lead to chemical losses and may affect 
toxicity assessments [62]. Eventually, the use of nominal values can lead to an underestimation of the 
risk of chemicals to the aquatic flora and fauna. Unfortunately, the nominal concentrations (i.e., 
without analytical verification) remain often used in publications. A survey of the 2012 publications in 
the journal Environmental Toxicology and Chemistry showed that among seventy-three tested 
chemicals, the concentrations of 45% were not measured, although 23% of them were suspected to be 
poorly hydrophilic (LogKow > 3), as it is the case for tamoxifen. The major reason why nominal 
concentrations of lipophilic molecules are still often used is probably the burden of analyses. Indeed, 
analysing each test concentration is time and cost consuming, particularly in long-term 
ecotoxicological experiments. Therefore, an efficient prediction method might represent an interesting 
alternative to derivate effect levels close to real exposure concentrations. For instance, Groothuis et al. 
[62] recommend an algorithm for appropriate and feasible dose measurement to improve toxicological 
risk assessment. In this study, we propose a predictive method for tamoxifen exposure that can be 
applied to any long-term aquatic experiment. First, we assessed the stability of tamoxifen in daphnia 
medium (without daphnids but in the presence and absence of food). Then, we randomly selected the 
test solutions that were intended to be analysed in the two-generation experiment. The concentrations 
that were measured prior to this long-term test, i.e., during pre-tests, acute tests and stability 
experiment, were also considered in this model. The measured concentrations of tamoxifen that were 
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determined during these experiments were plotted against their respective nominal level to establish 
the relationship between the nominal and measured concentrations. A nonlinear regression was finally 
used to predict the non-measured test concentrations. Although this method does not fully override the 
need for systematic and regular sampling, this approach spares workload and still prevents the use of 
nominal concentrations and, thus, the risk of misleading conclusions that is based on overestimated 
exposure levels. 
As expected indeed, the analytical results showed major differences in concentrations between the 
nominal and measured concentrations. The quantity of tamoxifen that was measured in final solutions 
ranged between 26% and 0.3% of the respective nominal, in accordance with a significant loss of the 
compound in the medium. Because the concentrations of tamoxifen degradation products that were 
measured in these solutions were not relevant, the differences between the nominal and the measured 
concentrations cannot be explained by a chemical degradation. Therefore, we hypothesise that this 
lipophilic pharmaceutical was adsorbed on glass surfaces, which reduced the amount of free tamoxifen 
in solutions. Chamart et al. [63] showed that 20% of the tamoxifen adsorbed on glass material after 
15-minutes contact time, when diluted in the minimum essential medium (MEM, [64]). This result is 
consistent with our findings, which revealed large differences between nominal and actual 
concentrations already at the initial time point (t0). This phenomenon was observed regardless of the 
DMSO percentage (method 1 and 2) in our study. Besides the lack of solvent influence, the presence 
of daphnia food in the incubation medium did not change tamoxifen concentrations in 87.5% of the 
total samples that were analysed. Conversely, the type of medium may influence tamoxifen-free 
concentrations. Indeed, Chamart et al. [63] observed adsorption of tamoxifen on glass vessels when 
diluted in the MEM but not when diluted in bi-distilled water. These authors hypothesised that one of 
the MEM components might trigger adsorption. This may also be the case with the daphnia medium, 
which is also supplemented with numerous compounds [3]. These results emphasise the requirement 
to measure the concentration exposure in the actual conditions, when ecotoxicity tests are performed.  
In our study, tamoxifen impaired reproduction and induced unusual toxic effects on D. pulex. In the 
acute assay for instance, tamoxifen caused severe internal tissue damage or prolonged immobilisation 
periods that were followed by sudden and extended energetic swimming. In the chronic assay, 
tamoxifen reduced reproduction and elicited teratogenic effects, such as abnormal neonates and 
aborted eggs. Teratogens are known to cause miscarriages and abnormalities in structure or function 
and growth that may affect embryo or foetus viability [65]. In higher animals, the mechanisms that 
may induce teratogenic effects are numerous, such as cytotoxicity, mutation, chromosomal damage, 
protein activity disruption, apoptosis alteration, etc., which, in turn, may lead to hormonal or 
immunological dysfunctions, implantation failure, foetal structure abnormalities and miscarriages 
[65,66]. Although our results are qualitative, we hypothesised that similar mechanisms could have 
been activated in the F0 daphnids that were exposed to tamoxifen, which may explain deformed 
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offspring, for instance. In vertebrates, tamoxifen is not only an anticancer agent but also a hormonal 
disruptor that works as a selective oestrogen receptor modulator. Similar to tamoxifen, other hormones 
or hormone-precursors (e.g., testosterone and androstenedione) and synthetic endocrine disruptors 
(e.g., 4-nonylphenol and the fungicide propiconazole) were reported to reduce fecundity and to induce 
developmental toxicities in daphnids [67–70]. In these studies, toxic effects were observed at the mg/L 
level, whereas tamoxifen already induced these effects at the µg/L level. Kast-Hutcheson et al. [67] 
conscientiously categorised embryonic development regarding time and maturation stages. Based on 
their results, we divided the morphological effects of tamoxifen into specific classifications, as 
described in Figure 2.9. The severity and type of malformations vary with embryonic developmental 
stages and with the exposure duration. Therefore, according to Kast-Hutcheson et al. [67] and LeBlanc 
et al. [68], the aborted eggs and morphologically abnormal neonates (dead or alive) that were observed 
in our study might reflect toxicity at early and late stages of development. Further experiments are 
however required to confirm the results observed in D. pulex and to identify the most sensitive 
developmental stage.  
Because our study primarily focused on reproductive performance of D. pulex exposed to tamoxifen, a 
test period, longer than 12-d, would have been of interest for the teratogenic assessment of the second 
generation. Indeed, this generation did not produce abnormal neonates during the 12-d of exposure to 
tamoxifen. The F0 generation released abnormal neonates after the 7th and/or the 13th day of exposure 
(Table 2.2), which suggests that abnormal neonate production in the F1 generation could have 
occurred after 12-d of exposure. Interestingly, the reproduction of the daphnids that were exposed to 
0.15 µg/L had elevated reproduction compared with controls and other concentrations. Physiological 
adaptation, such as resistance or higher metabolism-cost, which is intended for species survival, may 
be a reason for this increase in reproduction [71,72]. Another reason may be the pharmaceutical 
molecule activity itself. Indeed, tamoxifen has the ability to increase ovulation rates in patients [73], 
and we wonder whether some analogous mechanism was involved in daphnids that were exposed to 
this low concentration. 
In our study, daphnids showed a higher sensitivity to tamoxifen in the non-standard endpoints relative 
(severe tissue damage, abnormal neonates, etc.) to the standard endpoints (immobilisation, 
reproduction [3,74]). Consequently, exposure of aquatic organisms to tamoxifen might be better 
assessed using our non-standard endpoints. For instance, the standard immobilisation endpoint would 
not consider daphnids with organs hanging from abdomen because these daphnids were able to swim. 
In this case, the EC50 would be higher than our EC50 value that was based on viability. Similarly, 
chronic experiments that only focus on the reproductive endpoint (i.e., total number of neonates) 
would not consider aborted eggs and abnormally developed neonates. In our study, the morphological 
abnormalities in embryos appeared at lower concentrations than concentrations that adversely affected 
reproduction. These results highlight the need to consider non-classical endpoints in ecotoxicological 
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testing, and we wonder whether current standard testing is appropriate for pharmaceuticals with 
anticancer and endocrine disrupting properties. 
While the no observed effect concentration (NOEC) that was calculated for reproduction was 0.72 
µg/L; however, a NOEC of less than 0.15 µg/L was estimated for morphological abnormalities in the 
F0. This level is below the tamoxifen concentrations that were measured in STP effluents (0.02 to 0.37 
µg/L) [47–49] and in aquatic environments (0.01 to 0.21 µg/L) [49,50]. To the best of our knowledge, 
no NOEC of tamoxifen on daphnids has been reported to date in the open literature. These results raise 
concerns regarding the integrity of the aquatic flora and fauna and should stimulate further 
investigations to assess ecotoxicological risks at the population level.  
 
Conclusion 
Pharmaceutical residues are released into the aquatic environment every day, which justify growing 
concerns regarding their potential adverse effects on living organisms. Our data emphasise the 
importance of measuring the tested concentrations of hydrophobic drugs, such as tamoxifen, to avoid 
incorrect conclusions and an underestimation of their risk on aquatic systems. At a minimum, some 
concentrations can be measured and the rest can be predicted, as described in this study. 
In chronic experiments, tamoxifen reduced reproduction and showed teratogenic effects. These results 
raise questions regarding its potential impact on other relevant aquatic species and in experiments over 
several generations, particularly because the NOEC is low (< 0.15 µg/L). In general, little is known 
regarding long-term effects of pharmaceuticals on aquatic species [75], although these molecules are 
continuously present in aquatic systems. Multi-generational testing would be required to answer the 
question regarding long-term effects of pharmaceuticals.  
Furthermore, patients who are treated with tamoxifen primarily excrete the parent molecule and 4-
hydroxy-tamoxifen, which is known to be a potent active metabolite in humans [76–78]. This 
metabolite	   induced effects on the reproduction, survival and body length of D. pulex (chapter 3); 
however, its toxicity in other aquatic organism is unknown, although developmental effects were 
observed in organisms that were exposed to tamoxifen at environmental relevant concentrations. There 
is a clear need to further characterise the risk of tamoxifen and other anticancer compounds or 
metabolites on the aquatic flora and fauna.  
Finally, global cancer rates are expected to increase by 50% by 2020, with 15 million new cases [79]. 
This increase is closely related to the decline of other life-shortening conditions, such as infections and 
cardiovascular diseases. In 2000 in France, a survey that was performed by national authorities 
calculated that there were 800,000 people living with cancer, whereas 28,000 new cancer cases and 
150,000 deaths were reported [80]. Five years later, the number of new cases increased; however, the 
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number of deaths decreased, which indicated that cancer patients spend progressively longer periods 
of their lifetime under treatment. Therefore, the release of anticancer drugs into aquatic systems is 
expected to increase, which makes the assessment of their effects on aquatic organisms crucial.  
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Chapter 3  
 
 
 
Is D. pulex sensitive to the tamoxifen metabolites 4OHTam and endoxifen? 
In this chapter, the toxic effects of 4-hydroxy-tamoxifen (4OHTam) and endoxifen, two tamoxifen 
metabolites, are described and discussed. Endoxifen acute experiments are first presented in this 
chapter, as an addendum. In humans, 4OHTam and endoxifen interact with the same receptors as 
tamoxifen but with higher affinity and higher potency than their parent compound. Patients excrete 
tamoxifen, 4OHTam and endoxifen in faeces and tamoxifen was measured in wastewaters and natural 
waters. Contrary to their parent drug, the environmental concentrations of tamoxifen metabolites are 
unknown. The effects of 4OHTam and endoxifen in aquatic organisms have also never been reported 
yet. In March 2014, the Canadian Ministers of the Environment and of Health [1] have reported the 
results of a screening assessment of tamoxifen in which they consider 4OHTam and endoxifen as 
highly toxic to aquatic organisms, with a potential for endocrine disruption. The aim of this chapter 
was therefore to assess the sensitivity of daphnids toward 4OHTam and endoxifen. A two-generational 
study was performed in which each generation of daphnids (F0 and F1) was exposed 21 days to 
4OHTam or endoxifen. At the end of this chapter, a supplementary material is provided on: 1) the 
stability of 4OHTam and endoxifen in daphnia medium in test solutions and at different times, 2) a 
method to predict 4OHTam and endoxifen concentrations in daphnia medium 3) the choice of the 
concentration that were used in the two-generational study. 
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Endoxifen acute experiment on D. pulex (Addendum) 
 
Introduction 
Endoxifen is a secondary metabolite of the anticancer drug tamoxifen. In human, its potency and its 
affinity to estrogen receptors (ERs) is higher than the parent drug [2–4]. Endoxifen is mainly an ERα 
ligand, which has antiestrogen activity [3]. The aim of this study was to assess the sensitivity of D. 
pulex towards endoxifen during 48 hours. This acute toxicity experiment was performed to determine 
the range of effective concentration on daphnids as well as the concentrations that reduce mobility on 
50% of the treated animals. 
 
Material and method 
Chemical  
Endoxifen was purchased from Sigma/Fluka (> 99%, lot: H7904). The day before the experiments, the 
chemical was dissolved in pure DMSO [5]. A stock solution was prepared at the measured 
concentrations of 2.73E+06 µg/L. This stock solution was stored in glass bottle, in the dark at -80°C, 
and it was thawed at room temperature before used. 
 
Test organisms 
Individuals from the arenata strain of D. pulex were mass-cultured in Elendt M4 medium in which the 
water hardness was reduced to 95 mg/l CaCO3 [6]. They were reared in glass flasks, in a Coolstore® 
environmental chamber with 16-h light and 8-h dark photoperiods at 21 ± 1°C. These stock daphnids 
were fed daily with both 0.2 mgC/daphnia of Pseudokirchneriella subcapitata algae and suspension of 
tropical fish food such as Tetramin® [7,8].  
 
Acute experiment 
Three hundred and ten neonates (< 24 h, > 3rd brood) were exposed 48 hours to endoxifen in two 
acute experiments. Briefly, five individuals per vessel (3 replicates) were randomly pipetted in glass 
tubes at predicted concentrations ranging from 7.64 to 530.74 µg/L of endoxifen. Table 3.1 
summarises endoxifen nominal, measured and predicted concentrations. For explanations on predicted 
concentration, see supporting information “predicted concentrations”. During each acute experiment, 
two controls were performed: a blank (without chemical) and a solvent control that contained 0.1% 
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DMSO. This percentage corresponded to the maximum DMSO percentage that was used at the highest 
test concentration of each experiment. The studied endpoint was the immobilisation of daphnids > 20 
seconds, despite a gentle agitation of the tube. This endpoint was observed after 24 and 48 h of 
exposure. Individuals were not fed during the experiments. 
A potassium dichromate (K2Cr2O7) assay was also performed at the beginning of the acute 
experiments and the EC50 (± standard deviation) corresponded to the K2Cr2O7 results in our 
laboratory: 0.6 (± 0.25) µg/mL. 
 
Statistics  
The results of both acute experiments were combined and expressed as a sigmoidal dose-response 
curve, from which the acute EC50s and confidence intervals were calculated. The dose-response curve 
was generated by the following nonlinear regression: 
Y= 100/(1+10^((LogEC50-X)*HillSlope))      (2) 
where x is the logarithm of concentration. Y is the response, and Y starts at 0 and goes to 100 with a 
sigmoid shape. The HillSlope result was 2.5 for endoxifen and r2 was 0.86. 
 
Table 3.1: Endoxifen acute test concentrations. Predicted concentrations were calculated using a 
polynomial regression of measured vs nominal concentrations (n samples = 202). The measured 
concentrations are expressed as the mean of triplicate samples 
 
 
 
Nominal 
(µg/L)
Predicted 
(µg/L)
171 27.80
222 37.09
250 27.41 16.08 42.31
288 49.53
360 28.91 12.58 63.55
375 66.53
487 89.26
530 51.98 33.40 98.21
633 120.09
770 74.10 14.61 150.08
824 162.14
1071 218.92
1110 117.32 9.13 228.11
1392 296.11
1610 214.54 45.93 350.42
1809 401.18
2300 460.61 261.79 530.74
2352 544.79
Measured mean 
(µg/L)         SD
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Results and discussion 
The results of both experiments were combined and they are summarised in Figure 3.1. After 48-h of 
exposure, the calculated EC50 of endoxifen was 233 µg/L, which is higher than tamoxifen and 
4OHTam EC50s. Indeed, in previous acute experiments, tamoxifen and 4OHTam EC50s were 9.5 and 
42 µg/L, respectively (see chapter 4). These results show that endoxifen was less potent than 4OHTam 
and tamoxifen in daphnids. This is not the case in human, since endoxifen and 4OHTam have greater 
pharmacological effect than tamoxifen in vivo [9–11], but it is possible that endoxifen does not have 
similar targets in D. pulex as tamoxifen and 4OHTam. This hypothesis is in accordance with Hawse et 
al. [12], who reported that endoxifen’s mechanism of action was different from tamoxifen and 
4OHTam in gene transcription, cell cycle arrest and markers of apoptosis, although these three 
chemicals targeted the same gene, i.e., ERα in vertebrates. Hawse et al. also showed that endoxifen 
induced different effects depending on the concentrations, which may modulate the antitumor activity 
in patients. Taking together, we hypothesised that the mechanisms of endoxifen action might also be 
different with this of tamoxifen and 4OHTam in daphnids.  
 
 
Figure 3.1: Endoxifen acute toxicity experiment. The EC50 (95% IC) is 233 (199, 290) µg/L. The 
exposures are predicted from measured concentrations (µg/L). The HillSlope was 2.5, r2 was 0.86, n = 310 
(including controls) 
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Abstract 
Endoxifen and 4-hydroxy-tamoxifen (4OHTam) are two metabolites of the widely used anticancer 
drug tamoxifen for the prevention and treatment of breast cancers. Both metabolites have a high 
pharmacological potency in vivo, attributing prodrug characteristics to tamoxifen. Tamoxifen and its 
metabolites are body-excreted by patients, and the parent compound is found in both sewage treatment 
plan effluents and natural waters. The aim of this study was to assess whether medicinal drug residues 
induce long-term toxicities on Daphnia pulex, a freshwater microcrustacean that has already shown 
some susceptibility to tamoxifen. Two chronic tests of 4OHTam and endoxifen were run in parallel on 
two generations of D. pulex and several endpoints were assessed. Both metabolites induced effects on 
reproduction, survival and body length. The effects on reproduction were magnified on the second 
generation compared to the first. The intrinsic rate of natural increase (r) decreased with increasing 
4OHTam and endoxifen concentrations, with increased sensitivity observed in the F1 generation. The 
No-observed effect concentrations calculated for the reproduction of the second generation exposed to 
4OHTam and endoxifen were < 1.8 µg/L and 4.3 µg/L, respectively, while the NOECs that were 
calculated for the intrinsic rate of natural increased were < 1.8 and 0.4 µg/L, respectively. Our study 
raises questions about prodrug and active metabolites in environmental toxicology assessments of 
pharmaceuticals. Our findings also emphasize the importance of performing long-term experiments 
and considering multi-endpoints instead of the standard reproduction outcome. 
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Introduction 
Residues of pharmaceuticals have been detected in surface waters worldwide, leading scientists as 
well as non-scientists to wonder about their risks to aquatic systems [13]. Aside from veterinary use 
and industrial releases, the primary source of drugs in water appears to be human consumption [14]. 
After their absorption, pharmaceuticals are eliminated in either intact or metabolised forms through 
human excreta. They then follow urban sewage water networks to a sewage treatment plant (STP). 
New technological treatment processes are able to remove some pharmaceuticals from wastewaters 
[15], but the most current traditional plants were designed to eliminate organic matter, phosphates and 
nitrates, and not organic chemicals, such as pharmaceuticals. Therefore, numerous pharmaceuticals 
and their derivatives with pharmacological activities escape STP processes and continuously reach the 
aquatic compartment [13]. Such bioactive molecules are capable of chronic interactions with the 
biological processes of aquatic species and their offspring, even at low concentrations. For example, 
this is the case for the synthetic steroid analogue 17-alpha-ethinylestradiol, for which a predicted no-
effect concentration (PNEC) was proposed at the level of 0.1 ng/L [16]. Among other pharmaceutical 
groups, the anticancer agents are of particular concern because of their potential mutagenic, 
carcinogenic, teratogenic and/or embryotoxic properties [17]. 
Tamoxifen is a chemotherapeutic selective estrogen-receptor modulator that is widely prescribed 
worldwide for the prevention and treatment of hormone-receptor-positive breast cancers [11,18,19]. 
This anticancer drug has partial agonist and antagonist activity on alpha and beta estrogen receptors 
(ERα, ERβ) depending on the tissues. Tamoxifen is nearly considered as a prodrug [20] and releases 
active metabolites, i.e., 4-hydroxy-tamoxifen and endoxifen, after enzymatic and/or chemical 
transformation in vivo.  
Tamoxifen was recently found in wastewater effluents and surface waters at concentrations up to 0.37 
µg/L and 0.22 µg/L, respectively [21–26]. No data have been reported addressing actual 
concentrations of endoxifen and 4OHTam in aquatic environments up to now, but we assume that 
these metabolites could be found in wastewaters and natural waters, such as their parent compound, 
because they are also body-excreted, mainly via faeces [18,27,28]. Their concentrations in excreta are 
scarcely known because they have never been studied in a respectable cohort of patients. For instance, 
the concentrations of tamoxifen, 4OHTam, and endoxifen were measured in faeces of three patients, 
and these concentrations ranged between 230-1092 µg, 123-579 µg, and 92-189 µg, respectively [27]. 
Because information is lacking, it is difficult to estimate their concentration in wastewaters and STP 
effluents. However, both metabolites share similar physical-chemical properties with their parent 
compound, which suggests that they may escape sewage treatment processes [26]. Furthermore, it is 
known that pharmaceutical metabolites can be found in STP effluents and natural water, such as the 
anti-inflammatory metabolites carboxy-ibuprofen and hydroxyl-ibuprofen [29,30], the antidepressant 
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metabolites norfluoxetine and desmethylsetraline [31], and the analgesic metabolite salicylic acid 
[32,33]. The salicylic acid was found also at high concentrations, up to 0.28, 0.37 and 12.7 µg/L in 
lake, river and STP effluent waters, respectively [31,33].  
Tamoxifen metabolites are of particular interest because of their high potency that was discovered 
only recently, long after tamoxifen commercialisation. In vertebrates, tamoxifen is primarily 
metabolised by the hepatic P450 cytochromes into hydroxylated and demethylated metabolites, such 
as N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen (4OHTam), tamoxifen N-oxide, and alpha-hydroxy-
tamoxifen [34]. In a second step, N-desmethyl-tamoxifen is transformed into 4-hydroxy-N-desmethyl-
tamoxifen (endoxifen). Although tamoxifen is already an active molecule, the 4OHTam and 
endoxifen metabolites have an affinity to ERs 100 times that of the original molecule, and their 
potency to suppress cell proliferation in breast cancer is also 30 to 100 times that of tamoxifen 
[4,9,35]. Furthermore, tamoxifen and 4OHTam also interact with estrogen-related receptors (ERRs) 
that are nuclear receptors present in many organisms, including invertebrates [36,37]. ERRs bind and 
regulate transcription through estrogen response elements (EREs) and estrogen-related response 
elements (ERREs). In mammals, three types of ERRs exist: ERRα, ERRβ and ERRγ. The ERRs have 
distinct function than ERs. They are related to ERs but are unable to bind natural estrogenic ligands 
[38]. In vitro, 4OHTam has higher affinity than tamoxifen with ERRβ and ERRγ, and none of them 
bind ERRα [39]. Finally, the action of tamoxifen and its metabolite via the ERRs may play an 
important role in breast tumour therapy [36]. 
In a recent study, Thomson et al. [37] found that a single copy of the gene ERR (dappu-ERR, NR3 
subfamily) was present in the freshwater microcrustaceans Daphnia pulex, among the twenty-five 
nuclear receptor genes that were identified in this species [37]. Daphnids lack ERs but their ERR gene 
is close structurally to the human homologs ERRα, ERRβ and ERRγ, and close also to human ERα 
and ERβ [37]. Indeed, the phylogenetic relationship of the ERR in D. pulex and the ERRs and ERs in 
Homo sapiens belongs to the same sub-familly of nuclear receptors [37]. In D. pulex, the endogen 
ligand and the functions of the ERR family are unknown [37], but they may be involved in estrogen 
signalling and metabolism pathway [40,41]. In a parallel study, we investigated if D. pulex that was 
sensitive to tamoxifen. We observed reproductive impairments, aborted eggs and/or morphologically 
abnormal neonates [42]. The No-observed effect concentrations (NOECs) were < 0.15 µg/L and 0.72 
µg/L when calculated for morphological abnormalities and for reproduction, respectively. 
Interestingly, Suillvan and Thummel [43] found that  the orphan ERR in drosophile may have 
embryonic functions and that they are expressed during embyogenesis.  
Because of the presence of ERR gene in daphnids, of the high potency of 4OHTam and endoxifen, and 
of their potential continuous inputs of in the aquatic environments, we hypothesise that tamoxifen 
metabolites may induce long-term effects on aquatic organisms. Also, 4OHTam and endoxifen were 
recently considered to be highly toxic to aquatic organisms, with a potential for endocrine disruption 
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[1]. Tamoxifen was so identified as a priority molecule for assessment because of its inherent toxicity 
to non-human organisms. The aim of this study was therefore to assess the long-term toxicities of 
4OHTam and endoxifen on D. pulex that has already shown some susceptibility to tamoxifen [42]. To 
reach this goal, we exposed the daphnids to low doses of these chemicals during two generations. The 
primary objective was to observe whether these two anticancer drug metabolites affect the survival, 
reproduction and/or size of D. pulex. Second, we aimed to calculate the intrinsic rate of natural 
increase (r) to reflect how metabolite concentrations would restrict population growth. 
 
Materials & Methods 
Chemicals and drug concentration measurements 
Endoxifen and 4-hydroxy-tamoxifen (4OHTam) were purchased from Sigma/Fluka and used without 
further purification (>99%, lot: 110M4107V for endoxifen and 099K46042 for 4OHTam). Endoxifen 
and 4OHTam were initially dissolved in pure dimethyl sulfoxide, DMSO [5,44]. A day before the test, 
stock solutions were prepared in glass bottles at mean measured concentrations of 2.11·106 µg/L and 
2.04·106 µg/L for 4OHTam and endoxifen, respectively. Throughout the test duration, both stock 
solutions were stored in the dark at -80°C and thawed every two days, i.e., before each use. 
Predicted concentrations of 4OHTam and endoxifen 
Endoxifen and 4OHTam are lipophilic molecules that are slightly soluble in water. After sampling 
analyses of these chemicals in Elendt M4 solutions [8], differences between nominal and measured 
concentrations were observed, primarily with the solutions freshly diluted (see supporting information, 
SI, part I, for detailed explanations on the stability of 4OHTam and endoxifen in incubation medium). 
During ecotoxicological experiments, the OECD [8] suggests to sample test solutions at renewal (t0) 
and after 48 hours (t48) of exposure. In the two-generational experiment performed in this study, the 
test solutions were not all measured because this OECD follow up would have required analysis of 
about 900 samples (i.e., about 8 concentrations sampled at t0 and t48, in triplicate at least, during 2 
generations). Also, this requirement may discourage and slow down the science of ecotoxicology to 
move forward. Therefore, a good prediction method was required to determine the 4OHTam and 
endoxifen exposures to daphnids, and a polynomial regression of the measured concentrations versus 
the nominal concentrations of each chemical was performed. In this study, exposure levels are 
predicted concentrations that were calculated from the fitted model of 4OHTam and endoxifen 
(equation S1 and S2, SI, part I). 
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Test organisms 
D. pulex from the arenata strain have been mass-cultured for two years in our laboratory [42]. They 
are reared in conditions that maintain parthenogenetic reproduction (total hardness 90 ± 5 mg/l as 
CaCO3; pH 7.9 ± 0.2; conductivity adjusted to 25°C, 286 ± 14 µS/cm; dissolved oxygen > 5 mg/L). 
Stock daphnids as well as individuals exposed to chemicals were reared in glass beakers placed in a 
Coolstore® environmental chamber (16: 8 h light: dark photoperiods at 21 ± 1°C).  
 
Two-generation testing procedure 
Endoxifen and 4OHTam chronic assays were performed in parallel over two generations of D. pulex 
(F0 and F1). This two-generation study was adapted from previous ecotoxicological experiments, such 
as acute and chronic pre-tests performed with 4OHTam and endoxifen (SI, part II), and the framework 
of the experimental design is illustrated in Figure 3.2. Briefly, the parental generation (F0) was 
randomly selected from a single stock of mothers. Forty neonates (< 24 h, > 3rd brood) were pipetted 
and placed in separate glass beakers with 50 mL of medium (four replicates per concentration). The 
exposure concentrations were 1.8, 6.8, 23.8, and 98.9 µg/L and 0.4, 4.3, 51.8, and 202.4 µg/L for 
4OHTam and endoxifen, respectively. The DMSO percentage was not analysed. On the fifteenth day 
of maternal exposure, seventy-four neonates (< 24-h) were collected to form generation F1. Three 
neonates per beaker (three replicates) were transferred to 150 mL of corresponding maternal 
concentration medium. Note that on the fifteenth day, the mothers (F0) exposed to 23.8 µg/L of 
4OHTam produced only five neonates. These five were distributed between two different beakers to 
form F1.  
Two controls were included for both the endoxifen and 4OHTam chronic tests (four replicates for F0 
and F1 generations): a blank (i.e., without solvent or chemicals) and a solvent control referring to the 
DMSO percentage at the highest endoxifen and 4OHTam concentration in the F0 (i.e., 0.04% of 
DMSO). Daphnids from the controls were reared in the same environmental conditions as the test 
organisms. Daphnids were fed daily with 0.2 mg C/daphnia of Pseudokirchneriella subcapitata algae 
and a suspension of Tetramin® tropical fish food [8,45]. At the beginning of the experiment, a 
potassium dichromate (K2Cr2O7) assay was performed to assess daphnia sensitivity. Additionally, a 
K2Cr2O7 assay was conducted every 21 days. Dissolved oxygen, pH and conductivity were measured 
at least twice a week.  
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Figure 3.2: Experimental design for the chronic toxicity test on D. pulex. On the fifteenth day, neonates 
were kept to form the second generation (F1) and they were exposed to corresponding maternal 
concentration medium. The concentrations of 4OHTam at 98.9 µg/L and endoxifen at 202.4 µg/L were not 
tested on F1 because there were no survivors from F0. * 1 organism/beaker (4 replicates per 
concentration), *** 3 organisms/beaker (3 replicates per concentration), ** 2 or 3 organism/beaker (2 
replicates for 23.8 µg/L of 4OHTam)  
 
 
Daphnia mortality, reproduction and size 
The mortality (i.e., number of dead parents) and number of offspring per beaker were recorded daily 
(the neonates were then discarded, except on day 15). The reproductive performance of the daphnids 
in each group was expressed as the average number of neonates per adult during the 21-d exposure 
period. Visual body-size differences with the controls were noted for the daphnids exposed to 
chemicals during the experiment. Body-size was defined as the body shape that includes body breadth 
and length. 
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Intrinsic rate of natural increase (r) 
The intrinsic rate of natural increase r was calculated using mortality and birthrate data and by 
iteration of the Euler-Lotka equation [46]: 
Σ lxmxe-rx = 1         (1) 
where lx is the proportion of individuals surviving to age x, mx is the number of neonates produced per 
surviving adult at age x, and x is time expressed in days. In accordance with van Leeuwen [47], a 21-
day study is sufficient to estimate the intrinsic rate of natural increase, as r calculated in D. pulex after 
21 days is identical to the estimated r for their entire lifespan. In this work, r was calculated for each 
replicate on both generations. Similarly to Tanaka [48], the r function of each exposure concentration 
was fitted according to the following equation: 
r(x) = r(0) [1-(x/ α)β]        (2) 
where x is the exposure concentration, r(x) is the mean of the intrinsic rate of natural increase under x, 
α corresponds to the concentration at which r reaches zero (i.e., at which the population stops 
growing), and β is the curvature shape of the response. The α and β values are estimated with the least 
chi-squared method (Levenberg-Marquardt algorithm; SPSS Statistics 21:0). The intrinsic mean rate 
of the control (blank and solvent controls together) was used here as r(0), here equal to 0.4 (Table 3.2).  
 
Statistics 
For the two-generation testing, the reproduction and intrinsic rate were first compared between the 
blank and solvent controls using a one-way ANOVA test followed by the Bonferroni correction  (α < 
0.05). No significant differences were observed between these controls; therefore, both controls were 
gathered and used as the unique control for each multiple comparison. The calculations were carried 
out with GraphPad Prism (version 4.00 for Mac OS X, GraphPad Software, San Diego California 
USA, www.graphpad.com). 
 
Results 
Daphnia reproduction and mortality 
The effects of endoxifen and 4OHTam on D. pulex were assessed for generations F0 and F1 (Table 
3.2). With 4OHTam, the reproduction of the F0 and F1 generations displayed a systematic trend 
following exposure concentrations. The F0 mortality was 100% at the highest concentration, i.e., 98.9 
µg/L, and daphnids died on the fourth day, before the age of reproduction was reached (on average the 
6.5th day). The average number of neonates produced by the F0 generation exposed to 6.8 and 23.8 
µg/L of 4OHTam was significantly reduced (p < 0.001) compared to the controls, by about 25 and 56 
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%, respectively. On the fifteenth day, when neonates were kept to form generation F1, the mothers 
exposed to 23.8 µg/L of 4OHTam produced only five neonates. The reproduction of F1 was reduced 
in each test concentration, by about 21, 28 and 73 % for 1.8, 6.8 and 23.8 µg/L, respectively. The no-
observed effect concentration for reproduction (NOECrep), which is the highest tested level where the 
total number of young produced was not significantly different from the controls, was 1.8 µg/L for the 
F0. For the F1, the NOECrep could not be calculated because effects were observed in each test 
concentration. Therefore, this NOECrep was below the lowest test concentration, i.e.,  < 1.8 µg/L. 
 
Table 3.2: Survival, size and fecundity of two D. pulex generations (F0 and F1) exposed 21 days each to 
4OHTam and endoxifen in the two-generation study (mean ±  SD, n = 40 and 74 for F0 and F1, 
respectively). The exposure refers to predicted concentrations that were calculated from measured 
concentrations. Reproduction is the total number of neonates per female. Size is capitalized as 0 and 1 for 
no visual differences and visual differences compared to controls, respectively. The F1 generation was 
exposed to corresponding maternal concentration medium. * and ** indicate statistical significance in 
comparison with controls  
 
 
For endoxifen, the concentration of 202.4 µg/L was lethal in 100% of the daphnids after four days of 
exposure. At 51.8 µg/L of endoxifen, mortality as well as reproduction was affected in both the F0 and 
F1 generations. Half of the F0 individuals were dead after sixteen days of exposure, and the 
reproduction of the other half was highly significantly reduced (p < 0.001) by about 67 % compared to 
the controls at the end of the exposure period. In addition, a high variability was observed for F0 
Treatment Exposure...
(μg/L)
Longevity.
(days)
size Reproduction Intrinsic.rate.
(r)
NOEC.
reproduction
NOEC.(r)
1.8 21%±%0 0 76%±%8.2 0.418%%±%0.0276.8 19.3%±%3.5 0 64%±%8.3%** 0.376%±%0.03723.8 21%±%0 1 37%±%6.1%** 0.333%±%0.033%*98.9 4%±%0%** 1 0 0**0.4 21%±%0 0 92%±%4.2 0.398%±%0.0394.3 21%±%0 0 88%±%6.5 0.376%±%0.02351.8 18.3%±%3%** 1 28%±%17.3%** 0.286%±%0.126%*202.4 4%±%0%** 1 0 0**
Control 21%±%0 86%±%10.3 0.394%±%0.0281.8 21%±%0 0 82%±%3.4%* 0.359%±%0.018%**6.8 21%±%0 0 74%±%7.5%** 0.368%±%0.014%*23.8 21%±%0 1 28%±%0%** 0.309%±%0**98.9 /0.4 20.9%±%0.3 0 105%±%5.9 0.398%±%0.0114.3 21%±%0 0 95%±%8.5 0.372%±%0.026%*51.8 5.2%±%2.6%** 1 %0** 0**202.4 /
Control 20.6%±%1.4 103%±%10.6 0.404%±%0.017*%%%p%<%0.05%(Bonferroni%correction) /%%no%neonates%for%the%F1%assay**%p%<%0.01%(Bonferroni%correction)
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reproduction at this concentration. For example, one individual that died on the sixteenth day of 
exposure produced a total of forty neonates, which was higher than the total reproduction of the 
daphnids that survived until the end of the test. Conversely, another individual that died on the 
fifteenth day produced only two neonates. The F1 daphnids died between the second and eleventh 
days of exposure and did not produce any offspring at the concentration of 51.8 µg/L. Seven of them 
died before the age of reproduction was reached, and the last three did not reproduce before dying. No 
effect was observed at the two lowest test concentrations, so the reproductive NOEC for endoxifen in 
both generations is therefore 4.3 µg/L. Finally, the mortality in the solvent controls and blanks of the 
F0 and F1 generations were the same for both tested chemicals and never exceeded 10%. At the end of 
the test, their mean number of offspring produced was above 60 neonates, as recommended by the 
OECD guideline [8]. 
 
Figure 3.3: Body-size of maternal D. pulex after 21 d of exposure to 51.8 µg/L of endoxifen or blank (same 
generation). On the left, the photo is magnified 4 times, compared to the photo on the right. Photos were 
taken using an Olympus polarisation microscope BX51 with a digital imaging system (Colorview) 
 
Daphnia size 
Differences in body length were observed in the daphnids exposed to 23.8 and 98.9 µg/L of 4OHTam 
and to 51.8 and 202.4 µg/L of endoxifen. These daphnids were smaller than the controls after 21 d of 
exposure. As an example, Figure 3.3 shows the visual difference in body-size between two randomly 
selected individuals exposed for 21 d to 51.8 µg/L endoxifen or to daphnia medium exempted of 
chemical. The F0 daphnids exposed to the highest concentration of both chemicals exhibited impaired 
growth. They all died at a size corresponding to a 24-h neonate from the controls (i.e., solvent and 
blank). No size difference was observed at lower concentrations. 
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Intrinsic rate of natural increase (r) 
The intrinsic rate of natural increase r, which estimates population growth of D. pulex, was calculated 
for the F0 and F1 generations exposed to 4OHTam and endoxifen (Table 3.2). For the F0 individuals 
exposed to 98.8 and 202.4 µg/L of 4OHTam and endoxifen, respectively, and for the F1 daphnids 
exposed to 51.8 µg/L of endoxifen, no individual survived and r was zero. The r of the F0 daphnids 
exposed to 23.8 µg/L of 4OHTam was significantly lower (p < 0.05) than the controls, and they were 
all significantly lower in the F1 (p < 0.01 for 1.8 and 23.8 µg/L, p < 0.05 for 6.8 µg/L). The r of the F0 
and the F1 exposed to 51.8 and 4.3 µg/L of endoxifen, respectively were significantly lower (p < 0.05) 
when compared to the control. The NOECs of 4OHTam that were calculated for r, NOEC(r), were 6.8 
µg/L for the F0 and this NOEC was < 1.8 µg/L for the F1. The NOECs(r) of endoxifen were 4.3 and 
0.4 µg/L for the F0 and F1, respectively. Figure 3.4 shows how population growth under exposure to 
endoxifen or 4OHTam decreases with increasing concentrations. The estimation of the second 
generation exposed to 4OHTam was performed with r = 0 at the concentration of 98.9 µg/L. Indeed, 
the daphnids exposed to this concentration died in the F0 and therefore, the intrinsic rate is null. 
 
 
Figure 3.4: Population-level effect of endoxifen and 4OHTam on D. pulex: intrinsic rate of natural 
increase variation as a function of endoxifen or 4OHTam concentrations.     F0, ¢F1. 4OHTam r2 = 0.91 
and 0.72 for F0 and F1 respectively, and endoxifen r2 = 0.87 and 0.73 for F0 and F1 respectively. The 
estimation of the second generation exposed to 4OHTam was performed with r = 0 at the concentration of 
98.9 µg/L 
 
 
	   82	  
Discussion 
In a two-generational study performed on D. pulex, the tamoxifen metabolites 4OHTam and endoxifen 
induced effects on reproduction, survival and body length. These chemicals were able to disrupt 
physiological mechanisms at the µg/L level, i.e., at levels that were close to the environmental 
concentrations of their parent compound [21–26].  
For both metabolites, the sensitivity of D. pulex increased in the second generation. The effects on 
reproduction and the estimation of population growth were indeed magnified in the F1 exposed to 
4OHTam and endoxifen, respectively. For instance, the reproduction of F0 exposed to 23.8 µg/L of 
4OHTam dropped, and continued to decline in the F1 generation. Similarly, the reproduction of the 
survivors exposed to 51.8 µg/L of endoxifen decreased, and their offspring (F1) did not survive when 
maintained at the same concentration. Several studies have also reported increased sensitivity and 
decreased fitness of the second generation of daphnids exposed to endocrine disruptors [48–50]. In 
accordance with the authors, we hypothesise that the second generation of daphnids was weakened by 
maternal exposure in our study. The F1 individuals exposed to 1.8, 6.8 and 23.8 µg/L of 4OHTam and 
51.8 µg/L of endoxifen were probably affected at an early life stage, contrary to their parents, which 
were not exposed during embryonic development. Our experiment started with F0 neonates from 
previously unexposed parents, meaning that the first generation was not exposed to the chemical 
during the oogenesis and embryogenesis processes. Therefore, the F0 generation could better survive 
and reproduce than neonates pre-exposed to chemicals in the maternal brood chamber. In addition, a 
potential toxicant transfer from mothers to offspring might not be excluded, as 4OHTam and 
endoxifen are lipophilic molecules. Although slightly less lipophilic than their parent compound 
tamoxifen, their calculated XLogP3 (i.e., online logP calculator; Pubchem.ncbi.nlm.nih.gov) is 6.3, 
which is close to the experimental tamoxifen logP of 7.1 [51]. This high lipophilicity allows molecules 
to accumulate in fat and pass physiological barriers (e.g., protein membranes, [52]). Because adult 
daphnids provide energy to their eggs in the form of fat [53,54], a bioaccumulation process is possible 
in the case of 4OHTam and endoxifen. Supporting this hypothesis, a recent study reported a positive 
correlation between bioaccumulation and logP for daphnids exposed to xenobiotics from the 
perfluoroalkyl acid family [55]. Further studies investigating the bioaccumulation of tamoxifen 
metabolites in daphnids and in neonates would therefore be interesting to perform.  
In addition to mortality and reproduction, qualitative differences in body-size were observed for 
daphnids exposed to 4OHTam or endoxifen. At the two highest concentrations tested, the F0 
generation did not grow and remained at a size similar to control < 24-h neonates. The offspring from 
daphnids that were smaller than controls after 21-d of exposure were also smaller at the end of their 
respective test period. Other studies have reported size differences in both adult daphnia and their 
offspring exposed to low chemical concentrations, such as dispersants or pesticide mixtures [56,57]. 
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This size reduction may be crucial for population survival, as Villarroel and al. [58] observed a 
positive relationship between small body-size and a diminished reproduction rate in D. magna 
exposed to the tetradifon insecticide. In our work, body breadth and length were not measured but 
most of the daphnids that had apparent reduced size either died or produced fewer neonates than the 
controls. To our knowledge, studies that report daphnia sizes after xenobiotic exposures are scarce, 
although this effect seems to reflect daphnids sensitivity to chemicals. Indeed, Hammers-Wirtz and 
Ratte [57] argued that changes in neonate size reduce individual fitness, enhance mortality or impair 
the reproduction of daphnids. Therefore, the question of measuring treated daphnids may be posed 
when the sensitivity and the survival of daphnia population is assessed. 
The intrinsic rate of natural increase (r) is an interesting calculation that considers significant 
parameters, such as reproduction, mortality, time of the first brood, etc. Although, the total number of 
neonates is often considered a more sensitive endpoint than the r dynamic [59], this calculation 
provides some evidence that relevant effects may occur at the population level. In the concerted effort 
that is made by the international scientific community to develop adverse outcome pathways that 
consider population level effects [60–62], these parameters seem also important to included in risk 
assessment. In our study, the calculated r showed a similar tendency than the other studied endpoints, 
i.e, the increase of sensitivity of the animals between the F0 and the F1 generations. Interestingly, the 
intrinsic rate r of the F0 daphnids exposed to 6.8 µg/L of 4OHTam was not statistically different from 
the controls, although a significant effect on reproduction was observed. This may be due to a 
decrease in reproductive performance from the third brood [63], because the dynamic of r is strongly 
influenced by the effects on reproduction and mortality during the few first broods and less so during 
the rest of the exposure period. However, the plot of modelised r as a function of exposure shows well 
the increased effect of endoxifen on daphnids’ fitness between the first (F0) and second (F1) 
generations (Figure 3.4). For this chemical, the calculated population growth was clearly reduced in 
the second generation, which is in accordance with the hypothesis of a generation weakened by 
maternal exposure. In the second generation exposed to 4OHTam, the estimated r was reduced at each 
exposure level and this result raises question about the offspring fitness in the next generations, and at 
lower concentrations than those used in this study. For 4OHTam indeed, the NOECs for r and for the 
reproduction were considered as below the lowest concentrations tested in this study, i.e., < 1.8 µg/L. 
The NOEC of endoxifen that was calculated for the intrinsic rate of the population growth was 0.4 
µg/L, which is close to the concentrations of tamoxifen that were measured in the natural aquatic 
environment (i.e., up to 0.22 µg/L [23,25]). However, because only few points are available for 
modelling r, the tendency of population growth of both molecules should be confirmed. Also, 
multigenerational experiments and risk investigations of these chemicals at the population level are 
encouraged.  
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In spite of their pharmacological high potency and increased releases into the environment, before the 
present study, endoxifen and 4OHTam had never been tested on aquatic species. Although here we 
show the effects of these tamoxifen metabolites on D. pulex, additional chronic experiments should be 
conducted on daphnids and other aquatic species to compare the results and better understand these 
chemicals’ effects in aquatic environments. In general, pharmaceutical metabolites are not well studied 
in ecotoxicology [64,65], and we believe that the question of prodrugs is too little considered in this 
field. However, the problem of active, or more active, metabolites should be fully integrated in any 
environmental ecotoxicology assessment of pharmaceuticals. Prodrugs are often used in 
chemotherapy, e.g., Miproxifene Phosphate, Capecitabine, Captopril, Cyclophosphamide, 
Sulfasalazine, Loperamide, Fosphenytoin, Bambuterol, etc. [20,66,67], and also in several other 
treatments against nausea, convulsion, anesthesia, inflammation, etc., such as valganciclovir, sulindac, 
prednisolone phosphate, propofol phosphate [68], etc. They improve absorption, limit side effects and 
increase the selectivity of target cells. Before 2008, 5-7% of world pharmaceutical sales were prodrugs 
[69], and now, according to Rautio [20] this percentage is close to 10%. We therefore hope that the 
present study will help to promote more integrated assessments of pharmaceutical ecotoxicity, to give 
some evidence that metabolites can impair non-target organisms, and to stimulate monitoring of the 
metabolites in the environment. 
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Supporting information (SI) 
 
Part I 
 
 
 
Predicted 4OHTam and endoxifen concentrations used for ecotoxicity tests 
To predict concentrations of 4OHTam and endoxifen, a two steps procedure was followed: (1) we 
estimated the stability of 4OHTam and endoxifen in daphnia medium, (2) we measured the 
concentration of the two metabolites in different test solutions, and we established a relationship 
between the nominal (i.e., theoretical) and measured concentrations.  
 
Stability of 4OHTam and endoxifen in incubation medium (step 1) 
The stability of 4OHTam and endoxifen in the incubation medium were assessed in parallel 
experiments that were performed during a master thesis [70]. The design of these experiments is 
shown in Figure 3.5. Briefly, the nominal concentrations in final solutions were 1, 3, 100 and 300 
µg/L of 4OHTam and endoxifen, with DMSO percentages of 0.1, 0.0001, 0.1 and 0.01%, respectively. 
These metabolites and DMSO concentrations corresponded to those that would be used if chronic 
ecotoxicological tests were performed on daphnids. The final concentrations contained 50 mL of 
incubation medium (without daphnids). Each dilution was prepared in laboratory glassware with the 
incubation medium (Elendt M4 [8]) that is used for daphnids in ecotoxicological experiments. Final 
solutions were stored for two days in a Coolstore® environmental chamber (16: 8 h light: dark 
photoperiods at 21 ± 1°C), which corresponds to conditions that are used in ecotoxicological 
experiments. 
The final test solutions were sampled immediately after preparation (t0), after 12 h (t12), 24 h (t24) 
and 48 h (t48) of exposure to the Coolstore® conditions. The stock solutions were sampled just after 
preparation (i.e., the day before the test) and just before t0. Solutions were collected in PP microtubes 
(400 µg/L, 3 replicates per concentration, n = 60 for each chemical) and the aliquots were immediately 
frozen at -80°C until analyses. 4OHTam and endoxifen concentrations were analysed by liquid 
chromatography coupled to triple stage tandem mass spectrometry (LC-MS/MS), according to a 
validated method developed at the Laboratory of Clinical Pharmacology of the CHUV (University 
Hospital Centre of the Canton of Vaud, Switzerland [71]).  
	   86	  
 
Figure 3.5: Experimental design of the analytical methods that were run in parallel with 4OHTam and 
endoxifen (nominal concentrations). Sampling was performed at different times (3 replicates per 
concentration, n = 60 for each chemical). The volume of the final concentrations was 50 ml each (without 
daphnia)  
 
The means of the measured concentrations (triplicate) were compared over time (time zero compared 
with other times) to evaluate the stability of the molecules during 48h (Fisher's least significant 
difference method, 95% confidence level, Stagraphics Centurion software, version 16.07 for 
Windows, Virginia USA, www.statgraphics.com). The results show that main differences in 
concentrations occurred during the first 12 hours, and that the mean measured concentrations were 
stable afterward until t48 (Table 3.3), except for 300 µg/L and 100 µg/L of 4OHTam. Note that 
measured concentrations were lower than the nominal by more than 90% in almost every solution, and 
we assumed that interactions with the incubation medium and glass adsorption were the causes of 
chemical loss, as Chamart et al. [72] observed it for tamoxifen. 
 
Concentrations of 4OHTam and endoxifen in ecotoxicological experiments (step 2) 
Three ecotoxicological experiments were performed with 4OHTam and endoxifen: acute-, chronic 
pre-, and two-generational- tests. During these experiments, randomly chosen test solutions were set 
aside in separate glass flasks (without daphnids). These test solutions were sampled at t0 and after 48 
hours (t48) of exposure to the Coolstore® environmental chamber. The stock solutions were sampled 
after preparation and the day of the experiment. At the end of the experiments, a total of 344 samples 
(206 and 138 for 4OHTam and endoxifen, respectively, including the samples from the stability 
experiments) were analysed by LC-MS/MS system of the CHUV [71]. 
Predilution3.00E+03 µg/LDMSO 0.1%
Stock solution2.50E+06 µg/LDMSO 100%
Predilution1.00E+05 µg/LDMSO 100%
Final concentration 300 µg/L DMSO 0.01% Final concentration 3 µg/LDMSO 0.0001% Final concentration 100 µg/LDMSO 0.1% Final concentration 1 µg/LDMSO 0.1%
Sampling time (hour)
t0 - t12 - t24 - t48
Sampling time (hour)
t0 
Sampling time
after preparation and after thawed
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Table 3.3: Stability of 4OHTam and endoxifen in daphnia medium (without daphnids). The measured 
concentrations are expressed as the mean of triplicate samples. Statistical significant differences between 
means of a concentration over times are calculated at the 95.0% confidence level. Difference between the 
nominal and the actual concentrations are expressed in percent 
 
 
 
Predicted concentration of 4OHTam and endoxifen 
 
Polynomial regression 
The measured concentrations of 4OHTam and endoxifen obtained during the stability and the 
ecotoxicological experiments were plotted against their respective nominal concentrations. Then, they 
were fitted using a polynomial regression analysis (Figure 3.6). The equations of the fitted model of 
4OHTam and endoxifen are:  
Ln(pC) of 4OHTam = -2.61748 + 1.19858*Ln(nC) + 0.0244905*Ln(nC)2    (S1) 
Ln(pC) of endoxifen = -1.59776 + 1.14688*Ln(nC) + 0.013011*Ln(nC)2   (S2) 
where pC = predicted concentration, nC = nominal concentration, and the unit = µg/mL (natural log). 
The R2 = 0.95 and 0.97 for 4OHTam and endoxifen, respectively (residual plots were also used to 
check that the assumptions for regression analysis were met, Stagraphics Centurion software, version 
[ stock ] 0 100 2.5E+06 4.2E+06 2.2E+02 -68.622 3.1E+06 1.4E+05 -22.420
[ pre-diluted ] 0 100 1.0E+05 1.5E+05 1.2E+04 -54.205 1.5E+05 2.3E+04 -54.041
[ pre-diluted ] 0 0.1 3000 764.701 310.998 74.510 2.6E+03 5.0E+02 14.141
[ 1 ] 0 0.01 300 17.340 ** 6.049 94.220 43.022  11.941 85.659
[ 1 ] 12 0.01 300 14.045 3.591 95.318 31.512  6.745 89.496
[ 1 ] 24 0.01 300 12.549 4.459 95.817 79.783 34.765 73.406
[ 1 ] 48 0.01 300 7.851 2.363 97.383 66.522 9.957 77.826
[ 2 ] 0 0.1 100 7.430 * 1.205 92.570 16.292 * 6.301 83.708
[ 2 ] 12 0.1 100 4.416 ★ 1.065 95.584 8.724 2.160 91.276
[ 2 ] 24 0.1 100 4.863 ** 1.395 95.137 8.916 0.750 91.084
[ 2 ] 48 0.1 100 2.104 0.342 97.896 8.467 2.125 91.533
[ 3 ] 0 0.0001 3 0.940 * 0.089 68.664 0.263 0.082 91.225
[ 3 ] 12 0.0001 3 0.122 0.058 95.920 0.352 0.146 88.255
[ 3 ] 24 0.0001 3 0.092 0.045 96.924 0.401 0.214 86.647
[ 3 ] 48 0.0001 3 0.134 0.015 95.526 0.227 0.046 92.418
[ 4 ] 0 0.1 1 0.858 * 0.116 14.171 0.274 * 0.071 72.626
[ 4 ] 12 0.1 1 0.056 0.011 94.356 0.115 0.047 88.525
[ 4 ] 24 0.1 1 0.085 0.018 91.453 0.126 0.054 87.364
[ 4 ] 48 0.1 1 0.053 0.034 94.697 0.105 0.035 89.482
** p < 0.05 when compared to t48 ★  p < 0.05 when compared to t24 and t48
*   p < 0.05 when compared to t12, t24, t48 ♯   p < 0.05 when compared to t24
4OHTam
Measured 
(µg/L) SD
Measured 
/ Nominal 
(%)
Endoxifen
DMSO   
(%)ID
Time 
(h)
Nominal 
(µg/L)
Measured 
(µg/L) SD
Measured 
/ Nominal 
(%)
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16.07 for Windows, Virginia USA, www.statgraphics.com). As explained in the materials & methods 
(part 2.1) the unmeasured and measured concentrations of the two-generational study were predicted 
concentrations from the equations S1 or S2. 
Note that even with less analysed concentrations the equation of the fitted model gives an r2 of 0.99 
for 4OHTam and endoxifen, and the predicted concentrations are close to the nominal (Table 3.4). 
This is the case for the results of the stability experiment, for example. 
 
 
 
 
Figure 3.6: Polynomial regression of measured concentrations vs nominal concentrations of 4OHTam and 
endoxifen (natural log). The 60 measured concentrations obtained in the stability experiment were fitted 
against their respective nominal concentration (non-linear regression on the left graph). On the right 
graph, additional measured concentrations (n = 206 and 138 for 4OHTam and endoxifen, respectively) 
were fitted using a new non-linear regression curves (on the right of the table). Graphs show the 95.0% 
prediction intervals for new examination (i.e., predicted concentration) and 95.0% confidence intervals 
for the mean of observations. The prediction and confidence intervals correspond to the inner and outer 
bounds, respectively. Unit = µg/L  
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Table 3.4: Predicted concentrations of 4OHTam and endoxifen and their confidence limits. The measured 
concentrations are expressed as the mean of triplicate samples. Predictions were calculated using a 
polynomial regression of measured concentrations vs nominal concentrations from a stability experiment 
 
 
 
Part II 
 
4OHTam and endoxifen concentrations in the two-generational experiment 
The concentrations of 4OHTam and endoxifen that were tested on daphnids during the two-
generational experiments (21 days of exposure per generation) were selected on the basis of 
preliminary ecotoxicological experiments. An acute toxic test (2 days of exposure) was performed 
first, to find the range of concentrations that induced toxic effects on daphnids. Then, a pre-chronic 
experiment over two generations (21 days of exposure per generation) was run at low concentrations, 
i.e., at concentrations that had no effect in the acute experiment. The two-generational experiments of 
this study were performed using concentrations that covered some acute effect and no chronic effect 
levels. Figure 3.7 summarises the predicted concentrations, the nominal concentrations, and the 
adverse effects of 4OHTam and endoxifen in the acute tests, the chronic pre-tests and the two-
generational tests. 
[ stock ] 2.5E+06 4.2E+06 2.2E+02 5.7E+06 ( 3.5E+06 ; 9.2E+06 ) 100
[ pre-diluted ] 1.0E+05 1.5E+05 1.2E+04 4.0E+04 ( 3.0E+04 ; 5.4E+04 ) 100
[ pre-diluted ] 3000 764.701 310.998 311.826 ( 238.948 ; 406.927 ) 0.1
[ 1 ] 300 12.946 4.115 17.541 ( 13.791 ; 22.310 ) 0.01
[ 2 ] 100 4.703 1.002 4.844 ( 3.895 ; 6.024 ) 0.1
[ 3 ] 3 0.322 0.052 0.116 ( 0.093 ; 0.144 ) 0.0001
[ 4 ] 1 0.263 0.045 0.040 ( 0.030 ; 0.054 ) 0.1
[ stock ] 2.5E+06 3.1E+06 1.4E+05 4.3E+06 ( 2.7E+06 ; 6.6E+06 ) 100
[ pre-diluted ] 1.0E+05 1.5E+05 2.3E+04 6.2E+04 ( 4.7E+04 ; 8.1E+04 ) 100
[ pre-diluted ] 3000 2.6E+03 5.0E+02 795 ( 623 ; 1016 ) 0.1
[ 1 ] 300 55.210 15.850 52.830 ( 42.335 ; 65.928 ) 0.01
[ 2 ] 100 10.60 2.83 15.093 ( 12.348 ; 18.448 ) 0.1
[ 3 ] 3 0.31 0.12 0.330 ( 0.270 ; 0.404 ) 0.0001
[ 4 ] 1 0.16 0.05 0.105 ( 0.081 ; 0.138 ) 0.1
4O
H
Ta
m
E
nd
ox
ife
n
Solutions
Predicted [ug/L]
Confidence limit 95%                    
(lower; upper)
DMSO   
(%)
Nominal 
(µg/L)
Mean 
measured 
(µg/L)
SD
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Figure 3.7: Overview of the test concentrations and the toxic effects of 4OHTam and endoxifen that were 
used in different ecotoxicological tests. The two-generational experiments of this study are named as 
chronic test on the figure (21 days of exposure per generation). In the acute test (2 days of exposure), the 
studied end points were death and immobilisation (n =165 and 180 for 4OHTam and endoxifen 
respectively), while they were death and the total neonates produced per individual (no replicate) in the 
chronic pre-test (n = 6 and 4 for F0 and F1 exposed to 4OHTam chronic pre-test, and n = 6 and 3 for F0 
and F1 exposed to endoxifen, respectively). The exposure periods in the chronic pre-test were 21 and 13 
days for F0 and F1, respectively. The dotted zones are uncertainty areas in which toxic effect may be 
possible. 
 
Acute testing procedure 
Acute experiments were performed on D. pulex neonates (< 24 h, > 3rd brood) exposed 48 hours to 
4OHTam or endoxifen with a protocol adapted from the OECD procedure. Three hundred and forty-
five neonates (n =165 and 180 for 4OHTam and endoxifen, respectively) were randomly pipetted and 
placed in 10 mL of test concentrations (5 individuals per concentrations, 3 replicates). The predicted 
concentrations exposure were 2.61, 4.03, 6.25, 15.41, 24.49, 39.25, 63.40, 103.25, 169.50 µg/L for 
4OHTam, and 7, 11, 18.35, 28.62, 44.84, 79.53, 111.44, 176.81, 281.75, 450.88 µg/L for endoxifen. 
These concentrations correspond to nominal concentrations of 52, 78, 117, 263, 395, 593, 889, 1333, 
2000 µg/L for 4OHTam and endoxifen, as shown in Table 3.5. Both experiment were run in parallel. 
They included a blank (i.e., no chemicals) and a solvent control (0.08 % for 4OHTam and endoxifen) 
that corresponded to the highest percentage of DMSO used in the tests. Same replicates as for 
chemicals were performed in controls. The individuals were not fed and they were place in a 
Coolstore® environmental chamber with 16: 8 h light: dark photoperiods at 21 ± 1°C. The study 
endpoints were death and immobilisation after 24 and 48 hours of exposure to chemicals. 
F0 F1 F0 F1 F0 F1 F0 F1
1 0.14 106 59
3 0.40 92 105
1 0.06 106 44 10 1.36 77 77 no effect
4 0.21 95 53 30 4.26 78 88 95 effects
10 0.49 89 54 52 7.00 0 incertity
30 1.47 107 52 76 82 78 11.00 0
52 2.61 0 100 15.46 75 59
78 4.03 0 117 18.35 0
100 5.26 dead 64 74 176 28.62 0
117 6.25 0 263 44.84 0
263 15.41 0 300 51.83 dead 28 0
300 17.86 dead 37 28 395 70.53 0
395 24.49 0 593 111.44 0
593 39.25 0 800 156.76 x
889 63.40 40 889 176.81 20
1000 72.99 0 1000 202.35 0
1333 103.25 60 1333 281.75 40
2000 169.50 100 2000 450.88 100
0 109 59 82 100 0 109 59 82 100Control (DMSO) Control (DMSO)
Predicted 
(µg/L)
4OHTam effects
Nominal 
(µg/L)
Acute 
test
Nominal 
(µg/L)
Acute 
test
Chronic pre-test Chronic test
Endoxifen effects
Chronic pre-test Chronic testPredicted 
(µg/L)
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Chronic pre-testing procedure 
4OHTam and endoxifen chronic pre-tests were run in parallel over two generations of D. pulex (F0 
and F1). The F0 generation was randomly selected from a single stock of mothers.  
Eighteen neonates (< 24 h, > 3rd brood) were pipetted and isolated in separate glass beakers with 50 
mL of medium (1 individual per concentration, no replicate). The predicted test concentrations were: 
0.06, 0.21, 0.49, 1.47, 5.26, 17.86 µg/L for 4OHTam and 0.14, 1.36, 4.26, 15.46, 51.83, 156.76 µg/L 
for endoxifen. Theses predicted concentrations corresponded to the nominal concentrations of 1, 4, 10, 
30, 100 and 300 µg/L for 4OHTam, and of  1, 10, 30, 100, 300 and 800 µg/L for endoxifen, as shown 
in Table 3.5. Two controls were performed in parallel: a blank (i.e., without chemical) and a solvent 
control (0.03 % of DMSO) that corresponded to the highest solvent percentage used in endoxifen test 
(1 individual per beaker, 3 replicates). On the twenty-first day of maternal exposure, thirteen neonates 
(< 24 h) were collected to form the generation F1. One neonate per beaker (no replicate for chemicals 
and 3 replicates for controls) was transferred to 50 mL of corresponding maternal concentration 
medium for thirteen additional days. The predicted concentrations at 5.26 and 17.86 µg/L of 4OHTam, 
and at 51.83 and 156.76 µg/L of endoxifen were not performed because effects in the first generation 
were already observed. Studied endpoints were the total neonates produced per individual and 
maternal death after 21 and 13 days of exposure for F0 and F1, respectively. The effects were daily 
recorded and the neonates produced were discarded except on the twenty-first day. Daphnids were fed 
daily with a suspension of Tetramin® and 0.2 mgC/daphnia of Pseudokirchneriella subcapitata. The 
test medium was renewed every two days and individuals were maintained in the Coolstore® 
environmental chamber with 16: 8 h light: dark photoperiods and at 21 ± 1°C. 
In the acute test and the chronic pre-experiments, chemical parameters (i.e., pH, T°, water hardness, 
conductivity and oxygen) were measured at the beginning and end of the experiment. The results fell 
within standard values [73]. Potassium dichromate (K2Cr2O7) assay were also performed to follow 
daphnia fitness. The results were consistent with our previous laboratory K2Cr2O7 experiments, where 
the mean (±SD) was: 0.76 (± 0.27) µg/mL. 
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Table 3.5: Nominal and predicted concentrations of 4OHTam and endoxifen in the acute (2 days), the pre-
chronic (21 and 13 days for F0 and F1, respectively) and the chronic toxicity tests (21 days for F0 and F1). 
Predictions were calculated using a polynomial regression of measured concentrations vs nominal 
concentrations. The highest DMSO percentage of each experiment is shown in the last rows 
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Chapter 4   
 
 
 
Are the toxic effects magnified over four generations of D. pulex? 
In this chapter, the multigenerational effects of tamoxifen and 4OHTam on D. pulex are reported and 
discussed. These chemicals were chosen because they were the most toxic anticancer compounds 
among the pharmaceuticals tested in this thesis and because magnified effects over generations were 
suspected, even at low concentrations. Therefore, four generations of daphnids were exposed 14 days 
each to increasing concentrations of tamoxifen or 4OHTam. The aim of this study was to assess 
whether daphnids sensitivity towards these chemicals increased over generations. The studied end 
points on daphnids were the size, the reproduction, the viability and the intrinsic rate of natural 
increase (r). The design of the study was adapted from previous experiments that were performed on 
daphnids with tamoxifen and its metabolites (see chapter 2 and 3). In this chapter, additional 
prospective experiments are also presented about organisms’ ability to recover when animals were 
withdrawn from chemical, and about daphnids exposed to tamoxifen and 4OHTam used in 
combination.  
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Abstract  
Tamoxifen and its metabolite 4-hydroxy-tamoxifen (4OHTam) are two potent molecules that have 
anticancer properties on breast cancers. After consumption, patients excrete both chemicals in 
wastewaters and tamoxifen was measured in wastewaters and natural waters. The concentrations of 
4OHTam in waters have never been reported. A single study reported 4OHTam effects on the 
microcrustacean Daphnia pulex. The effects of tamoxifen and 4OHTam over more than two 
generations are unknown in aquatic invertebrates. The main goal of this study was to assess the 
sensitivity of the microcrustacean Daphnia pulex over four generations, based on the size, the 
reproduction, the viability and the intrinsic rate of natural increase (r). Additional experiments were 
carried out to observe whether the effects of tamoxifen and 4OHTam were reversible in the next 
generation after descendants were withdrawn from chemical stress (i.e., recovery experiment), and 
whether the lowest test concentration of each chemical induced toxic effects when both concentrations 
were combined (i.e., mixture experiments). Our results showed that tamoxifen and 4OHTam induced 
adverse effects at environmentally relevant concentrations. Tamoxifen and 4OHTam impaired size, 
viability, reproduction and intrinsic rate of natural increase (r) in the four generations of treated 
daphnids but these effects were not magnified over generations. Tamoxifen was more potent than 
4OHTam on D. pulex. When used in mixture, the combination of tamoxifen and 4OHTam induced 
effects in offspring while no effects were observed when these chemicals were tested individually. In 
the recovery experiment, the reproduction and the size were reduced in offspring withdrawn from 
chemicals. Our results suggest that tamoxifen and its metabolite may be a relevant pharmaceutical to 
consider in risk assessment. 
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Introduction 
Pharmaceuticals are among thousand of other xenobiotics that invade the aquatic environment (for 
reviews see [1,2]). Over the last decades, thousands of tons of drugs have been produced yearly to 
treat human ailments [3,4], and human consumption seems to be the primary pathway for 
pharmaceuticals to reach the aquatic environment [5]. Once consumed, intact and/or metabolised 
forms of the drug are excreted via faeces and urine. Traditional sewage treatment processes remove 
organic matter [6], but some classes of synthetic pharmaceuticals are not efficiently eliminated.  
Although ozone and activated carbon treatments have been proposed to remove these chemicals more 
efficiently, many sewage treatment plants (STPs) continue to operate without these technologies [7]. 
Therefore, the excreted pharmaceuticals and their metabolites were identified in STP effluents and in 
natural waters [2,3,8–13]. 
Pharmaceuticals in the environment are of great concern because of their potentially harmful impact 
on ecosystem structure and functioning, including humans via water and fish consumption [14]. 
Anticancer compounds are an important family to consider for four main reasons among others. First, 
they may be toxic to living organisms, even at therapeutic concentrations.  Indeed, traditional 
anticancer agents rarely target abnormal cells exclusively [15], and frequent side effects are observed 
in normal cell types, such as mutagenic, carcinogenic or teratogenic effects [16]. Second, the 
manufacture, consumption, and final release of anticancer pharmaceuticals may rise with time in 
response to an increase in cancer patients [17,18]. Third, these pharmaceuticals were measured in STP 
effluents and natural waters [3,9,16,19–23], proving that they reach aquatic environments. Finally, the 
distribution, the half-life and the long-term effects of anticancer drugs in the aquatic environment are 
sparsely known. As other pharmaceuticals, their continuous release in waters gives them the status of 
pseudo-persistent compounds [24]. This prolonged presence exposes fauna and flora to potentially 
long-term effects, which can adversely modulate eukaryotic organisms homeostasis [2,25]. 
Tamoxifen is a carcinogen and an endocrine disruptor that is used worldwide as a treatment or an 
adjuvant treatment of early and advanced breast cancer in males and females. In 1980, tamoxifen was 
approved as a hormonal agent mainly due to its similar efficiency in humans, but less toxic, as 
dietylstilboestrol [26,27]. Additionally, tamoxifen is a triphenylethylene drug that behaves as a 
selective estrogen receptor modulator with anti-estrogenic effects (inhibiting agent) and estrogenic-
like effects (stimulating agent) on alpha and beta estrogen receptors (ERα, ERβ) depending on the 
target tissues. Its anticancer action in breast tumours may also be explained by its antagonist properties 
on the estrogen-related receptors (ERRs) [28] with an amino acid sequence that is over 60% identical 
to ERα and ERβ [29]. In addition to its own pharmacological potential, tamoxifen is considered a 
pseudo-prodrug [30] because active metabolites are formed by liver metabolism in vertebrates [31]. Its 
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metabolite, 4-hydroxy-tamoxifen (4OHTam), has a higher potency and affinity for ERs than 
tamoxifen and also a higher affinity for ERRα and ERRγ [32–34]. 
Tamoxifen and 4OHTam are mainly excreted in faeces.  Tamoxifen also has a long half-life in humans 
[35]. For example, less than 10% of an oral tamoxifen dose of 90 mg was reported to be excreted after 
10 days [36]. In patients chronically treated with tamoxifen, the concentrations in 24-h samples of 
faeces ranged from 230-1092 µg and 123-579 µg for tamoxifen and 4OHTam, respectively [37]. 
Tamoxifen can pass through STPs unchanged. It was measured in effluents [38,39,13] and natural 
waters, including groundwater [40,13,41], in concentrations ranging from 0.02 to 0.37 µg/L, and from 
0.01 to 0.21 µg/L, respectively. No data exists for metabolites. Tamoxifen causes reproductive effects 
on fish [42,43], immobilises the microcrustacean Daphnia magna [44] and inhibits the naupliar 
development [45]. These adverse effects were observed in either acute or one generational 
experiments. Recently, a two generational study showed morphological abnormalities on D. pulex 
descendants that were exposed to environmentally tamoxifen concentrations (Borgatta et al. [46], 
submitted). Another two generational study reported a decrease in reproduction and offspring size 
when daphnids were treated with 4OHTam. Based on the calculated population growth (i.e., intrinsic 
rate of natural increase), this study also suggested that magnified effects were possible if experiments 
had been performed on additional generations (Borgatta et al.[47] submitted). To the best of our 
knowledge, the effects of tamoxifen or of 4OHTam on more than two generations of daphnids have 
not been studied. Also, several authors have risen concerns about the serious lack of chronic exposure 
studies of drug residues in aquatic organisms [16,25,48]. Brennan et al. [49] drew attention to the 
paucity of multigenerational testing and underlined the needs of multigenerational ecotoxicity 
experiments with estrogen-like compounds considering the shorter life cycle of animal in general with 
respect to human. While alarming effects were observed in humans, the case of diethylstilbestrol still 
remains an classic example [50], nothing is known on the possible effects on other organisms. In 
invertebrates, Brennan et al. [49] showed a significant decrease in daphnids fertility over consecutive 
generations after long-term exposure to diethylstilbestrol. The experiment performed by Kidd et al. 
[51] on fathead minnows was also an impressive example of the long-term effects of 17α-
ethynylestradiol, a synthetic estrogen used in birth-control pills. By the second year of this study, a 
complete crash of fathead minnow populations and a near extinction of this species from the studied 
lake were observed. 
The first aim of this study was to evaluate the sensitivity of the primary consumer D. pulex exposed to 
acute and chronic levels of tamoxifen and 4OHTam. The second goal of the study was to observe 
whether the effects were magnified over four generations exposed during 14-d to tamoxifen and 
4OHTam, considering the size, the reproduction and the longevity of the daphnids, which were 
sensitive endpoints in our previous studies [46,47]. Fourteen days of exposure was chosen because 
daphnids produce about 4 to 5 clutches during this period in our laboratory conditions, which is 
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sufficient to highlight the reproductive tendency of treated animals. It is also assumed that daphnids 
rarely survive beyond the stage of the 4th adult instar under natural conditions [52]. In this study, 
prospective experiments were performed to observe whether the effects of tamoxifen and 4OHTam 
were reversible in offspring after removal of the chemical stress. Indeed, it is known that tolerance or 
adaptation to environmental stress exists in treated organisms, which involves physiologic acclimation 
or genetic modifications by natural selection, respectively [53,54]. Additionally, side effects can 
persist in animals that were withdrawn from chemicals, such as the anti-inflammatory drug ibuprofen 
[55]. Finally, we performed another prospective experiment to observe whether the lowest test 
concentration of each chemical, which singularly does not affect the daphnids, induces toxic effects 
when the animals were exposed to both chemicals because the aggregate action of tamoxifen and its 
metabolites is suspected to result in therapeutic beneficial effect of tamoxifen [34,56,57].  
 
Materials & Methods 
Chemicals 
Tamoxifen and 4-OHTam were purchased from Sigma/Fluka (>99%, lot: 011M1682V and E8284 for 
tamoxifen and 4OHTam, respectively). A day before the experiments, the chemicals were dissolved in 
pure DMSO [58]. These stock solutions were prepared at the measured concentrations of 3.87E+06 
µg/L and 1.34E+07 µg/L for 4-OHTam and tamoxifen, respectively. They were stored in glass flasks, 
in the dark at -80°C for no longer than the tests duration. The stock solutions were thawed at room 
temperature before each use. 
 
Test organisms 
In our laboratory, D. pulex from the arenata strain have been reared for three years in conditions that 
maintain asexual reproduction [47]. Individuals that were mass-cultured and individuals that were 
chronically exposed to chemicals were fed daily with both 0.2 mgC/daphnia of Pseudokirchneriella 
subcapitata algae and suspension of Tetramin®[59,60]. They were reared in glass flasks placed in a 
Coolstore® incubator sets to 21°C with a 16/8 hour light/dark cycle. After feeding, the location of 
these flasks was randomized and changed daily. Daphnids respective medium was renewed every two 
days in conditions that maintain parthenogenesis reproduction: total hardness 90 ± 5 mg/l as CaCO3; 
pH 8 ± 0.2; conductivity adjusted to 25°C, 283 ± 13 µS/cm; dissolved oxygen > 5 mg/L. These 
chemical parameters were measured every four days. Potassium dichromate (K2Cr2O7) assays were 
performed weakly and at the beginning and the end of each experiment. During the experiments, their 
EC50s (±SD) corresponded to the K2Cr2O7 results in our laboratory and were 0.6 (± 0.23) µg/mL. 
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Acute toxicity experiment 
Daphnids were exposed two days to tamoxifen and 4OHTam in acute experiments. For each chemical, 
these experiments were performed twice and the results were combined. Neonates (< 24 h, > 3rd 
brood) were randomly pipetted in glass tubes at the following concentrations: 2.78, 3.79, 5.26, 6.02, 
7.31, 8.87, 10.46,12.60,14.44, 15.32, 18.37, 20.48, 22.34, 29.34, 42.40 µg/L of tamoxifen, and 18.89, 
25.13, 26.28, 31.04, 36.73, 38.40, 47.59, 50.58, 59.06, 80.85, 93.18, 111.07, 126.44, 138.72 µg/L of 
4OHTam (five individuals per vessel, 3 replicates). These exposure levels are predicted concentrations 
that were calculated from measured concentrations. Test solutions were regularly sampled and 
analysed, the measured concentrations were plotted against their respective nominal level using a 
polynomial regression. The equations of the fitted models, the number of samples and the nominal 
concentrations are presented in the supplementary information. Two controls, in four replicates, were 
performed in parallel: a blank (i.e., with no chemicals) and a solvent control that contained 0.004% 
and 0.063% DMSO for tamoxifen and 4OHTam, respectively. These percentages corresponded to the 
maximum solvent percentage that was used at the highest test concentration of each chemical. Note 
that DMSO levels were not analysed in the test solutions. The studied endpoint was the 
immobilisation of the living daphnids > 20 seconds, despite a gentle agitation of the tube, and they 
were observed after 24 and 48 h of exposure. The individuals were not fed during the experiment. 
 
Multigenerational test procedure 
Tamoxifen and 4OHTam toxicity tests were performed over four generations (F0, F1, F2 and F3). The 
concentrations used in these experiments were based on results from acute tests and from previous 
range-finding tests. The experimental design is shown in Figure 4.1. Neonates (< 24-h, > 3rd brood) 
were randomly pipetted from parthenogenetic mothers to form the first generation (F0, n = 111). Three 
individuals per beaker (3 replicates per concentration) were placed in 150 mL of test solutions. Based 
on previous experiments, the predicted test concentrations were: 0.16, 1.48, 17.86 and 72.99 µg/L of 
4OHTam and 0.12, 0.67 and 5.26 µg/L of tamoxifen (see supplementary information for 
corresponding nominal concentrations). The solvent percentage in each test concentrations was 0.01% 
and 0.002% of DMSO for 4OHTam and tamoxifen, respectively. The same percentages of DMSO 
were used in solvent controls (DMSO level was not analysed), and a blank was performed in parallel. 
Solvent controls and blanks were performed in four replicates. On the fourteenth day, neonates aged < 
24 h were collected to form the second generation (F1, n = 100). Whenever possible, three individuals 
per concentrations were placed in 150 mL of corresponding maternal concentration medium (3 
replicates). Each fourteenth day of exposure, the same procedure was repeated to form the next 
generations F3 (n = 93) and then the F4 (n = 92).  
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Prospective recovery and mixture experiment procedures 
Prospective recovery performances were observed on eighteen neonates aged < 24-h. Three neonates 
per beaker (2 replicates) were pipetted from the F1 that was exposed to 1.48 and 17.86 µg/L of 
4OHTam, and to 0.67 µg/L of tamoxifen. These neonates were named as R1, R2 and R3, respectively 
(Figure 4.1) and they were placed in daphnia medium exempted from chemicals. The selected 
concentrations corresponded to toxic and non-toxic reproductive concentrations in the F0. No recovery 
follow-up was performed at 5.26 µg/L of tamoxifen because not enough neonates were produced at 
day 14. Mixture experiment was performed with twelve additional neonates. They were exposed to the 
lowest concentrations of each chemical, i.e., 0.12 and 0.16 µg/L of tamoxifen and 4OHTam, 
respectively. Three neonates (2 replicates) were pipetted from the F2 that was exposed to 0.12 µg/L of 
tamoxifen, and they were named M1. Three other neonates (2 replicates) were taken from the blank 
F2, and they were named M2. Individuals used in the recovery and the mixture toxicity experiments 
were reared during 14 days in similar manner as individuals that were reared in the multigenerational 
test. 
 
Figure 4.1:  Experimental design for multigenerational tests. Four successive generations (from F0 to F3) 
of D. pulex were exposed 14 days each to tamoxifen or 4OHTam (n = 184 and 212 for tamoxifen and 
4OHTam, respectively). In grey background, thirty additional individuals were placed in daphnia 
medium exempted from chemical (i.e., R1, R2 and R3) or in mixture medium (i.e., M1 and M2, n = 12) of 
0.12 and 0.16 µg/L of tamoxifen and 4OHTam, respectively. “*” 3 organisms/beaker (3 replicates) except 1 
replicate with 2 individuals, “**” 3 organisms/beaker (3 replicates) except 1 replicate with 1 individuals, 
“+” 3 organisms/beaker (2 replicates), blank and solvent control = 3 organisms/beaker (4 replicates). The 
DMSO solvent percentages were 0.01 and 0.002 % for 4OHTam and tamoxifen, respectively 
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D. pulex reproduction, mortality and size 
In each 14 days experiment, the number of dead parents (i.e., mortality) and the number of neonates 
produced per beaker were recorded daily. The neonates were discarded, except on day 14 of each 
generation. On the fourteenth day of exposure, the size of parents was measured from the rostrum to 
the end of caudal spine, using an Olympus polarization microscope BX51 with digital image system 
(Colorview). The size differences between individuals, X %, were calculated as follow:  
X = 1-(z / y)*100        (1) 
where z is the mean size of the control in µm, and y is the mean size of the treated organism in µm. 
 
Intrinsic rate of natural increase (r) 
The intrinsic rate of natural increase (r) was calculated using mortality and birthrate results in each 
beaker. The results were performed by iteration of the Euler-Lotka equation [61]: 
Σ lxmxe-rx = 1         (2) 
where lx is the proportion of individuals surviving to age x, mx is the number of neonates produced per 
surviving adult at age x, and x is time expressed in days.  
 
Statistics 
Acute testing results of each chemical were expressed as a sigmoidal dose-response curve, from which 
the acute EC50s and confidence intervals were calculated. The chemicals were tested at least two 
times (two independent assays). The results from the two respective assays were pooled and analysed 
using Prism5 (Graphpad Inc., CA, USA) to estimate the concentrations giving x% effect ECx by non-
linear regression (log agonist vs. normalized response-variable slope). The dose-response curves were 
generated by the following nonlinear regressions: 
Y= 100/(1+10^((LogEC50-X)*HillSlope))     (3) 
where x is the logarithm of concentration. Y is the response, and Y starts at 0 and goes to 100 with a 
sigmoid shape. The HillSlope results were 2.1 and 4.5 and for tamoxifen and 4OHTam, respectively. 
EC50 values, corresponding to the 50% immobilization for D. pulex, were the test endpoints in acute 
tests, whereas no-observed effects concentrations (NOECs) were used in chronic tests. In the 
multigenerational experiment, the reproduction was calculated as the average of total neonates that 
was produced per adult over the exposure period. Reproduction and size results were first compared 
between blank and DMSO controls. Because no significant differences in daphnia size, reproduction 
and intrinsic rate were observed between these two controls, both were combined and used as unique 
control. Effects on daphnids exposed to mixture were compared to the combined control of 4OHTam 
 106 
of the same generation. Comparisons were run using a one-way ANOVA test, which was followed by 
the Bonferroni post hoc test (α < 0.05). Calculations were performed using the software GraphPad 
Prism (Stagraphics Centurion software, version 16.07 for Windows, Virginia USA, 
www.statgraphics.com). 
 
Results 
Acute toxicity experiment 
The acute effects of tamoxifen and 4OHTam on D. pulex are shown in Figure 4.2. Tamoxifen was the 
most toxic compound followed by 4OHTam; the concentration that immobilized 50% of the 
individuals, i.e., EC50 (IC 95%), was: 9.49 (8.1 to 11.14) and 42.04 (38.29 to 46.18) µg/L for 
tamoxifen and 4OHTam, respectively. 
 
Figure 4.2: Acute toxicity effects on D. pulex. Immobilization was recorded after 2 days of exposure to 
tamoxifen or 4OHTam. For tamoxifen, the HillSlope is 2.1, r2 is 0.89, EC50 is 9.49 µg/L, n is 115, while for 
4OHTam the HillSlope is 4.52, r2 is 0.94, EC50 is 42.04 µg/L, n is 250. The exposures are predicted 
concentrations from measured test solutions (µg/L) 
 
Multigenerational testing 
Daphnia reproduction, mortality and size 
D. pulex were exposed 14 days to tamoxifen and 4OHTam, upon four generations (i.e., from F0 to 
F3). The toxic effects are summarized in Table 4.1 and Table 4.2. The reproduction and size of the F0 
generation exposed to 5.26 µg/L of tamoxifen were significantly reduced (p < 0.05) compared to 
controls by about 93% and 31%, respectively. Note that size differences were already observed by 
visual assessment during the first week of F0 exposure since these one week-old individuals looked 
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like neonates < 24-h of the control. At day 14, the seven living parents that were exposed to 5.26 µg/L 
of tamoxifen produced a total of seven neonates to form the next generation F1. This result represents 
an average of one neonate per daphnids, while the average neonate per daphnia from the control was 
6.5. Among these seven individuals, five died before maturity  (i.e., before day 6.5 in our laboratory 
conditions) and their size was visually equal to control neonates. The sixth individual died on day 9, 
and it size was measured and compared to neonates (< 24-h) of controls (Figure 4.3). Its body-length 
was 844.42 µm, whilst mean neonate size of controls was 771.74 µm (± 32.18). At the end of the 14 
day exposure, no neonates were produced by the F1 and only one adult survived with a size 36% 
smaller than controls. The size and reproduction of F1 and F2 in all other concentrations were not 
significantly different from control. The size of the F3 exposed to 0.12 and 0.67 µg/L of tamoxifen 
was statistically higher than control, by about 6 and 3%, and the reproduction was not different from 
controls. The no observed effect concentration (NOEC), which is the highest tested concentrations 
where the studied endpoint was not significantly different from the controls, was calculated for 
reproduction (NOECrep), size (NOECsize) and calculated growth population (NOECr). In each 
generation, these NOECs of tamoxifen were 0.67 µg/L, except in the F1, whose NOECr was 0.12, and 
in the F3 where the NOECsize and the NOECr could not be calculated because they were below the 
lowest test concentration. Therefore, these two NOECs were considered as < 0.12 µg/L. 
In the 4OHTam experiment, 100% of the individuals died within the first 24 hours of exposure to 
72.99 µg/L. The size and the reproduction of the four generations exposed to 17.86 µg/L were 
significantly different (p < 0.001) from control: the size of the F0, F1, F2 and F3 was reduced by 12%, 
21%, 37% and 11%, respectively, and the reproduction of the F0, F1, F2 and F3 was reduced by 26%, 
49%, 47% and 32%, respectively. The size of the F1 and the F2 that were exposed to 1.48 µg/L of 
4OHTam was significantly reduced by 9% and 6%, respectively. Finally, the mean size of the F0 
exposed to 0.16 µg/L was significantly higher than control, by 4%. This increase in size was 
considered as adverse effect. Therefore, the NOECsize was 0.16 µg/L in each generation, except in the 
F0, whose NOEC was below the lowest test concentration, i.e., < 0.16 µg/L. Regarding reproduction, 
the NOECrep was 1.48 µg/L in each generation. 
Reproductive and developmental toxicities observed in daphnids treated with tamoxifen and 4OHam 
in this study were equivalent with side effects already described in a previous study [46]. Although 
morphological abnormalities were not studied in this multigenerational experiment, we randomly 
chose neonates to be examined under microscope to confirm our previous observation. We found 
premature neonates that were smaller than 24-h neonate from controls, and neonates with abnormal 
morphology, i.e., curved spine and large antennas; as an example, Figure 4.4 shows one individual 
with such abnormalities. 
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Figure 4.3: Size of D. pulex exposed nine days to 5.26 µg/L of tamoxifen. On the left, a 9 day-old daphnia 
exposed to tamoxifen. On the right, a neonate aged < 24h produced by DMSO control of the same 
generation. 
Figure 4.4: Abnormal D. pulex exposed to 0.16 µg/L of 4OHTam. On the left, neonate < 24-h 
with curved spine and thick antennas. On the right, neonate of the same aged from control. 
 
Intrinsic rate of natural increase (r) 
The intrinsic rate of natural increase (r) of F0 and F1 exposed to 5.26 and 0.67 µg/L of tamoxifen, 
respectively, was significantly reduced compared to control, while r was significantly increased in the 
F3 exposed to 0.12 and 0.67 µg/L (p < 0.05, Table 4.1 and Table 4.2). The calculated r was also 
significantly reduced in each generation exposed to 17.86 µg/L of 4OHTam. The estimated population 
growth was not different from controls in all other concentrations. 
 
Recovery and mixture experiments 
In the recovery experiment, the size of the R1 and the R2 were statistically smaller than control, by 
5% and 7%, respectively (p < 0.05). The reproductive performance of R2 and R3 was significantly 
lower than control, by 30 and 15%, respectively. The intrinsic rate of natural increase r was also 
significantly reduced in R3 (Table 4.1 and Table 4.2). 
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The F1 neonates (< 24-h) that were born in blank (M2) or in solution of 0.12 µg/L of tamoxifen (M1), 
were placed in combined solution of 0.12 and 0.16 µg/L of tamoxifen and 4OHTam, respectively, 
during 14 days. The reproduction was significantly decreased in M1 and M2 by 20% and 21%, 
respectively. Pre-exposure to tamoxifen did not influence the toxicity of the mixture and these results 
were considered as similar in this study (Table 4.3). 
 
Table 4.1: Multigenerational effects of tamoxifen on D. pulex. Four generations were exposed to tamoxifen 
during 14 days each. R3 are individuals that were removed at birth from solutions of 0.67 µg/L of 
tamoxifen and that were placed in daphnia medium exempted from chemical for 14 days. The size, 
reproduction and intrinsic rate of natural increase (r) are shown with mean ± standard deviation 
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size,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
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Intrinsic,,,,,,,,
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Control ! 7 14%±%0.4 2263.64%±%67.67 41%±%3.4 0.38%%±%0.020.12 0 14%±%0 2289.01%±%72.61 44%±%6.9 0.39%±%0.020.67 0 14%±%0 2282.46%±%27.53 45%±%3.8 0.39%±%0.015.26 22 12%±%4.0 1559.73%±%119.90%** 3%±%2.6%** 0.06%±%0.06%**
Control ! 5 14%±%0.2 2282.29%±%141.22 43%±%2.6 0.37%%±%0.010.12 0 14%±%0 2322.80%±%81.65 44%±%8.1 0.37%±%0.020.67 22 12%±%3.6 2346.58%±%74.14 43%±%1.5 0.33%±%0.01%**5.26 89 7%±%3.5 1462.15%%♯ 0%♯ 0%♯
Control ! 0 14%±%0 2341.69%%±%147.68 53%±%3.6 0.41%%±%0.010.12 0 14%±%0 2405.95%±%97.09 51%±%3.2 0.42%±%0.010.67 0 14%±%0 2347.86%±%71.98 51%±%3.0 0.40%±%0.015.26R3 0 14%±%0 2350.52%±%60.14 45%±%3.5%* 0.36%±%0.01%*
Control ! 0 14%±%0 2322.02%±%97.13 57%±%5.2 0.41%%±%0.010.12 0 14%±%0 2478.35%±%54.40%** 52%±%1.1 0.44%±%0.01%**0.67 11 14%±%1.0 2395%±%102.08%* 57%±%9.8 0.44%±%0.01%**5.26*%% %p%<%0.05%(Bonferroni%correction) ♯ 1%individual%at%the%end%of%the%test** %p%<%0.001%(Bonferroni%correction)F
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Table 4.2: Multigenerational effects of 4OHTam on D. pulex. Four generations were exposed during 14 
days each to chemical. R1 and R2 are individuals that were removed at birth from solutions of 1.48 and 
17.86 µg/L of 4OHTam, and that were placed in daphnia medium exempted from chemical for 14 days. 
The size, reproduction and intrinsic rate of natural increase (r) are shown with mean ± standard deviation 
 
 
Table 4.3: Mixture effects of tamoxifen and 4OHTam on D. pulex. Neonates of the F2 exposed to blank 
(M1), or neonates of the F2 exposed to 0.12 µg/L of tamoxifen were reared during 14 days in mixed 
solution of 0.12 µg/L and 0.16 µg/L of tamoxifen and 4OHTam, respectively. The size, reproduction and 
intrinsic rate of natural increase (r) are shown with mean ± standard deviation 
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Control ! 7 14%±%0.4 2283.64%%±%49.55 48%±%4.8 0.4%%±%0.020.16 11 13%±%2.0 2379.10%±%10.63%** 49%±%3.9 0.38%±%0.041.48 0 14%±%0 2293.44%±%21.02 53%±%0.8 0.41%±%017.86 11 13%±%2.3 2020.77%±%77.10%** 35%±%8.4%** 0.37%±%0.05%**72.99 100 1%±%0 %! %! 0%**
Control ! 5 14%±%0.2 2325.16%%±%71.08 43%±%4.8 0.35%%±%0.010.16 0 14%±%0 2246.64%±%139.11 40%±%9.6 0.35%±%0.031.48 11 13%±%1.7 2108.25%±%140.19%** 36%±%2.2 0.33%±%0.0117.86 44 10%±%4.5 1827.67%±%120.78%** 22%±%3.6%** 0.21%±%0.07%**72.99
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Control ! 0 14%±%0 2405.84%±%69.28 59%±%3.6 0.42%%±%0.010.16 0 14%±%0 2479.55%±%103.17 61%±%8.0 0.42%±%0.031.48 0 14%±%0 2396.77%±%152.65 58%±%14.7 0.41%±%0.0217.86 0 14%±%0 2154.45%±%133.62%** 40%±%9.4%* 0.37%±%0.04%**72.99*% p%<%0.05%(Bonferroni%correction) R1:%individuals%from%the%F1%parents%exposed%to%1.48%μg/L** p%<%0.001%(Bonferroni%correction) R2:%individuals%from%the%F1%parents%exposed%to%17.86%μg/L
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Treatment Predicted,
(μg/L)
Mortality,
(%)
Longevity,
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size,(μm) Reproduction,
(mean)
Intrinsic,
rate
Control 0 0 14$±$0 2405.84$±$69.28 59$±$3.6 0.42$$±$0.01
Tamoxifen 0.12
+ + 0
,4OHTam 0.16
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+ + 0
,4OHTam 0.16
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M1
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47$±$3.5$**14$±$0 2435.54$±$90.36 0.43$$±$0.01
14$±$0 2400.53$±$60.57 46$±$2.4$** 0.41$$±$0.01
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Discussion and conclusion 
In the acute and multigenerational experiments, D. pulex was sensitive to tamoxifen and its metabolite 
4OHTam. These chemicals were able to disrupt physiological processes of treated animals, such as the 
size, the viability or the reproduction, at concentrations of the same magnitude of order as the 
tamoxifen concentrations measured in natural waters, i.e., up to 0.21 µg/L [40,13,41]. Indeed, the 
NOECs of tamoxifen were between 0.12 µg/L and 0.67 µg/L, while the NOECsize and the NOECr 
were below 0.12 µg/L in the fourth generation. The NOECrep and the NOECr of 4OHTam were 
similar over the fourth generations, but the NOECsize increased with generations until 1.48 µg/L in 
F3. In our previous studies [46,47], the NOECrep of tamoxifen and 4OHTam were 0.72 and 1.48 
µg/L, respectively, which are similar values than those obtained here, but the NOECrep and NOECr of 
the second generation exposed to 4OHTam suggested magnified effects (i.e, NOECs < 1.8 µg/L), 
which is not confirmed in this study. Further investigations would be needed to therefore confirm or 
infirm this observation.  
In both acute and multigenerational experiments, tamoxifen displayed a higher toxicity than 4OHTam, 
particularly when comparing mortality and reproductive success. For examples, the second generation 
(F1) did not survive at 5.26 µg/L of tamoxifen, while the same generation was still living at 17.86 
µg/L of 4OHTam, which is about 3-times the tamoxifen concentration. Furthermore, the lethal 
concentration was about 14-time higher than tamoxifen lethal concentration (i.e., 5.26 µg/L). In 
vertebrates conversely, tamoxifen is less potent than 4OHTam [56,62]. In addition, tamoxifen 
therapeutic concentrations in human are higher than the effect concentrations in daphnids. Although 
the internal exposure levels of tamoxifen and its metabolite are unknown in daphnids, the external 
concentrations (i.e., the test concentrations) were compared to the effective concentrations in treated 
patients, which are also considered as safe concentrations. In humans, tamoxifen plasma concentration 
ranges between 140 and 160 µg/L at steady-state, after chronic administration of 20 and 30 mg of 
tamoxifen citrate daily [37,63], which is higher than the toxic tamoxifen concentrations in daphnids. 
After same daily doses of tamoxifen, the plasma concentrations of 4OHTam are lower than tamoxifen, 
with values between 2.4 to 3.7 µg/L [37,64]. Our results show that daphnids reduced their size when 
exposed to 1.48 µg/L of 4OHTam already. Therefore, daphnia sensitivity to both chemicals seems to 
be higher than human, and this is not the case with all pharmaceuticals. For instance, in a 21 days 
study that was performed with daphnids exposed to diclofenac, a nonsteroidal anti-inflammatory drug, 
the NOEC was 25,000 µg/L, while the maximal plasma concentration in human was 588 µg/L of 
dicolfenac after an oral dose 25 mg [65]. Similarly, the reproduction decreased in D. magna exposed 
to 110 µg/L (nominal concentration) of the β-blocker propranolol, while the effective plasma 
concentrations of the drug is considered as 40 µg/L, with a maximum effect at 100 µg/L after chronic 
treatments [66,67].  
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In the recovery experiment, daphnids that were placed in medium exempted from chemical were not 
able to recuperate totally. For instance, the reproduction decreased in R1 and R2, and R2 size was also 
reduced. The same effects were observed in their treated parents (F1) and sisters (F2) exposed to 
4OHTam. In R3, the decrease in reproduction and population growth was not fully understood 
because no effect was observed in their treated parents exposed to tamoxifen. For R1 and R2, we 
hypothesize that repair processes failed, despite the absence of chemicals in medium. Such repair 
processes occur at different levels of the biological organizations, such as the molecular, cellular and 
tissue levels. Molecular damages involve protein, lipids or/and DNA damages that can be reversed by 
a return to normal state or direct/indirect repairs, while cellular recovery is usually possible by cell 
replacement. Tissue damages are repaired by cells elimination and regeneration, and also by 
extracellular matrix production, such as scar tissue, or by apoptosis [68,69]. Epigenetic regulations, 
which causes changes in phenotype or gene expression without changes in DNA sequence [70,71] 
may also be responsible of the observed effects. Indeed, epigenetic regulations were discovered in 
cells exposed to tamoxifen [72–74] and recently, Vandegehuchte et al. [75] shown that epigenetic 
dysregulations occurred in daphnids that were exposed to various compounds. However, based on our 
results it is only possible to say that 4OHTam induced persistent adverse effects in daphnids 
withdrawn from chemical solution, without evident explanations on repair processes failure or 
epigenetic inheritance. Further investigations may also be required to clarify whether the adverse 
effects were induced when daphnids grew in maternal brood chamber or whether changes were 
inherited directly from treated mothers. In toxicology, embryogenesis is known to be a critical window 
during which chemical can induce deleterious effects in embryos [76,77]. For instance, ex vivo assays 
could be performed in which eggs are removed from maternal brood chamber, individually deposited 
in separate wells and exposed at different time to tamoxifen or 4OHTam. Such experiments would 
determine the developmental stage at which embryos are the most susceptible to chemicals. Besides, 
our results show that these chemicals induced effect in developing organisms because morphological 
abnormalities in offspring were observed with tamoxifen and 4OHTam treatments, and also because 
reproduction was reduced in individuals that were either pre-exposed or not to chemical during the 
mixture experiment. 
In the mixture experiment indeed, the reproduction was impaired in daphnids when they were exposed 
to the lowest test concentration of both chemicals, while daphnids exposed to each substance 
separately at the same concentration were not affected. Moreover, the sum of both concentrations 
tested in mixture was 7.36E-10 g/mol (i.e., 3.23E-10 g/mol + 4.13E-10 g/mol for 0.12 µg/L of 
tamoxifen and 0.16 µg/L of 4OHTam, respectively), which is below the NOECs that were calculated 
for reproduction of each generation exposed either to 4OHTam or tamoxifen. A synergic effect of 
tamoxifen and 4OHTam in daphnids [78] may be suspected, but the combined potential of these 
chemicals needs to be verify in complete mixture experiments (i.e., with complete individual dose 
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response curves) to confirm whether the mixture would not followed the concept of concentration 
addition. The latters are recommended without the presence of solvent, because this chemical may also 
have contributed to the reproductive effect found in our experiment. Our results however are in 
accordance with authors who claimed that tamoxifen clinical effect is the result from the aggregate 
effect of tamoxifen and its metabolite [34,56,57].  
Regarding the calculated population growth, the intrinsic rate of natural increase (r) mainly decreased 
when reproduction was low, which is in accordance to Meyer et al. [79] who stated that the dynamic 
of r is primary influenced by the effects on reproduction and mortality during the few first broods. In 
the 4OHTam experiment, the smallest daphnids produced the least neonates, but they were able to 
survive until the next generation was formed. Low concentrations of tamoxifen and 4OHTam were 
able to increase daphnia size, and to our knowledge, increased size in daphnids was observed in 
response to stressors such as predator [80], but not in response to chemical exposure. This increase 
was considered as an adverse effect because it would not have been induced in absence of chemical. 
Although not significant, the body-sizes of the F0, F1 and F2 that were exposed to each tamoxifen 
concentration were higher than controls, except F3 that displayed a statistical significance. Actually, 
these little differences may have been magnified through generations until significant differences were 
observed in F3. This hypothesis would be in line with the statements that mother sizes are positively 
correlated to the size of neonates [52,81,82], and that females born larger mature to larger sizes than 
those born smaller [83]. Another hypothesis that may explain why size increased in daphnids exposed 
to low concentrations could be related to endocrine system, which may be modulated differently 
depending on exposure levels. For instance, it is known that the dose-related pattern of tamoxifen in 
certain biomarkers is different [84]. In liver cancer cells indeed, high concentrations of tamoxifen are 
agonistic, while low concentrations are predominantly antagonistic to the sex hormone-binding 
globulin (SHBG) gene expression [85]. In daphnids, the mechanisms of action of tamoxifen and its 
metabolites are unknown, but in vertebrates, tamoxifen and 4OHTam interact with ERs and ERRs. 
Although daphnids lack of ER, we hypothesized that these chemical may act in their ERR because a 
copy of the gene ERR (dappu-ERR, NR3 subfamily) was discovered in D. pulex [86]. This gene is 
close structurally to their human homologs ERRs and ERs [86]. Therefore, the sensitivity of D. pulex 
may be explained by the presence of this receptor. 
In summary, our results showed that tamoxifen and 4OHTam induced adverse effects at 
environmental relevant concentrations and that daphnids were not able to recover after have been 
removed from chemical exposure. The effects on size and reproduction were not magnified over 
generations but morphological abnormalities were observed on offspring and the mixture of these 
chemicals may have a synergic action on daphnids. These results and the effects of tamoxifen in 
daphnia neonates or in other aquatic species, such as masculinization on fish [87,88] and 
developmental effects in sea urchin embryos [46,89], suggest that tamoxifen may be a relevant 
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pharmaceutical to consider in risk assessment. More general, anticancer drugs are overall an important 
family of chemicals to consider in ecotoxicology because of the expected growth in demand for these 
compounds, with consequent increase of their presence in the environment, and because of the release 
of new molecules on the market. Indeed, the global cancer rate is estimated to increase by 50% by 
2020 [17] and the number of new cancer cases is expected to grow to 23.6 million each year by 2030. 
Such growth represent about 68% more cases than in 2012 [18]. As a consequence, new oncological 
molecules will be released, but probably without too much consideration on their end-life in the 
environment. Indeed, pre-clinical studies assess the beneficial impact of pharmaceuticals on a target 
population [90], but they are mainly biomedically oriented. They are performed on human cells and 
vertebrates organisms, primary on short-term and at high concentrations [91], while their chronic and 
multigenerational effects on non target species, such as the fauna and flora, are still set aside. We 
therefore hope that this study will help to develop awareness of the scientific community to this 
increasing threat for the environment. 
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Supporting information  
 
Predicted concentrations 
During the assay, the test concentrations were regularly sampled and analyzed, following the 
procedure proposed in (see chapter 2). A total of 318 and 259 were analyzed for 4OHTam and 
tamoxifen, respectively Table 4.4. The data were used to fit a non-linear regression that explains the 
relation between the measured and nominal concentrations of the respective molecule. The equations 
of the fitted models are: 
Ln(pC) of tamoxifen = -3.60211 + 1.07666*Ln(nC) + 0.0333645*Ln(pC)2  (S1) 
Ln(pC) of 4OHTam = -2.61748 + 1.19858*Ln(nC) + 0.0244905*Ln(nC)2   (S2) 
where pC = predicted concentration, nC = nominal concentration, and the unit = µg/L. The r2 = 0.94, 
and 0.95 for tamoxifen and 4OHTam, respectively (the assumptions for regression analysis were 
checked using residual plots). In this study, the exposure concentrations of each chemical were 
predicted concentrations that were calculated from the equation (S1) or (S2).  
Table 4.4: Tamoxifen and 4OHTam predicted concentrations. Predictions were calculated using a 
polynomial regression of measured concentrations vs nominal concentrations (n = 318 and 259 for 
4OHTam and tamoxifen, respectively). The measured concentrations are expressed as the mean of 
triplicate samples 
 
Nominal 
(µg/L)
Measured 
mean 
(µg/L)
SD
Predicted 
(µg/L)
Nominal 
(µg/L)
Measured 
mean 
(µg/L)
SD
Predicted 
(µg/L)
3 0.16 0.06 0.16 2 0.11 0.04 0.12
30 1.45 0.59 1.48 20 0.61 0.40 0.67
300 11.49 6.15 17.86 200 7.78 3.36 5.25
1000 51.37 26.28 72.99
315 18.89 220 5.77
404 11.55 6.46 25.13 230 1.00 0.28 6.02
420 26.28 264 6.90
485 31.04 280 1.05 0.21 7.31
560 36.73 317 8.27
582 15.53 1.71 38.40 340 2.55 2.62 8.87
698 47.59 381 9.95
735 50.58 400 0.90 0.14 10.46
838 36.56 6.68 59.06 457 11.98
945 68.21 480 1.55 0.92 12.60
1089 80.85 548 14.44
1225 93.18 580 2.55 0.92 15.32
1416 75.82 26.71 111.07 658 17.48
1575 126.44 690 3.85 2.19 18.37
1699 138.72 830 3.20 1.27 22.34
947 25.71
1000 3.50 1.84 27.27
n = 318 n = 259
Tamoxifen4OHTam
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Chapter 5  
 
 
 
Is D. pulex sensitive to imatinib? 
In this chapter, the anticancer drug imatinib was tested on the aquatic invertebrate species D. pulex. 
Imatinib has revolutionized the treatment and the survival of patients suffering from chronic myeloid 
leukaemia or gastrointestinal stromal tumours because it has a very specific mode of action in these 
tumour cells. The aim of this study was to observe the sensitivity of two generations of D. pulex 
towards imatinib. The range of test concentration was chosen using a preliminary chronic experiment 
on a single generation exposed 21 days to this chemical. The viability, the size, the reproduction and 
the intrinsic rate of natural increase were not impaired in D. pulex at the concentrations that were 
chosen in this experiment, except at the highest concentrations where the reproductive performance 
was decreased in the first treated generation. 
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Ecotoxicological experiment of imatinib on two generations of D. pulex 
 
Introduction  
Among the pharmaceuticals that are continuously released in the aquatic system, anticancer drugs 
were measured in sewage treatment plant (STP) effluents and in natural waters [1–4]. Consumers are 
considered as the primary source of pharmaceutical release in the aquatic system by sewage treatment 
plant (STP) effluents [5]. After consumption, pharmaceuticals are metabolised and excreted via urine 
and faeces. A general hypothesis may therefore be made such as: the more people consume 
pharmaceuticals, the more pharmaceuticals residues would be released in sewage waters by excreta. 
Because the incidence of cancers is increasing worldwide, the consumption of anticancer drugs may 
follow this trend. Indeed, the number of new cancer cases is expected to grow to 23.6 million each 
year by 2030, which would be 68% more cases than in 2012 [6]. Besides, oncology represents one of 
the most active fields of pharmaceutical innovation and progress [7]. The use of signal transduction 
inhibitors provides a typical example that illustrates the recent evolution of cancer treatments [8,9]. 
For instance, imatinib (Gleevec®) and the next generations of tyrosine kinase inhibitors (TKIs) are 
recent family of anticancer drugs that targets specific mechanisms of tumour cell biology. Imatinib 
was the first TKI that reached the market and this molecule has revolutionized the treatment and the 
survival of patients suffering from chronic myeloid leukaemia or gastrointestinal stromal tumour 
[10,11]. Indeed, TKIs prolong life of patients with certain types of cancers compared to other 
traditional treatment [12–15]. These anticancer drugs are able to disrupt specific signalling pathways 
that maintain cellular proliferation and this specificity is considered as higher than in the traditional 
anticancer therapies [16]. 
As other molecules, TKIs are eliminated in urines and/or faeces [17]. For instance, 68% and 13% of 
the imatinib dose is eliminated in faeces and in urine, respectively, within seven days [18]. About 25% 
of the recovered dose is unchanged imatinib and 20% is the active metabolite CGP 74588. The 
remaining portion is oxidised derivatives of both compounds. Considering that this treatment has a 
lifesaving efficacy, provided that it is taken indefinitely, its consumption should increase and thus its 
arrival in sewage treatment plants (STPs). Traditional and new sewage treatment processes remove 
efficiently organic matter [19] but not some class of chemicals such as synthetic pharmaceuticals 
[3,20–22]. To the best of authors' knowledge, imatinib has never been monitored in sewage and 
natural waters. Therefore, this molecule is considered here as a possible unremoved pharmaceutical 
that may reach continuously the natural water with STP effluents. The aquatic flora and fauna may be 
chronically exposed to the tyrosine kinase action of imatinib because a variety of related tyrosine 
kinases are present in eukaryotic cells [23], such as in cells of aquatic or terrestrial invertebrates [24–
26]. The tyrosine protein kinases whose signal transduction pathways have been preserved throughout 
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the evolution are found in a variety of living organisms from yeast to mammal, including aquatic 
invertebrate such as mussels [27,28]. Seiler [28] specified that “although in mammalian cells there is a 
redundancy in signal transduction pathways that reduces the cytotoxic effects of imatinib on normal 
cells, thus resulting in it is relative specificity of action towards targeted neoplastic cells, this 
redundancy might not be as developed in non-mammalian organisms, making them potentially more 
vulnerable against the inhibitory actions of drugs like Gleevec®”. This author also underlined that 
new antineoplastic drugs such as imatinib and others from the same family, which targets and inhibits 
the abl-kinase constitutively expressed through the recombinant form of BCRabl in chronic 
myelocytic leukaemia for example, could influence cellular events on orthologs of the c-abl (or c-kit) 
mediated signal transduction pathway in non-target organisms. In the water fleas Daphnia pulex for 
instance, insulin-like peptides and tyrosine kinase receptor family, such as insulin receptor and 
complex neurotrophin signalling system that includes three paralogous Trks (a neurotrophin receptor) 
were recently found [23,25,26,29], making it potential sensitive to the tyrosine kinase inhibitors 
imatinib. 
Daphnids have short parthenogenic life-cycle and they are easy to maintain under laboratory 
conditions. This microcrustacean family is widely used in ecotoxicology experiments, and their acute 
and chronic sensitivity to toxicants were correlated to other species [30,31]. The aim of the study was 
to assess the sensitivity of D. pulex towards imatinib and to observe whether the effects were 
magnified in the descendants. The size, the reproduction and the longevity of treated animals were 
followed in a two-generational experiment in which each generation was exposed 14 days to imatinib. 
 
Materials and Methods 
Chemicals 
Imatinib Mesylate was purchased from LC Laboratoires (>99%, lot: 10127223). The day before the 
experiment, the chemical was dissolved in ultrapure water  (LaboStar™ 7-TWF-DI and UV systems). 
This stock solution was prepared at the mean measured concentrations of 790 ± 204 mg/L (mean ± 
standard deviation). It was stored in glass bottle, in the dark at -80°C, and thawed at room temperature 
before each use. Each 14-d, the stock solution was sampled and the concentration was analysed by 
liquid chromatography that was coupled to a triple stage tandem mass spectrometry system (LC-
MS/MS). The limit of quantification (LOQ) of the LC-MS/MS assay for imatinib was 1 µg/L. 
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Test organisms 
D. pulex from the arenata strain have been mass-cultured for three years in our laboratory (Borgatta et 
al., submitted). They are reared in conditions that maintain parthenogenetic reproduction (total 
hardness 85 ± 5 mg/l as CaCO3; pH 8 ± 0.2; conductivity adjusted to 25°C, 280 ± 14 µS/cm; dissolved 
oxygen > 5 mg/L). Stock daphnids as well as individuals exposed to chemicals were reared in glass 
beakers placed in a Coolstore® environmental chamber (16: 8 h light: dark photoperiods at 21 ± 1°C). 
They were fed daily with 0.2 mg C/daphnia of Pseudokirchneriella subcapitata algae and a suspension 
of Tetramin® tropical fish food (Gouvernement du Canada and Environnement Canada, 1996; OECD 
Guidelines for the Testing of Chemicals, 2008). 
 
 
Figure 5.1: Imatinib experimental design for the two-generation toxicity test on D. pulex. On day 14, 
neonates were kept to form the second generation (F1). They were exposed to corresponding maternal 
concentration medium (measured concentrations). * 3 organism/beaker (3 replicates per concentration), 
** 3 organisms/beaker (4 replicates per concentration)  
 
Two-generation testing procedure 
Imatinib long-term assay was run over two generations of D. pulex (F0 and F1). This two-generational 
study was adapted from previous multigenerational experiments (see chapter 4), and the framework of 
the experimental design is illustrated in Figure 5.1. Briefly, the parental generation (F0) was randomly 
selected from a single stock of mothers. Fifty-seven neonates (< 24 h, > 3rd brood) were pipetted and 
placed in separate glass beakers with 150 mL of medium. Each beaker contained three daphnids in 
triplicate. The mean measured exposure levels were: 1.2, 6.5, 29, 93.2, 626 µg/L. On the fifteenth day 
of maternal exposure, fifty-seven neonates (< 24-h) were collected to form the second generation, 
F0 ge
nerat
ion
D. pulex stock culture 
14 daysexposure Reproduction
Body-length
Longevity
neonates < 24 hrs, > 3rd brood
Controls(blank) ͸ʹ͸ɊȀͻ͵ǤʹɊȀʹͻɊȀ͸ǤͷɊȀ1.2 ɊȀ 
*** ****
F1 ge
nerat
ion 14 daysexposure
neonates < 24 hrs
͸ʹ͸ɊȀͻ͵ǤʹɊȀʹͻɊȀ͸ǤͷɊȀ1.2 ɊȀ 
*** ****
Controls(blank) Reproduction
Body-length
Longevity
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named F1. Three neonates per replicate were transferred to 150 mL of corresponding maternal 
concentration medium (3 replicates). A water medium control (blank) was included in four replicates 
and daphnids from the controls were reared in the same environmental conditions as the test 
organisms. The exposure medium was renewed every two day. Imatinib test solutions were sampled 
and measured every two medium renewal (i.e., at renewal and just before, after 2-d of exposure in the 
environmental chamber, without daphnia). The nominal and measured concentrations are summarised 
in Table 5.1. 
 
Table 5.1: Nominal and measured concentrations of imatinib. LOQ is 1 µg/L 
 
 
At the beginning of the test, and each week until the end of the experiment, a potassium dichromate 
(K2Cr2O7) assay was performed to assess daphnia sensitivity. The K2Cr2O7 results fell within the 
values of our laboratory, i.e., 0.6 µg/mL ± 0.23 (mean EC50s ± standard deviation). Chemical 
parameters in test medium were measured every two days, at medium renewed, and the conditions 
allowed parthenogenetic reproduction during the whole experiment. 
 
Statistics 
Daphnia mortality, reproduction and size 
The mortality (i.e., number of dead parents) and the number of offspring per replicate were recorded 
daily. The neonates were then discarded, except on day 14. On the fourteenth day of exposure, the size 
of parents was measured from the rostrum to the end of caudal spine, using an Olympus polarization 
microscope BX51 with digital image system (Colorview). Then, the mothers were discarded. The size 
differences X between individuals were calculated as follow:  
X = (y - z / y)*100         (1) 
where y is the the mean size of the control in µm, and z is the mean size of the treated organism in µm. 
Unit = % 
Nominal (µg/L)
Mean measured 
(µg/L)    SD
850000 790000 203647
3 1 0
16 6 2
80 29 16
400 93 71
2000 627 135
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Intrinsic rate of natural increase (r) 
The intrinsic rate of natural increase r was calculated using mortality and birthrate data and by 
iteration of the Euler-Lotka equation (Lotka, 1913): 
Σ lxmxe-rx = 1          (2) 
where lx is the proportion of individuals surviving to age x, mx is the number of neonates produced per 
surviving adult at age x, and x is time expressed in days. Intrinsic rate of natural increase (r) was 
calculated for each replicate and the results are presented as the mean per replicate. 
The no-observed effects concentration (NOEC), which is the highest test concentration at which the 
studied endpoint was not significantly different from controls, was calculated for reproduction 
(NOECrep), for size (NOECsize) and for r (NOECr). The reproduction was calculated as the average 
of total neonates that was produced per adult during the exposure period. Reproduction and size 
results were compared with the control. Comparisons were run using a one-way ANOVA test, which 
was followed by the Bonferroni post hoc test (α < 0.05). Calculations were performed using the 
software GraphPad Prism (Stagraphics Centurion software, version 16.07 for Windows, Virginia 
USA, www.statgraphics.com). 
 
Results and discussion 
The results of the two-generational experiment in D. pulex exposed to imatinib are summarised in 
Figure 5.2. The reproduction, the size and the calculated population growth of the F0 were not 
different at any concentration when compared with control, except at the exposure level of 626 µg/L. 
At this high concentration, daphnids’ reproduction was reduced by 15.9 % (p < 0.001). In cancer 
patients treated with imatinib, the effective plasma concentration required to induce an effect is also 
high. In patients treated with 400 mg/day of imatinib for instance, a steady-state of approximately 979 
µg/L is reached in plasma after 29 days [11], which is higher than the exposure level that induced an 
effect on daphnids of the first generation. 
However, in the second generation of daphnids exposed to imatinib, no effect was observed at any 
concentration. Our results cannot explain the reason of this lack of toxicity, which can either result 
from the physical-chemical properties of the molecule itself or the organism tolerance or adaptation to 
the chemical stress [32,33].  
The no-observed effect concentrations (NOECs) could not be calculated because they were above the 
test concentrations, except for F0 whose NOECrep was 93.2 µg/L. Therefore, the NOECs were 93.2 
and > 626 µg/L for the F0 and F1, respectively. A single study reported the effects of imatinib on 
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daphnids and the toxic concentrations were lower than those in our study [34]. After 7 and 21 days of 
exposure, NOECrep were 0.3 µg/L and 3 µg/L in C. dubia and D. magna, respectively, which is lower 
by an order of magnitude of 300 to 30 when compared with the NOEC found in this study. Although 
no difference were generally observed in the overall sensitivity of the D. pulex and the D. magna when 
animals were exposed to several chemicals [35], a difference in sensitivity to imatinib seems here to 
exist between D. pulex, D. magna and C. dubia. 
 
 
Figure 5.2: Reproduction and size of two generations (F0 and F1) of D. pulex exposed 14 days to imatinib. 
Reproduction is the mean number of neonates per concentration that was produced during 14-d of 
exposure. The size is the mean body-length of individual aged 14 days (mean ± SD, n = 57 for F0 and F1). 
** p < 0.01 
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In this study, imatinib is not considered as toxic to D. pulex. However, other ecotoxicological 
experiments should be performed on different aquatic species such as algae and vertebrates to confirm 
that imatinib is a non-toxic molecule for the aquatic fauna and flora. Also, other TKIs have been 
marketed after imatinib, such as gefitinib, sunitinib, nilotinib, dasatinib, sorafenib and lapatinib. These 
new generations of molecules are used against various cancers but still with a broad prevalence for 
chronic myelogenous leukemia and gastrointestinal stromal tumours. Because these molecules 
demonstrated a definite efficacy on survival of advanced cancer patients - however less impressive 
than for imatinib in its specific indications - a progressive increase in their use and in their release in 
the environment is expected to occur. Therefore, it would be interesting to monitor these compounds 
in the environment and to determine their potential effects in aquatic vertebrates and invertebrates. 
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Chapter 6   
 
 
 
Does tamoxifen induce effects at the protein level? 
The aim of this chapter was to identify and quantify proteins in daphnids exposed to tamoxifen using a 
so-called ecotoxicoproteomic experiment. Ecotoxicoproteomics aims to understand changes that occur 
at the protein level in cells or an organism in response to stress, such as D. pulex exposed to the 
anticancer drug tamoxifen. First, preliminary steps about extraction of daphnia proteins are described, 
because little is known on this procedure with aquatic invertebrates. The objective of this preliminary 
part was to determine an easy and efficient technic procedure to obtain sufficient biological material. 
The second part of the chapter contains the protein analysis results of the ecotoxicoproteomic 
experiment that was performed with D. pulex exposed for 2 and 7 days to tamoxifen. 
  
 132 
Ecotoxicoproteomics: preliminary steps (Addendum) 
 
Introduction 
The aim of ecotoxicoproteomics is to find protein changes that occur in cells or in organisms that were 
exposed to toxins, such as pollutants or drugs. In a classical workflow, proteins extracted from 
organisms, tissues or cells are fractionated, digested into peptides with an enzyme (usually trypsin), 
and peptides are analysed by liquid chromatography coupled to mass spectrometry (LC-MS/MS). 
Identification of peptides and proteins is carried out by search of mass spectrometry data against 
databases containing protein sequences of the organism investigated [1]. In this way, several 
thousands of protein can typically be identified and quantified in biological samples if a 
comprehensive protein sequence database of the test organism is available. Unfortunately, little has 
been published on the extraction of daphnia proteins [2] for proteomic analyses. For an efficient 
application of proteomics to daphnids, three following steps were assessed and optimized: 
1. preparation of daphnia samples 
2. daphnia homogenisation and cell lysis 
3. protein extraction and fractionation 
The aims of this preliminary experiment were twofold. First, the quantity of daphnids needed for 
protein extraction was assessed. Second, the best procedure for a relevant and reproducible protein 
extraction was assessed and chosen. 
 
Procedure 
Sample preparation 
Two different life steps were used because the protein expression profile may be different depending 
on the age of the daphnids: neonates 2-days old and adults 7-days old (i.e., daphnids that have just 
laid). Therefore, 75 and 20 individuals were reared in daphnia medium exempted from chemical 
during 2 and up to 7 days, respectively.  
After 2 and 7 days, individuals were pipetted from the daphnia medium into 15 ml falcon tubes. Then, 
water was rapidly pulled out through a homemade plastic vacuum tube until the volume drops down to 
< 0.5 ml. Samples were immediately immersed in liquid nitrogen to freeze the contents. Each falcon 
tube was stored at – 80°C until homogenization and cell lysis. Protease inhibitor and urea 8M was 
added into frozen samples just before homogenization process. No replicate was performed. 
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Daphnia homogenization and cell lysis 
Cell lysis and protein extraction were optimized to obtain sufficient biological material and 
reproducible results. The cell lysis and homogenization of the daphnids was performed with the 
FastPrep® homogenizer instruments or ultrasonic probe.  
The FastPrep® homogenizer instrument crushed daphnids by multidirectional jerky movements of 1.4 
mm glass beads. The homogenizing intensity was 5.5, for 10 seconds (5x). Eight samples could be run 
at the same time. The ultrasonic probe homogenized daphnids using amplitude of 30%, for 10 seconds 
(3x). With the available instrument samples could be only treated one by one. 
 
LC-MS/MS analyses 
Proteins were extracted and fractionated by SDS-PAGE 1D gel (i.e., sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) according to their molecular weight, and quantified in-gel by 
densitometry. Gel lanes were cut into 10 pieces and proteins were in-gel digested with trypsin. 
Resulting peptides were analysed by LCMS/MS with a hybrid linear trap LTQ-Orbitrap XL mass 
spectrometer for protein identification and quantification based on spectral counting. 
 
 
Figure 6.1: FastPrep® homogenizer (on the left) and ultrasonic probe (on the right) instruments 
 
 134 
Results 
The yield per adult daphnia (7 days old) was 8.3 and 19.6 µg of proteins for FastPrep® homogenizer 
and ultrasonic instrument, respectively, while the number of identified proteins was similar for both 
methods, with 880 and 908 identified proteins respectively (Figure 6.2). Both protocols provided 
sufficient material for LC-MS/MS analyses, although the homogenizer instrument was less efficient 
compared to ultrasonication. But the FastPrep® instrument was finally chosen, as it allows an easy, 
fast and parallel extraction of proteins (8 samples treated in similar manner and at the same time). 
Nevertheless, the bead size had to be changed for an efficient protein extraction of 2-days old 
daphnids, as the beads were bigger than daphnia size, decreasing their ability to crush young daphnia 
body. We decided therefore to use smaller beads, of 0.5-0.75 mm instead of 1.4 mm, in further 
ecotoxicoproteomics experiments. The number of 2-days old daphnids could thus be reduced from 100 
to 70. 
 
Figure 6.2: Number of identified proteins in D. pulex of 7 days old 
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Abstract 
Among pollutants released into the environment by human activities, residues of pharmaceuticals are 
an increasing matter of concern because of their potential impact on ecosystems. The aim of this study 
was to analyse differences of protein expression resulting from acute (2 days) and middle-term (7 
days) exposure of aquatic microcrustacean Daphnia pulex to the anticancer drug tamoxifen. Using a 
liquid chromatography - mass spectrometry shotgun approach, about 4000 proteins could be 
identified, providing the largest proteomics dataset of D. pulex published up to now. Considering both 
time points and tested concentrations, 189 proteins showed a significant fold change. The identity of 
regulated proteins suggested a decrease in translation, an increase in protein degradation and changes 
in carbohydrate and lipid metabolism as the major effects of the drug. Besides these impacted 
processes, which reflect a general stress response of the organism, some other regulated proteins play 
a role in Daphnia reproduction. These latter results are in accordance with our previous observations 
of the impact of tamoxifen on D. pulex reproduction, and illustrate the potential of 
ecotoxicoproteomics to unravel links between xenobiotic effects at the biochemical and at the 
organismal level. Data are available via ProteomeXchange with identifier PXD001257. 
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Introduction 
For years, residues of pharmaceutical agents have been identified worldwide in the aquatic 
environment (for review see [3]. Apart from industrial releases and veterinary usages, human 
consumption is the primary origin of pharmaceutical discharged into natural waters [4]. Once 
consumed, pharmaceuticals are body-excreted into sewage waters in either intact and/or metabolised 
forms. The processes of sewage treatment plants (STPs) are not efficient for all chemicals [5], and 
several pharmaceutical residues have been identified in STP effluents and natural waters, such as 
anticancer agents [4,6–14].  
Ecotoxicology studies the impact of chemicals on ecosystem health and function at various levels of 
the biological organisation, such as organism, population and ecosystem [15]. With the development 
of “omics” technologies, such as proteomics, it is possible now to unveil links between xenobiotic 
effects at the organism level and changes at the molecular level. Proteins in particular reflect the 
biochemical functions that may be directly or indirectly affected by chemical stress, and proteomics 
analyses may detect responses that are unforeseen and unobserved at the organism level during 
exposure to xenobiotics [15]. These sub-organism responses may be early signs of toxicity that would 
eventually impact organism health and functions. Until recently, most of ecotoxicoproteomics studies 
have focused on few vertebrate species because of a lack of complete protein sequence databases in 
invertebrate species relevant for ecotoxicology [15]. Nevertheless, the progress of genomic sequencing 
is steadily increasing the number of available protein sequence databases for invertebrates. A complete 
genomic sequence of Daphnia pulex, an aquatic micro-crustacean, was for example recently released 
(wfleabase.org). Froehlich et al. [2] showed that it could be used for LC-MS/MS proteomic analyses 
of this organism and another close species, Daphnia longicephala. Their data demonstrated 
proteomics to be very promising for ecotoxicological investigations of Daphnia species, although only 
a few publications have investigated the proteome of daphnids until now [15]. Indeed, daphnids are 
commonly used in ecotoxicology [16] because they are key organisms in the food chain and they 
produce clones by parthenogenesis.  
Most of ecotoxiproteomics studies used two-dimensional gel electrophoresis (2D-GE) coupled to mass 
spectrometry analysis, which is a low throughput technique, difficult to scale and with some bias 
against identification of membrane or basic proteins [17]. A more interesting alternative is the shotgun 
method, where proteins are extracted and digested into peptides, which are then analysed by liquid 
chromatography (LC) coupled with tandem mass spectrometry (MS/MS). With the possibility of 
adding fractioning steps, several thousands of proteins can potentially be identified and quantified in 
one experiment. As a proof-of-principle, Ralston-Hooper et al. [18] demonstrated the efficiency of a 
shotgun approach to investigate the effects of drug fadrozole, a known endocrine disruptor, in fish. 
This study focuses on the protein expression of D. pulex exposed to the anticancer drug tamoxifen. 
This pharmaceutical was measured in STP effluents and natural waters in concentrations up to 0.37 
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and 0.21 µg/L, respectively [12,19]. Tamoxifen is prescribed for the prevention and treatment of 
hormone receptor-positive breast cancers in humans [20–22]. It is a selective modulator of alpha and 
beta estrogen receptors (ERα and ERβ), which also bounds estrogen-related receptors (ERRs, [23]). 
Although D. pulex lacks homologs of estrogen receptors, it does contain a gene for an estrogen-related 
receptor (ERR,[24]), which may explain why D. pulex was sensitive to tamoxifen in a previous study 
that was performed in our laboratory [chapter 2]. Indeed, tamoxifen decreased reproduction and 
induced miscarriages and/or morphologically abnormal neonates. The aim of this study was to further 
investigate the impact of tamoxifen on daphnids at the biochemical level, and to analyse protein 
expression after acute (i.e., 2 days) and middle-term (i.e., about 7 days) exposure of D. pulex to 
tamoxifen. A gel-free, label-free quantitative proteomics approach was used, including a peptide 
fractionation step for maximal proteome coverage. 
 
Materials and Methods 
Chemicals 
Tamoxifen was purchased from Sigma/Fluka and used without further purification (>99%, lot: 
011M1682V). A stock solution was prepared in pure DMSO at the measured concentration of 
25 mg/L and was stored in a glass flask at -80°C. The solution was thawed at room temperature before 
each use.  
 
Test organisms 
D. pulex individuals from the arenata strain were mass-cultured in conditions that maintain 
parthenogenetic reproduction. Stock and treated daphnids were fed daily with 0.2 mgC/daphnia of 
Pseudokirchneriella subcapitata algae and a suspension of tropical fish food (Tetramin®) [25,26]. The 
medium Elendt (M4) and tamoxifen test solutions were renewed every two days. Daphnids were 
reared in glass beakers placed in a Coolstore® environmental chamber with 16-h light and 8-h dark 
photoperiods, at 21 ± 1°C. At the beginning of the experiments, a potassium dichromate (K2Cr2O7) 
assay was performed to assess daphnia sensitivity to chemicals and the results were conformed to the 
classical response given by the organisms. Dissolved oxygen, pH and conductivity were also 
controlled at the beginning and end of each medium change. The position of the beakers in the 
environmental chamber was randomized in order to minimize variability. 
 
Ecotoxicological test procedure 
Two and seven days experiments were carried out according to the experimental design shown in 
Figure 6.3. Seven hundred and sixty neonates, aged less than 24-h (3rd brood), were randomly 
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selected, placed in 900 mL of medium (70 individuals per glass beaker, 2 replicates) and exposed to 
tamoxifen at predicted concentrations of 0.1 (C1) and 2.4 (C2) µg/L, which correspond to nominal 
concentrations of 1.8 (C1) and 88.0 (C2) µg/L. Prediction of tamoxifen concentrations were based on 
a non-linear regression between nominal and measured concentrations (Daphnia medium without food 
and organisms) to take in account loss of the drug by adsorption, as described in chapter 2. After 2 
days of exposure, five hundred and sixty daphnids were removed and frozen in liquid nitrogen for 
proteomic analyses. The two hundred individuals left were placed in 450 mL of the corresponding 
medium with tamoxifen (25 individuals per glass beaker, 2 replicates) until first egg laying (4 to 6 
additional days), before being frozen for proteomics analyses. Two controls were carried out for both 
period exposures (2 replicates): a blank (i.e. Elendt M4 medium, without solvent and chemicals) and a 
solvent control with DMSO 0.0008 %, which corresponds to the highest concentration used in the 
tests. For both controls, 60 daphnids (2 replicates) were also selected for proteomics analyses after 4 
days of test, as additional time point to follow evolution of proteome during D. pulex development.  
 
Figure 6.3: Experimental design of the D. pulex ecotoxicity test. Tamoxifen concentrations are predicted 
concentrations based on a non-linear regression between theoretical (nominal) concentrations and 
measured concentrations in solution (see Material and Methods for more explanations). Nominal 
concentrations were 1.8 (C1) and 88.0 (C2) µg/L. All tests were performed in duplicates. 
 
Proteomics analyses 
For cell lysis, 1 ml of urea 8M containing protease inhibitors (complete Protease Inhibitor Cocktail 
Tablet, Roche Applied Science) was added to the samples, which were then homogenized by 
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FastPrep©-24 (www.mpbio.com) using 0.5-0.75 mm glass beads (intensity 6.5, 4 x 20 sec). After 
quantification by SDS-PAGE and densitometry, a volume corresponding to 90 ug of proteins was used 
for further sample preparation. Proteins were reduced with dithiothreitol (5 mM) and alkylated with 
iodoacetamide (20 mM). After a trichloroacetate-deoxycholate precipitation, they were resuspended in 
250 mM triethylammonium bicarbonate pH 8.0 containing 4M urea and digested overnight at 37°C 
with 2 µg of trypsin. The obtained peptide mixtures were desalted on SepPak C18 cartridges (Waters 
Corp., Milford, MA), dried, dissolved in 4M Urea with 0.1% Ampholytes pH 3-10 (GE Healthcare) 
and fractionated by off-gel focusing as described [27], using a 13 cm pH 3-10 strip. The 12 fractions 
obtained were desalted on a microC18 96-well plate (Waters Corp., Milford, MA), dried and 
resuspended in 20 µl 0.1% formic acid, 3% (v/v) acetonitrile for LC-MS/MS analysis. Fractions 10 
and 11 were pooled in the same volume. 
Mass spectrometry analyses were performed by the Protein Analysis Facility (University of 
Lausanne). The tryptic peptide samples were analyzed by LC-MS/MS on an Ultimate 3000 RSLCnano 
HPLC system coupled to a hybrid linear trap LTQ-Orbitrap XL mass spectrometer (Thermo 
Scientific). Mobile phases used were (A) H2O:MeCN 97:3 (v/v) + 0.1 % formic acid and (B) 
H2O:MeCN 20:80 (v/v) + 0.1 % formic acid. Five µL of sample were loaded onto a trapping 
microcolumn Acclaim PepMap 100 C18 (2 cm x 100 µm, Dionex) in H2O:MeCN 97:3 (v/v) + 0.1 
formic acid at a flow rate of 3.5 µL/min. After 12 min, they were eluted and separated on a reversed-
phase nanocolumn Acclaim PepMap RSLC C18 column (75 µm ID x 15 cm, 2 µm, Dionex) at a flow 
rate of 300 nl/min. The gradient used lasted 125 min, starting at 12 min with 2 % of solvent B, from 2 
to 11 % of B in 5 min, 11 to 40 % B in 73 min, 40 to 55 % in 9 min, 55 to 95 % in 2 min, 95 % B 
during 3 min, 95 to 2 % in 6 min and 15 min at 2 %. In data-dependent acquisition controlled by 
Xcalibur 2.0 software (Thermo Scientific), the ten most intense precursor ions detected in the full MS 
survey performed in the Orbitrap (range 350 - 1700 m/z, resolution 60 000 at m/z 400) were selected 
for fragmentation, and fragment ions were analyzed in the ion trap. MS2 was triggered by a minimum 
signal threshold of 10’000 counts and carried out at a relative collision energy of 35 % (CID), with an 
isolation width of 4.0 amu. Only precursors with a charge higher than one were selected for 
fragmentation and the m/z of fragmented precursors was then dynamically excluded from any 
selection during 60 s.  
LC-MS/MS data were analyzed and quantified with MaxQuant version 1.3.0.5 [28], using Andromeda 
as search software [29] against UniProt (release 2012_06) database restricted to Daphnia pulex 
taxonomy (30’137 sequences). Cleavage specificity was trypsin/P (cleavage after K, R, including KP 
and RP) with two missed cleavages. Mass tolerances were of 6 ppm for the precursor and 0.5 Da for 
CID tandem mass spectra. The iodoacetamide derivative of cysteine was specified as a fixed 
modification, and oxidation of methionine, protein N-terminal acetylation, deamidation of asparagine 
and glutamine were specified as variable modifications. Protein and peptide identifications were 
filtered at 1% FDR established by MaxQuant against a reversed sequence database. A minimum of 
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one unique peptide was necessary to discriminate sequences which shared peptides. Sets of protein 
sequences which could not be discriminated based on identified peptides were listed together as 
protein groups. Label-free quantification (LFQ) was performed by MaxQuant, as described in Cox et 
al. [30], using intensity maximum over the retention time profile and summing intensities of the 
different isotopic peaks. All proteins with quantified values were retained at first but filtered in 
subsequent steps. The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner 
repository with the dataset identifier PXD001257 [31]. 
LFQ data were further analyzed using R software and packages (R Core Team, 2013). Data were 
normalized using the variance stabilizing method (vsn), applying a generalized log2 transformation 
(glog2) on intensities [32]. For each tested concentration, fold change (in log2 scale) was calculated as 
the median of duplicate normalized protein intensities compared to corresponding DMSO controls (2 
or 7 days). For each comparison, only proteins appearing in all 4 replicates and quantified by a 
minimum of 1 peptide were considered. Statistical analyses were performed with local-pooled-error 
(LPE) estimates, allowing significance testing for a small number of replicates [33,34]. The 
Benjamini-Hochberg method was used for multiple testing correction [35], and a LPE-based test was 
carried out for outlier detection, as described by Jain et al. [33] , in order to compensate the decrease 
of LPE robustness for duplicate experiments. For each tested concentration and time point, significant 
proteins were further filtered, only keeping proteins with i) a p-value < 0.05 after Benjamini-Hochberg 
correction, ii) identified with at least 3 peptides, iii) not tagged as outliers by the LPE test at the 
concentration tested or for the DMSO control. For each time point (2 or 7 days), proteins showing also 
some significant effect of DMSO alone compared to control medium (M4) were discarded.  
Protein annotations (Gene Ontology, GO, PANTHER protein family) and functional analysis were 
done with PANTHER (www.pantherdb.org, [36]). Additional annotations were retrieved from UniProt 
knowledgebase (www.uniprot.org). Statistical overrepresentation tests of significant proteins were 
carried out for GO categories against the whole D. pulex genome using the PANTHER tool, and 
applying Bonferroni correction for multiple testing with a P-value threshold of 0.05. Test results and 
the subsequent graphs of GO terms were visualized using R (version 3.0.2, R Core Team, 2013) and 
the Cytoscape software package (version 2.8.3) [37]. The corresponding scripts are publicly available 
(https://github.com/PAFGit/PAF-Ecotoxicoproteomics-DPulex). Additional information about 
putative function of studied proteins was obtained using homology search with NCBI-BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) against the UniProtKB/Swiss-Prot database, and further 
processing BLAST results with Blast2GO (http://www.blast2go.com, [38]).  
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Results 
Experimental set-up, coverage and quality of data 
The impact of tamoxifen on D. pulex at the biochemical level was assessed by exposing neonates to 
two different concentrations of the drug (C1: 0.1, C2: 2.4  µg/L) during 2 days or until the first laying 
of eggs (6-8 days), before being processed for proteomic analyses.  
Considering the whole dataset, 3940 proteins were identified with a minimum of one unique peptide 
and quantified in at least one replicate sample (suppl. Table S1). Most of them (3662) obtained some 
biological annotations through the Panther database (suppl. Table S2). As a trade-off between on the 
one hand proteome coverage and number of experimental conditions, and on the other hand time of 
sample analyses, the number of biological replicates had to be reduced to 2 for each experimental 
condition. The Pearson correlation factor of log2 of intensities was nevertheless superior to 0.9 for all 
duplicates (r = 0.922-0.984), showing a good reproducibility of replicate experiments (suppl. Figure 
S1A and S1B). After filtering out proteins identified with less than 3 peptides and, for each 
comparison of treatment and DMSO control, those having one missing quantitative value, we obtained 
2711, 2685, 2474 and 2513 quantified proteins for C1 – 2 days, C2 – 2 days, C1 – 7 days and C2 - 7 
days treatments respectively (suppl. Table S3).  
Considering both time points and tested concentrations, 189 proteins showed a significant fold change 
with LPE test, after multiple-testing correction and removal of outliers (suppl. Table S4). Most of the 
regulated proteins were observed in the C2 – 7 days (170) treatment, i.e. at the highest concentration 
tested and for the longer exposure time, while the numbers of significant proteins were 32, 12 and 5 in 
C2 – 7 days, C2 – 2 days and C1 – 2 days treatments respectively. Noteworthily, we observed 
consistent results of increased or decreased expression of those 189 proteins between some of the 
different experimental conditions. In particular, the Pearson correlation factor of log2 of protein ratios 
was equal to 0.88 between C1 and C2 tamoxifen treatments at 7 days, and of 0.79 between 2 and 7 
days for the C2 treatment (suppl. Figure S2). For the following result presentation and discussion, all 
significant proteins of both time points and tested concentrations were considered together. About one 
third of hits were positively regulated, whereas the remaining two thirds showed a decreased 
expression after tamoxifen treatment. While a higher exposure (time and concentration) resulted in 
more significantly regulated proteins, a higher variance of DMSO control replicates in 2 days 
experiments probably decreased statistical testing sensitivity and the number of significant proteins 
with 2 days treatments. 
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Figure 6.4: Statistical overrepresentation tests of significantly regulated proteins (180) were carried out 
against the whole D. pulex genome using the PANTHER tool (www.pantherdb.org).  When a GO category 
had a p-value < 0.05, after Bonferroni correction for multiple testing, there was overrepresentation of 
proteins with this particular annotation compared to the reference list (whole genome/proteome). The 
histogram plot shows the number of regulated proteins observed in our dataset with a particular 
annotation (green columns) and the number of regulated proteins expected to have this annotation based 
on the whole proteome list (red columns). Only significant GO categories are shown: biological process 
and molecular function 
Biological process 
Molecular function 
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Among those 189 proteins, 180 were annotated with PANTHER database and 3 with UniProt, while 6 
proteins could not be annotated at all, even using BLAST homology search (suppl. Table S5). 
Statistical overrepresentation tests of the annotated proteins were carried out for Gene Ontology (GO) 
categories in Biological Process (BP) and Molecular Function (MF) classes. In each class, 20 GO 
categories showed significant enrichment of tested proteins compared to the whole D. pulex genome 
(Figure 6.4), altogether including 118 proteins with 97 and 109 proteins for BP and MF class 
respectively (suppl. Table S6). For a better understanding of relationships between proteins and 
significant GO categories, a graphical representation was used with proteins as nodes and shared 
annotations as edges. The edge width between 2 proteins was proportional to the minimum percentage 
of shared annotations and node color scaled according to log of fold change for the different 
concentrations and time points. In order to clarify the results, some annotations that were considered 
as too general, such as metabolic process, primary metabolic process, protein metabolic process (GO- 
BP) or catalytic activity, structural molecule activity, binding (GO-MF), were not included in the 
figures (Figure 6.5 and Figure 6.6, and suppl. Figure S2 & S3). 
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Figure 6.5: Graphical representation of relations between proteins and significant GO categories with 
proteins as nodes and shared annotations as edges (biological process). Edge width between 2 proteins was 
proportional to the minimum percentage of shared annotations and node colour scaled according to log2 
of protein fold change at 7 days for the highest tamoxifen concentration tested (C2). Results for other time 
points and concentrations tested are shown in supplementary figure S2 and S3. Only significant GO 
categories were used, but too general annotations, such as metabolic process, primary metabolic process, 
protein metabolic process (BP) or catalytic activity, structural molecule activity, binding (MF) were not 
included for a better clarity of the graphs. Proteins sharing the same annotation are included in colored 
boxes for the most relevant GO categories 
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Figure 6.6: Graphical representation of relations between proteins and significant GO categories with 
proteins as nodes and shared annotations as edges (molecular function). Edge width between 2 proteins 
was proportional to the minimum percentage of shared annotations and node colour scaled according to 
log2 of protein fold change at 7 days for the highest tamoxifen concentration tested (C2). Results for other 
time points and concentrations tested are shown in supplementary figure S2 and S3. Only significant GO 
categories were used, but too general annotations, such as metabolic process, primary metabolic process, 
protein metabolic process (BP) or catalytic activity, structural molecule activity, binding (MF) were not 
included for a better clarity of the graphs. Proteins sharing the same annotation are included in colored 
boxes for the most relevant GO categories 
 
Disruption of protein homeostasis 
Among the 118 proteins with significant GO enrichment terms, about 30 proteins were related to 
translation or regulation of translation (Figure 6.5 & suppl. Table S4), and they were all negatively 
regulated. We could identify in particular ribosomal proteins (16), aminoacyl tRNA-ligases (7), 
translation initiation factors (5) and a translation activation factor. We additionally observed the 
decrease of a nucleolar protein (E9H9X9) involved in ribosome biogenesis and of a Mago nashi-like 
protein (E9GA58), which is part of an mRNA splicing complex. Conversely, a protein (E9GNF0) 
involved in RNA catabolic processes and translation repression was clearly up-regulated with a fold 
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change higher than 2. In parallel, a protein (E9I5Q2) belonging to the “translocation protein SEC62” 
family, a signal peptidase complex subunit (E9G1G4) and two protein glycosyl transferases (E9GZ69, 
E9G6L8), involved in co-translational protein targeting to membranes, were also strongly down-
regulated (suppl. Table S4). The associated dolichol-phosphate mannosyl transferase (E9GN01), 
essential as mannosyl donor in pathways leading to protein glycosylation, was similarly decreased, as 
well as a calnexin isoform, potentially working as chaperone assisting glycoprotein synthesis 
(E9GMP2). In addition, expression of some proteins related to intracellular protein transport, such as 
Ras-related protein Rab-1B (E9G8G7), clathrin heavy chain (E9GTP3), a coatomer subunit (E9GA08) 
and an adaptin (E9GKM8), was reduced, with an exception represented by the increase of a translocon 
associated protein (E9GL54). 
In parallel with the decrease of protein translation, we observed an increase of proteasome components 
(E9GIX9, E9HAP5, E9GZ78, E9G7M2) involved in protein degradation, while some proteasome 
regulatory subunits (E9FTY4, E9H6N4) and Cand1 (E9GRL8), a negative regulator of ubiquitin 
ligases, were down-regulated (suppl. Table S4). In addition, a proteolytic protein such as ATP-
dependent Clp protease proteolytic subunit was increased after tamoxifen treatment. However, it 
should be noted we also observed a decrease of an ubiquitin-specific protease (E9HFQ5). 
Finally, we observed the up-regulation of a 10 kDa heat shock protein (E9G787), a chaperone induced 
by stress, which is essential for mitochondrial protein folding and is involved in apoptosis. 
 
Changes in carbohydrate/lipid metabolism and metabolic energy generation 
Twenty proteins were associated with the significant enriched GO term “carbohydrate metabolic 
process”, 12 with “lipid metabolic process”, 17 with metabolic energy production (GO: tricarboxylic 
acid cycle or respiratory electron transport chain process, Figure 6.5  & suppl. Table S4), and they 
included either up- or down-regulated hits. 
The proteins related to carbohydrate metabolism, in particular glycolysis or gluconeogenesis, included 
up-regulated phosphoglycerate kinase (E9FRQ6) and enolase (E9GAM4), while glucose-6-phosphate 
isomerase (E9GCK2) expression decreased. Linking the glycolytic pathway to the tricarboxylic cycle, 
one component of the pyruvate dehydrogenase complex (E9H1K6) also showed significant increase. 
In the tricarboxylic acid cycle, levels of citrate synthase (E9FRE7), isocitrate dehydrogenase 
(E9GAE4) and of an isoform of 2-oxoglutarate dehydrogenase (E9GLV0) were reduced, but 
expression of malate dehydrogenases (E9HGX0, E9HA96) and fumarate hydratase (E9G631) was 
augmented. Notably a mitochondrial 2-oxoglutarate/malate carrier protein (E9HM84), playing an 
important role in gluconeogenesis, was decreased. Among other impacted carbohydrate metabolic 
processes, two proteins of pentose-phosphate pathway, glucose-6-phosphate 1-dehydrogenase 
(E9GCL9) and 6-phosphogluconate dehydrogenase (E9GAM5), were down-regulated. Additionally a 
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putative glycogen phosphorylase (E9G2G6) and a glycogen synthase (E9H1V2) were also decreased 
after tamoxifen treatment. 
Oxidative phosphorylation was clearly impacted, with one cytochrome oxidase (E9GI31) and various 
NADH dehydrogenases (E9GX17, E9G5T1, E9FV79, E9H230, E9GPB6, E9H0Z6) down-regulated 
after treatment, whereas a cytochrome oxidase (E9GXW8) and a cytochrome b-c1 complex subunit 
(E9FW02) were increased. 
Regarding lipid metabolism, expression of two electron transfer flavoproteins (E9GYD9, E9FWX1), 
three acyl CoA dehydrogenases (E9H707, E9HI00, E9FRN7), an enoyl CoA hydratase (E9GVE9), an 
acetyl CoA acetyltransferase (E9HC70), and a 2-hydroxyacyl-CoA lyase (E9FYH7), which are all part 
of fatty acid oxidation pathways, was up-regulated after treatment. Conversely a mitochondrial 
tricarboxylate transport protein (E9G4Z8), playing an important role in fatty acid biosynthesis, was 
strongly down-regulated. An exception to this general trend was represented by the decrease of 
trifunctional enzyme subunit alpha (E9HN52), which is part of fatty acid beta-oxidation pathway. 
Related to the metabolic processes discussed above, we also observed an increase in several enzymes 
involved in the catabolism of cellular amino-acids in various metabolic intermediates, such as 3-
hydroxyisobutyrate dehydrogenase (E9GCN3) for valine degradation, dihydropteridine reductase 
(E9G3B9) for phenylalanine conversion to tyrosine, aspartate aminotransferase (E9H8T5) for 
aspartate degradation and lipoamide acyltransferase component of branched-chain alpha-keto acid 
dehydrogenase complex (E9G063) for branched amino-acids degradation. 
 
Constituents of cytoskeleton are impacted by tamoxifen treatment 
Thirteen proteins were associated with the significant enriched GO term “structural constituent of 
cytoskeleton” or “actin binding” (Figure 6.6 & suppl. Table S4). Among down-regulated proteins, we 
found several muscle proteins, such as alpha-actinin (E9G6P0) and myosin (E9FZS8), and two 
proteins playing a role in oogenesis: filamin-A (E9G2W4) [39] and moesin (E9H9F6) [40]. 
Additionally decreased proteins included a dynein heavy chain (E9FX66) and another myosin 
(E9H736), which could be important for the specification of the anterior/posterior axis of the embryo 
[41]. 
Tamoxifen treatment stimulated the expression of beta-tubulin (E9GER1), a F-actin-capping protein 
subunit (E9GL77), a calponin-like protein (E9H6I9), of which a Drosophila melanogaster homolog is 
known to be regulated by juvenile hormone [39], and two muscle-specific proteins (E9H215, 
E9GLP0) belonging to calponin family. Interestingly, profilin (E9H2U7) and villin-like protein quail 
(E9FXU5), involved in oogenesis [42,43] were also up-regulated. 
Other proteins related to muscle, a calcium-transporting ATPase (sarcoplasmic/endoplasmic reticulum 
type) (E9HR84), a ryanodine receptor (E9FTU9), a LIM-9 isoform (E9FSI1) and a PDZ and LIM 
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domain protein (E9HGQ3), known to interact with alpha-actinin, were decreased, as well as a glycosyl 
transferase (E9H0V8), which plays a role in collagen formation. It should also be noted that in 
Drosophila melanogaster a homolog of the ryanodine receptor was shown to be essential for larval 
development [44]. 
 
Effects of tamoxifen on proteins involved in reproduction 
Besides proteins with significant GO enrichment terms, we were also interested by regulated proteins 
related to reproduction (Table 6.1), as our previous results showed an effect of tamoxifen on daphnids 
in chronic tests [45]. In addition to the proteins involved in oogenesis that we mentioned in the 
previous chapter (filamin, moesin, profilin, villin, myosin), we identified two negatively regulated 
proteins (E9GDK0, E9GJA1), which are homologs of Drosophila melanogaster Rab6 and Rab11 of 
Rab GTPases family (suppl. Table S4). These proteins have many functions related to vesicle and 
membrane trafficking, and in particular have been shown to be involved, with another down-regulated 
protein of our dataset (maternal protein exuperantia, E9HLH8), in oocyte polarization, an essential 
step in embryo development [46–48]. Two other proteins playing an important role in oocyte 
development, E9H8M2 and E9G6B6, homologs to Drosophila aubergine [49] and baiser [50] proteins 
respectively, were also clearly decreased after tamoxifen treatment.  
In our dataset we also observed the decrease of four proteins (E9FVG7, E9H082, E9H8K5, E9HJQ1) 
classified in vitellogenin-2 family by PANTHER database, although they share only low homology 
between them and with vitellogenins from other invertebrate species. Two other vitellogenins fused 
with a superoxide dismutase domain were also impacted by tamoxifen, being either overexpressed 
(E9GVW7) or down-regulated (E9HZI5) after treatment. However, it should be noted that we also 
identified two other fused vitellogenins (E9GVW1, E9HZI6) and six other proteins from vitellogenin-
2 family which did not change their expression after treatment (suppl. Table S2). 
 
Potential effects of tamoxifen on nuclear hormone receptors 
Because of potential binding of tamoxifen on D. pulex estrogen-related receptor ERR, we were also 
interested in proteins potentially involved in regulation of nuclear hormone receptors (Table 6.1). 
Indeed, we observed an increase of a homolog of prohibitin-2 (E9GAM6), which is an estrogen 
receptor (ER)-selective co-regulator in vertebrates [51]. Additionally, an up-regulated protein 
(E9G0Y9) could be related to nuclear receptor co-activator 5, which has been shown to interact with 
nuclear estrogen receptors in humans [52] (suppl. Table S4).  
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Impact of DMSO solvent on protein expression 
As tamoxifen is a lipophilic molecule, DMSO was used as solubilization solvent. In order to assess 
potential impact of DMSO on D. pulex protein expression, comparisons were also carried out between 
blanks (i.e. only medium M4, without solvent and chemicals) and DMSO (0.0008%) control samples 
at all time points. After multiple-testing correction and removal of outliers, 13 and 45 proteins showed 
a significant fold change for 2 and 7 days of treatment respectively (suppl. Table S7). Altogether, 
about 20% of hits were negatively regulated, whereas the others showed an increased expression with 
DMSO. Among positively regulated proteins, about one third was related to protein translation 
(ribosomal proteins, translation initiation factors).  
 
Table 6.1: .  Selection of proteins potentially involved in D. pulex reproduction or development and 
showing a significant fold change with LPE test, after multiple-testing correction and removal of outliers. 
All tamoxifen treatment ratios are displayed (C1 – 2 days, C2 – 2 days, C1 – 7 days, C2 - 7 days), and 
significant ones are highlighted in grey. PANTHER family names (www.pantherdb.org) are shown as 
annotations, and UniProt ID of Drosophila homologs are included when they are referenced in the main 
text. 
 
 
UniProt ID
2 days log 
C1/DMSO
2 days log 
C2/DMSO
7 days log 
C1/DMSO
7 days log 
C2/DMSO PANTHER Family/Subfamily
UniProt ID of Drosophila 
homolog
E9FVG7 -0.53 -0.98 -0.4 -0.81 Vitellogenin-2 (PTHR23345:SF1)
E9FTU9 -1.29 -1.74 -0.84 -1.14 Ryanodine receptor 44F (PTHR13715:SF74) RY44_DROME
E9FXU5 0.42 0.47 0.66 1.07 Villin-like protein quail (PTHR11977:SF37) QUAI_DROME
E9G0Y9 0.49 0.8 0.47 0.76 Neosin (PTHR23295:SF2)
E9G2W4 0.12 -0.49 0.03 -1.03 Filamin-A (PTHR11915:SF251) FLNA_DROME
E9G6B6 0.31 -1.11 -1.61 -1.72 Transmembrane EMP24 domain-containing             
protein 10 (PTHR22811:SF58)
TMEDA_DROME
E9GAM6 0.11 0.39 0.45 1.05 Prohibitin-2 (PTHR23222:SF1)
E9GDK0 -0.89 -1.2 -0.83 -0.91 GH09086P (PTHR24073:SF352) RAB6_DROME
E9GJA1 -0.98 -1.39 -1.26 -1.25 DRAB11 (PTHR24073:SF87) O18335_DROME
E9GVW7 -0.76 -0.42 0.99 0.08
E9H082 0.2 -0.96 Vitellogenin-2 (PTHR23345:SF1)
E9H2U7 0.44 0.38 0.15 1.1 Profilin (PTHR11604:SF0) PROF_DROME
E9H736 -2.21 -0.74 -0.76 -1.01 Dilute class unconventional myosin, isoform C 
(PTHR13140:SF191)
A1Z6Z8_DROME
E9H8K5 -1.14 -1.79 -0.68 -0.65 Vitellogenin-2 (PTHR23345:SF1)
E9H8M2 -0.54 -0.58 -1.58 -1.58 PIWI-like protein 1 (PTHR22892:SF32) AUB_DROME
E9H9F6 0.19 -0.84 -0.93 -1.32 Moesin/ezrin/radixin homolog 1            
(PTHR23281:SF18)
MOEH_DROME
E9HJQ1 -0.69 -1.18 -1.06 -1.24 Vitellogenini-2 (PTHR23345:SF1)
E9HLH8 0.67 0.25 -1.14 -0.84 Maternal protein exuperantia (PTHR12384:SF1) EXU_DROME
E9HZI5 1.28 -0.32 0.41 -0.95 Superoxide dismutase [CU-ZN]             
(PTHR10003:SF32)
 150 
 
Discussion 
With a total of 3940 identified and quantified proteins, we report what is to our knowledge the largest 
proteomic dataset from D. pulex published until now. This high number was the result of multiple 
proteomics analyses at several stages of D. pulex life cycle, and of extensive sample fractionation by 
off-gel focusing prior to LC-MS/MS analyses. It should be noted that since the seminal paper by 
Froehlich et al. [2] showing the potential of LC-MS/MS for high-throughput gel-free proteomics of D. 
pulex, we only found one article using this technique, but it was restricted to the study of D. pulex 
phosphoproteome [53]. We did not discuss all our data here because of the paper focus on tamoxifen 
effects on D. pulex. In particular, the results of proteomics analyses after 4 days of test (without 
tamoxifen treatment) were not considered, but they are available for the scientific community as 
additional time point, which allows following proteome evolution during D. pulex development.  
One of our concerns for data interpretation was the incomplete annotation of D. pulex proteome, as 
many proteins are still labeled as “putative uncharacterized protein” in UniProt database. Indeed, 
Colbourne et al. [54] showed that more than a third of Daphnia’s genes had no detectable homologs in 
any other available proteome. This issue could be partly alleviated in our study using the PANTHER 
database, completed by BLAST homology search, which allowed getting some annotation for about 
93% of our identified proteins, and 96% of the 189 significantly regulated proteins. Nevertheless, 
while most conserved proteins from primary metabolism and translation machinery could be readily 
characterized, many other proteins were either scarcely annotated or had only low homology with 
more annotated homologous proteins, which complicated functional interpretation of our results. In 
this context, most useful information came from the well characterized and complete proteome of 
D. melanogaster, as it belongs to the same Pancrustacea taxon as D. pulex. 
The identity and annotations of the 189 significantly regulated proteins showed a decrease in 
translation, an increase in protein degradation, changes in carbohydrate/lipid metabolism, and an 
impact on reproduction as the major effects of tamoxifen. These impacted processes reflect most likely 
a general stress response of the organisms, shifting their energy allocation from growth, energy 
storage, and/or reproduction to survival adaptations. Indeed, Rowe et al. [55] [55] suggested that upon 
stress, such as environmental pollution, organisms may temporarily reduce other energy costly 
functions in order to maintain their basic metabolic rate (metabolic cost hypothesis). It should be noted 
that tamoxifen had similarly been shown on the one hand to induces oxidative stress and 
mitochondrial apoptosis in rat liver [56], and on the other hand to stimulate glycolysis and inhibit 
gluconeogenesis in rats as well [57]. In his review, Tomanek [58] also underlined the link between 
shift of energy metabolism (from aerobic metabolism to alternative pathways of ATP production, such 
as glycolysis and b-oxidation) and response to oxidative stress. He also suggested that cytoskeleton 
could be a common cellular target of various environmental stresses. 
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Jansen et al. [59] previously used the metabolic cost hypothesis to explain the decreased levels of 
vitellogenin-1 in Daphnia magna exposed to natural and anthropogenic stressors. Vitellogenins are the 
major precursors of the egg-yolk proteins, vitellins, which are sources of nutrients during embryonic 
development, and they are used as biomarkers of exposure to estrogenic chemicals in aquatic 
invertebrates [60,61]. In our study indeed, some proteins related to the vitellogenin-2 family were also 
down-regulated, although some other proteins from the same family did not change their expression 
after treatment. These contrasting results probably reflect the different, yet unknown, roles of the 
various members of this protein family. Interestingly, we also observed either the over-expression of 
one vitellogenin fused with superoxide dismutase domain or the decrease of another such fused 
vitellogenin, depending on tamoxifen concentration. Such fusion proteins have only been found in 
some crustaceans [62,63] and their exact function is not yet fully elucidated. Nevertheless, it can be 
hypothesised that stress situations are associated with oxidative stress at the cellular level, which could 
result in increased levels of anti-oxidative enzymes such as copper/zinc superoxide dismutases to 
prevent organisms from cell and tissue damages. 
The decrease of various proteins potentially involved in reproduction, that we observed in this study, 
can be related to previous results (chapter 2), where two generation of D. pulex were exposed to 
tamoxifen at concentrations from 0.15 to 5.15 µg/L. In those experiments, the reproduction rate of the 
first generation dropped drastically, with about 60% less neonates in the treated animals than in 
controls. This effect on reproduction was observed after 12 days of exposure to 5.15 µg/L of 
tamoxifen, while the highest concentration tested here was 2.4 µg/L (C2). Furthermore, teratogenic 
effects, such as abnormal neonates and aborted eggs, were found at concentrations from 0.15 to 0.72 
µg/L. As a comparison, tamoxifen was shown to impair reproduction in fish at a nominal 
concentration of 625 mg/L, while tamoxifen concentrations equal or higher than 25 mg/L induced 
various trans-generational effects in progeny and altered vitellogenin levels in adults [64].  
Tamoxifen was found in the aquatic environment, including groundwater, at concentrations up to 
0.21 µg/L [65,12,66], and the no observed effect concentration (NOEC) previously calculated in D. 
pulex for reproduction was 0.72 µg/L, whereas this NOEC was < 0.15 µg/L when based on observed 
morphological abnormalities [45]. Similarly, the lower concentration tested here (C1: 0.1 µg/L) is of 
the same order of magnitude as tamoxifen environmental concentrations. Because some effects of the 
drug on D. pulex protein expression were already observed at this concentration, we determined a 
proteomics NOEC < 0.1 µg/L. Morphological abnormalities as ecotoxicological endpoint seem 
therefore to have the same sensitivity as proteomics analyses in this particular case. 
It is not clear if tamoxifen has an effect on D. pulex reproduction because of the general stress 
response (metabolic cost hypothesis), or through some more specific mechanism, for example 
involving the homolog of the estrogen-related receptor known to be present in daphnids [24]. In our 
results, the up-regulation of some proteins potentially involved in regulation of nuclear hormone 
receptors seems however to support the second hypothesis. 
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One interest of this study was to highlight potential biomarkers for early detection of tamoxifen 
harmful effects on D. pulex. As most significantly regulated proteins were observed at the highest 
exposure in time and concentration, only a few candidates could be suitable for early detection of the 
drug impact on daphnids, based on our results at 2 days. It is actually expected that the most 
interesting effects of the drug on D. pulex reproduction cannot be observed before the daphnids have 
reached their sexual maturity. Then, among the significant hits observed with 2 days treatment, we 
should ideally select proteins with:  i) high abundance, ii) good annotation and clear function, iii) 
specific response to treatment, avoiding for example ribosomal proteins regulated by the general stress 
response of the organisms. The latest point is of course quite difficult as the exact mechanism of 
action of tamoxifen in daphnids is not known. Furthermore some significant effects observed at 2 days 
were not confirmed at longer exposures, either because of higher variance (and consequently lower 
statistical testing sensitivity) of some protein quantification or because of D. pulex adaptation to 
tamoxifen effects after some time. At this stage the most promising potential biomarkers seem 
therefore to be one protein of the vitellogenin-2 family (E9H8K5) and the ryanodine receptor 
(E9FTU9), which both were identified with a high number of peptides and were already down-
regulated after 2 days of treatment at the highest concentration tested. Of course, further experiments 
will be necessary to confirm this very preliminary choice or to select some other more promising 
candidates. 
Finally, an important question for future ecotoxicoproteomics experiments is the effect of DMSO on 
protein expression in D. pulex. Although DMSO is considered as non-toxic in daphnids [67] and is 
often used in ecotoxcological experiments to dissolve chemicals poorly soluble in water, our data 
seem to show that at all time points this solvent can have an impact on organisms, at least at the 
biochemical level. 
 
Conclusions 
We could show the effects of tamoxifen on D. pulex at the protein level, and unravel potential links 
between drug impact on daphnid reproduction and observations at the biochemical level. In agreement 
with our previous results, some tamoxifen effects were already observed at concentrations close to 
those detected in the aquatic environment. Nevertheless, further experiments would be needed to 
confirm and determine the robustness of our observations. New experiments would also benefit from 
constant advances in mass spectrometer performance. Our data were acquired on an Orbitrap mass 
spectrometer of the first generation, and much progress has since been done in instrument speed and 
sensitivity, as demonstrated by the Fusion Tribrid™, the last generation of Orbitrap mass 
spectrometer [68]. Using our sample preparation method, such instrumental improvements could allow 
either increasing proteome coverage, or having the same number of proteins identified with a smaller 
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number of sample fractions and/or lower instrumental analysis time. Ultimately, it will also be 
possible to study protein expression of daphnids at the individual level with fair proteome coverage. 
Further ecotoxicoproteomics studies should also ideally include quantification of protein post-
translational modifications (PTM), as it is an essential level of protein activity regulation in 
eukaryotes. As far as we know, there was however only one study of PTMs in daphnids by Kwon et 
al. [53]. After phosphopeptide enrichment by TiO2, they identified 103 phosphorylation sites in 91 D. 
pulex proteins, of which 21 sites in 20 proteins were conserved between D. pulex and humans. These 
are very useful data, as phosphorylation is the most studied PTM in proteomics, but post-translational 
modifications remain yet a largely unexplored area in daphnids 
Furthermore, as tamoxifen can be metabolized in more or equally toxic compounds, effects of most 
relevant metabolites on protein expression in daphnids also deserve to be tested. Indeed, it has been 
recently shown in a two-generation study that metabolites such as 4-hydroxy-tamoxifen and endoxifen 
had an effect on D. pulex reproduction at concentrations of the same order of magnitude as tamoxifen 
concentrations [69]. Further ecotoxicoproteomics experiments with tamoxifen and its metabolites 
should also be carried out in other organisms for a better assessment of tamoxifen impact on aquatic 
ecosystems. 
In conclusion, ecotoxicoproteomics studies cannot replace classical ecotoxicological tests, which can 
provide, relatively quickly and with little instrumentation, a view of chemical compound effects on 
organisms at the individual and population levels. But proteomics analyses allow understanding the 
xenobiotic effects at the biochemical level and highlighting their potential mechanisms of toxicity. It is 
therefore an essential complementary tool, which will be increasingly used in ecotoxicology in the 
near future to improve risk assessment of critical pollutants in the environment.  
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Supporting information 
 
Legends 
 
Supplementary table 1 (see original manuscript) MaxQuant output table (= proteinGroups) after 
removal of contaminants, reverse proteins and proteins only identified by site. Only the 3940 proteins 
identified with a minimum of one unique peptide and quantified in at least one replicate sample were 
then kept. Relative standard deviation of LFQ peak intensity was calculated for proteins quantified in 
both replicates of each experiment.  
 
Supplementary table 2. (see original manuscript) List of all proteins (3662) getting some 
annotations through PANTHER (www.pantherdb.org). 
 
Supplementary table 3. (see original manuscript) Quantitation results of comparison between 
samples and DMSO controls after, for each comparison, filtering out of proteins identified with less 
than three peptides and those having one missing quantitative value. Data were normalized using the 
variance stabilizing method (vsn), applying a generalized log2 transformation (glog2) on intensities. 
For each tested concentration and time point, fold change (in log2 scale) was calculated as the median 
of duplicate normalized protein intensities compared to corresponding DMSO controls, or to M4 
blanks for DMSO samples. For each comparison, only proteins appearing in all 4 replicates and 
quantified by a minimum of 1 peptide were considered. Statistical analyses were performed with local-
pooled-error (LPE) estimates. Benjamini-Hochberg method was used for multiple testing corrections 
and a LPE-based test was carried out for outlier detection. 
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Supplementary table 4.  List of the 189 proteins showing a significant fold change with LPE test, 
after multiple-testing correction and removal of outliers. PANTHER annotations are included and all 
tamoxifen treatment ratios are shown (C1 – 2 days, C2 – 2 days, C1 – 7 days, C2 - 7 days), with 
significant ones highlighted in grey.  
 
 
UniProt ID Peptides Log ratio C1/DMSO 2d
Log ratio 
C2/DMSO 2d
Log ratio 
C1/DMSO 7d
Log ratio 
C2/DMSO 7d Protein name PANTHER Family/Subfamily
C7DR07 11 -0.20 -0.66 -2.23 -1.93 Putative uncharacterized protein PROTEIN Y7A5A.1 (PTHR10801:SF2)
E9FQU4 8 0.68 0.82 0.92 0.85 Putative uncharacterized protein LETHAL (3) 03670 (PTHR21588:SF1)
E9FRE7 20 -0.02 -0.48 -0.10 -0.82 Citrate synthase CITRATE SYNTHASE, MITOCHONDRIAL (PTHR11739:SF8)
E9FRN7 12 0.83 1.03 0.89 0.88 Putative uncharacterized protein 3-HYDROXYACYL-COA DEHYDROGENASE TYPE-2 (PTHR24316:SF251)
E9FRQ6 22 0.51 1.05 0.90 0.76 Phosphoglycerate kinase PHOSPHOGLYCERATE KINASE (PTHR11406:SF6)
E9FS67 11 0.43 1.20 0.16 1.07 Putative uncharacterized protein PROTEIN C07D8.6 (PTHR11732:SF144)
E9FSI1 14 -0.15 -0.45 -1.39 -1.07 Putative uncharacterized protein LIM-9 ISOFORM (PTHR24205:SF4)
E9FSQ9 4 0.46 -0.33 -2.05 -1.37 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S25 (PTHR12850:SF5)
E9FSV8 11 -0.28 -1.65 -1.26 -2.00 Putative uncharacterized protein GDP-L-FUCOSE SYNTHASE (PTHR10366:SF259)
E9FTB0 8 -0.37 -1.40 -1.82 -2.34 Putative uncharacterized protein GM23292P (PTHR21106:SF2)
E9FTC5 20 -0.32 -0.80 -1.67 -0.97 Putative uncharacterized protein CYSTEINE--TRNA LIGASE, CYTOPLASMIC (PTHR10890:SF3)
E9FTU9 63 -1.29 -1.74 -0.84 -1.14 Putative uncharacterized protein RYANODINE RECEPTOR 44F (PTHR13715:SF74)
E9FTX7 11 -0.43 -1.85 -3.65 -3.26 Putative uncharacterized protein NAT1 (PTHR22767:SF2)
E9FTY4 9 -0.47 -1.42 -1.53 -1.35 Putative uncharacterized protein 26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 13 (PTHR10539:SF0)
E9FU59 23 0.15 -0.96 -1.44 -1.48 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S3A (PTHR11830:SF0)
E9FUJ2 11 -0.76 -1.12 -0.55 -0.89 Putative uncharacterized protein SUBFAMILY NOT NAMED (PTHR11590:SF16)
E9FUY1 13 -0.01 -0.76 -0.84 -1.09 ABC protein, subfamily ABCF ATP-BINDING CASSETTE SUB-FAMILY F MEMBER 2 (PTHR19211:SF15)
E9FV57 32 0.45 0.55 0.68 0.70 Putative uncharacterized protein ARGININE KINASE (PTHR11547:SF18)
E9FV79 9 -0.28 -0.76 -0.25 -0.85 Putative uncharacterized protein NADH DEHYDROGENASE [UBIQUINONE] 1 BETA SUBCOMPLEX SUBUNIT 10 (PTHR13094:SF1)
E9FV80 13 -0.62 -1.75 -3.92 Putative uncharacterized protein 60S RIBOSOMAL PROTEIN L3 (PTHR11363:SF5)
E9FVG7 201 -0.53 -0.98 -0.40 -0.81 Putative uncharacterized protein VITELLOGENIN-2 (PTHR23345:SF1)
E9FVV4 5 1.20 0.26 -0.56 -0.86 Putative uncharacterized protein
E9FW02 10 0.16 0.28 0.20 0.87 Cytochrome b-c1 complex subunit Rieske, mitochondrial
CYTOCHROME B-C1 COMPLEX SUBUNIT RIESKE, MITOCHONDRIAL 
(PTHR10134:SF4)
E9FWW3 6 0.36 -0.54 0.85 0.47 Putative uncharacterized protein DpGSTM1 SUBFAMILY NOT NAMED (PTHR11571:SF108)
E9FWW9 21 -0.38 -1.32 -1.96 -1.96 Alpha subunit of putative Na+/K+ ATPase SUBFAMILY NOT NAMED (PTHR24093:SF244)
E9FWX1 11 0.18 0.92 0.39 0.87 Putative uncharacterized protein ELECTRON TRANSFER FLAVOPROTEIN SUBUNIT BETA (PTHR21294:SF0)
E9FX66 64 -1.28 -1.53 -2.89 -1.91 Putative uncharacterized protein CYTOPLASMIC DYNEIN 1 HEAVY CHAIN 1 (PTHR10676:SF28)
E9FXJ7 16 -0.09 -1.09 -0.09 -1.36 Hemoglobin GLOBIN 1, ISOFORM A (PTHR11442:SF36)
E9FXU5 40 0.42 0.47 0.66 1.07 Putative uncharacterized protein VILLIN-LIKE PROTEIN QUAIL (PTHR11977:SF37)
E9FYH7 13 0.46 0.48 0.49 1.25 Putative uncharacterized protein 2-HYDROXYACYL-COA LYASE 1 (PTHR18968:SF6)
E9FYV4 7 -1.00 -1.22 -1.99 -2.03 Putative uncharacterized protein PROTEIN DHS-20 (PTHR24316:SF215)
E9FZ14 29 0.28 0.53 0.64 0.88 Putative uncharacterized protein ATPASE, H+ TRANSPORTING, LYSOSOMAL V1 SUBUNIT B2-RELATED (PTHR15184:SF11)
E9FZ54 3 0.53 -0.44 -2.96 -1.77 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S26-RELATED (PTHR12538:SF0)
E9FZS1 8 0.46 1.21 1.21 1.12 Putative uncharacterized protein CARBONYL REDUCTASE 1-RELATED (PTHR24322:SF58)
E9FZS8 189 0.54 -0.44 -0.53 -1.19 Myosin heavy chain isoform 3 MYOSIN HEAVY CHAIN, ISOFORM O-RELATED (PTHR13140:SF364)
E9G063 13 0.20 0.80 0.65 1.54 Putative uncharacterized protein LIPOAMIDE ACYLTRANSFERASE COMPONENT OF BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX, MITOCHONDRIAL (PTHR23151:SF46)
E9G064 15 -0.67 -1.45 -2.60 -1.64 Putative uncharacterized protein PUMILIO DOMAIN-CONTAINING PROTEIN KIAA0020 (PTHR13389:SF0)
E9G0H6 3 0.82 1.76 -1.07 -3.17 Putative uncharacterized protein
E9G0P4 33 -0.22 -0.67 -0.61 -0.83 Putative uncharacterized protein SUBFAMILY NOT NAMED (PTHR11590:SF40)
E9G0Q9 14 -0.14 -0.39 0.96 0.40 Putative uncharacterized protein GLUCOSAMINE-6-PHOSPHATE ISOMERASE (PTHR11280:SF5)
E9G0Y9 12 0.49 0.80 0.47 0.76 Putative uncharacterized protein NEOSIN (PTHR23295:SF2)
E9G119 9 0.00 -0.27 0.04 -0.85 Prostaglandin D2 synthase-like protein HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE (PTHR11571:SF118)
E9G121 14 0.01 -0.74 -1.57 -1.15 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S16 (PTHR21569:SF4)
E9G153 11 -1.08 -1.52 -1.17 -1.62 Beta subunit of putative Na+/K+ ATPase AT04468P-RELATED (PTHR11523:SF22)
E9G1G4 3 -0.16 -1.16 -1.08 -1.37 Putative uncharacterized protein SIGNAL PEPTIDASE COMPLEX SUBUNIT 3 (PTHR12804:SF0)
E9G1N6 4 0.59 0.34 -4.12 Putative uncharacterized protein PROTEIN C13B4.1, ISOFORM A (PTHR23130:SF66)
E9G230 12 -0.01 -0.21 -0.45 -0.90 Uroporphyrinogen decarboxylase UROPORPHYRINOGEN DECARBOXYLASE (PTHR21091:SF2)
 156 
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UniProt ID Peptides Log ratio C1/DMSO 2d
Log ratio 
C2/DMSO 2d
Log ratio 
C1/DMSO 7d
Log ratio 
C2/DMSO 7d Protein name PANTHER Family/Subfamily
E9G2A6 33 -0.03 -0.74 -1.05 -1.35 Putative uncharacterized protein FI05224P (PTHR11451:SF22)
E9G2G6 54 -0.49 -0.97 -1.12 -1.24 Phosphorylase GLYCOGEN PHOSPHORYLASE, MUSCLE FORM (PTHR11468:SF5)
E9G2I4 9 0.58 1.24 0.75 1.16 Putative uncharacterized protein PROTEIN ATH-1 (PTHR10655:SF17)
E9G2W4 100 0.12 -0.49 0.03 -1.03 Putative uncharacterized protein FILAMIN-A (PTHR11915:SF251)
E9G341 29 -0.37 -0.53 -0.70 -1.11 Putative uncharacterized protein CAD PROTEIN (PTHR11405:SF5)
E9G3B9 13 0.40 1.26 1.41 2.00 Putative uncharacterized protein DIHYDROPTERIDINE REDUCTASE (PTHR15104:SF0)
E9G3M6 11 0.57 -0.15 -1.00 -0.40 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S14 (PTHR11759:SF1)
E9G4Z8 5 -1.48 -1.98 -3.00 -3.60 Putative uncharacterized protein TRICARBOXYLATE TRANSPORT PROTEIN, MITOCHONDRIAL (PTHR24089:SF102)
E9G5T1 18 -0.16 -0.79 -0.55 -1.00 Putative uncharacterized protein NADH DEHYDROGENASE [UBIQUINONE] 1 ALPHA SUBCOMPLEX SUBUNIT 9, MITOCHONDRIAL (PTHR12126:SF1)
E9G631 16 0.54 0.93 0.73 0.94 Putative uncharacterized protein FUMARATE HYDRATASE, MITOCHONDRIAL (PTHR11444:SF1)
E9G6B6 5 0.31 -1.11 -1.61 -1.72 Putative uncharacterized protein TRANSMEMBRANE EMP24 DOMAIN-CONTAINING PROTEIN 10 (PTHR22811:SF58)
E9G6C5 4 1.46 0.26 -1.49 -1.39 Putative uncharacterized protein
E9G6H2 11 -0.09 -0.63 -0.37 -1.07 Putative uncharacterized protein GLUTAMATE--CYSTEINE LIGASE CATALYTIC SUBUNIT (PTHR11164:SF0)
E9G6K9 10 0.22 -1.82 -3.04 -2.62 Putative uncharacterized protein (Fragment) 60S RIBOSOMAL PROTEIN L13 (PTHR11722:SF0)
E9G6L8 7 -0.72 -2.34 -2.51 -2.54 Putative uncharacterized protein DOLICHYL-DIPHOSPHOOLIGOSACCHARIDE--PROTEIN GLYCOSYLTRANSFERASE SUBUNIT STT3A (PTHR13872:SF21)
E9G6P0 57 -0.24 -1.08 -1.04 -1.04 Putative uncharacterized protein ALPHA-ACTININ, SARCOMERIC (PTHR11915:SF270)
E9G6S7 3 -1.08 -1.32 -1.70 -1.72 Putative uncharacterized protein PROTEIN DPY-11 (PTHR18929:SF81)
E9G787 5 1.04 1.54 0.51 0.98 Putative uncharacterized protein 10 KDA HEAT SHOCK PROTEIN, MITOCHONDRIAL (PTHR10772:SF5)
E9G7M2 5 -0.13 0.28 0.52 0.69 Proteasome subunit beta type PROTEASOME SUBUNIT BETA TYPE-4 (PTHR11599:SF5)
E9G8G7 7 -0.67 -0.97 -1.19 -1.32 Putative uncharacterized protein RAS-RELATED PROTEIN RAB-1B (PTHR24073:SF212)
E9G8L4 12 -0.19 -1.48 -3.05 -3.06 Putative uncharacterized protein MIP08013P1 (PTHR24089:SF50)
E9G8S6 4 2.13 0.44 -1.68 -1.11 Putative uncharacterized protein
E9G927 16 0.33 1.17 1.12 1.43 Putative uncharacterized protein ALCOHOL DEHYDROGENASE CLASS-3 (PTHR11695:SF269)
E9GA02 6 -0.05 -0.81 -3.61 -2.47 40S ribosomal protein S24 40S RIBOSOMAL PROTEIN S24 (PTHR10496:SF0)
E9GA08 35 -0.50 -0.81 -1.32 -1.07 Putative uncharacterized protein COATOMER SUBUNIT ALPHA (PTHR19876:SF1)
E9GA58 8 0.13 -0.91 -1.19 -1.44 Mago nashi-like protein PROTEIN MAGO NASHI HOMOLOG (PTHR12638:SF0)
E9GA96 12 0.36 -0.40 -1.29 -0.23 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S7 (PTHR11278:SF0)
E9GAE4 28 0.00 -0.36 -0.13 -0.92 Isocitrate dehydrogenase [NADP]
E9GAI5 14 -0.29 -0.39 0.29 0.85 Putative uncharacterized protein PROTEIN Y59C2A.1 (PTHR11705:SF61)
E9GAM4 26 -0.41 -0.09 0.83 1.06 Enolase ENOLASE (PTHR11902:SF7)
E9GAM5 13 -0.74 -1.14 -1.61 -1.77 6-phosphogluconate dehydrogenase, decarboxylating
6-PHOSPHOGLUCONATE DEHYDROGENASE, DECARBOXYLATING 
(PTHR11811:SF25)
E9GAM6 11 0.11 0.39 0.45 1.05 Putative uncharacterized protein PROHIBITIN-2 (PTHR23222:SF1)
E9GB46 5 -0.14 -1.44 -2.86 -2.57 Putative uncharacterized protein 60S RIBOSOMAL PROTEIN L28 (PTHR10544:SF0)
E9GBH6 11 -0.17 -1.18 -2.28 -1.67 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S11 (PTHR10744:SF9)
E9GBP0 27 -0.40 -1.11 -1.04 -0.84 Putative uncharacterized protein ISOLEUCINE--TRNA LIGASE, CYTOPLASMIC (PTHR11946:SF11)
E9GCC8 11 -0.20 -0.97 -0.09 -1.02 Putative uncharacterized protein SERINE--TRNA LIGASE, CYTOPLASMIC (PTHR11778:SF0)
E9GCI5 7 -0.89 -1.38 -0.99 -1.79 Hemoglobin NEUROGLOBIN (PTHR22924:SF30)
E9GCK2 20 -0.35 -1.50 -1.48 -1.44 Glucose-6-phosphate isomerase GLUCOSE-6-PHOSPHATE ISOMERASE (PTHR11469:SF4)
E9GCL9 13 -0.83 -1.19 -0.03 -0.91 Glucose-6-phosphate 1-dehydrogenase GLUCOSE-6-PHOSPHATE 1-DEHYDROGENASE (PTHR23429:SF0)
E9GCN3 12 0.11 1.04 0.66 0.88 Putative uncharacterized protein 3-HYDROXYISOBUTYRATE DEHYDROGENASE, MITOCHONDRIAL (PTHR22981:SF7)
E9GD42 6 -0.37 -0.80 -0.10 -1.38 Putative uncharacterized protein HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE (PTHR11571:SF118)
E9GDK0 10 -0.89 -1.20 -0.83 -0.91 Putative uncharacterized protein GH09086P (PTHR24073:SF352)
E9GDV9 11 0.08 -0.88 -0.49 -1.51 Putative uncharacterized protein CYTOSOLIC SULFOTRANSFERASE 1-RELATED (PTHR11783:SF15)
E9GE27 5 0.96 2.16 1.19 2.19 Putative uncharacterized protein PROTEIN DHS-13 (PTHR24322:SF239)
E9GER1 27 0.23 0.56 0.28 0.81 Putative uncharacterized protein TUBULIN BETA-1 CHAIN (PTHR11588:SF9)
E9GER2 19 -0.86 -1.32 -2.06 -1.44 Putative uncharacterized protein EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT L (PTHR13242:SF0)
E9GEV7 11 -0.42 -1.00 -1.99 -2.03 Putative uncharacterized protein RIBOSOMAL PROTEIN S15A (PTHR11758:SF4)
E9GEY1 12 0.30 -0.98 -1.56 -1.46 Eukaryotic translation initiation factor 3 subunit E
EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT E 
(PTHR10317:SF0)
E9GHX8 30 0.02 -0.78 -1.00 -0.85 Putative uncharacterized protein CLUSTERED MITOCHONDRIA PROTEIN HOMOLOG (PTHR12601:SF6)
E9GI31 10 -0.26 -1.29 -1.47 -2.69 Putative uncharacterized protein CYTOCHROME C OXIDASE SUBUNIT IV ISOFORM 1 (PTHR10707:SF10)
E9GIX9 11 0.34 0.85 0.95 1.89 Proteasome subunit alpha type PROTEASOME SUBUNIT ALPHA TYPE-2 (PTHR11599:SF16)
E9GJA1 10 -0.98 -1.39 -1.26 -1.25 Putative uncharacterized protein DRAB11 (PTHR24073:SF87)
E9GKM8 15 -0.59 -1.33 -1.00 -1.23 Putative uncharacterized protein AP-2 COMPLEX SUBUNIT ALPHA (PTHR22780:SF4)
E9GL54 3 -1.31 0.72 0.28 1.53 Putative uncharacterized protein TRANSLOCON-ASSOCIATED PROTEIN SUBUNIT BETA (PTHR12861:SF3)
E9GL77 7 0.64 0.87 0.58 0.79 Putative uncharacterized protein F-ACTIN-CAPPING PROTEIN SUBUNIT BETA (PTHR10619:SF0)
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UniProt ID Peptides Log ratio C1/DMSO 2d
Log ratio 
C2/DMSO 2d
Log ratio 
C1/DMSO 7d
Log ratio 
C2/DMSO 7d Protein name PANTHER Family/Subfamily
E9GLP0 6 -0.01 0.98 0.59 0.85 Putative uncharacterized protein SUBFAMILY NOT NAMED (PTHR18959:SF51)
E9GLV0 32 0.07 -0.43 -0.58 -0.87 Putative uncharacterized protein NEURAL CONSERVED AT 73EF, ISOFORM I (PTHR23152:SF6)
E9GMB1 15 -0.66 -1.37 -1.22 -1.35 Putative uncharacterized protein ATP-DEPENDENT RNA HELICASE DDX6-RELATED (PTHR24031:SF76)
E9GMP2 12 0.64 0.10 -0.95 -1.32 Putative uncharacterized protein CALNEXIN 99A, ISOFORM C (PTHR11073:SF1)
E9GN01 7 -0.46 -1.66 -2.04 -1.88 Putative uncharacterized protein DOLICHOL-PHOSPHATE MANNOSYLTRANSFERASE (PTHR10859:SF37)
E9GN74 11 0.79 1.87 0.93 0.95 Putative uncharacterized protein
E9GN81 4 0.23 0.55 0.87 1.27 ATP-dependent Clp protease proteolytic subunit
ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT, MITOCHONDRIAL-
RELATED (PTHR10381:SF11)
E9GN88 14 -0.16 -0.45 -0.78 -0.83 Putative uncharacterized protein EUKARYOTIC TRANSLATION INITIATION FACTOR 2 SUBUNIT 3 (PTHR23115:SF9)
E9GNF0 9 0.36 1.06 0.79 1.17 Putative uncharacterized protein GH08269P (PTHR13586:SF0)
E9GPB6 15 -0.57 -1.12 -0.56 -1.02 Putative uncharacterized protein NADH DEHYDROGENASE [UBIQUINONE] FLAVOPROTEIN 1, MITOCHONDRIAL (PTHR11780:SF0)
E9GR53 11 -0.32 -1.46 -2.38 -2.38 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S2 (PTHR13718:SF4)
E9GRL8 18 -1.27 -1.34 -1.23 -1.34 Putative uncharacterized protein PROTEIN CAND-1 (PTHR12696:SF0)
E9GTP3 67 -0.67 -1.26 -1.19 -1.15 Putative uncharacterized protein CLATHRIN HEAVY CHAIN (PTHR10292:SF1)
E9GVE9 9 0.43 0.43 0.53 0.82 Putative uncharacterized protein ENOYL-COA HYDRATASE, MITOCHONDRIAL (PTHR11941:SF24)
E9GVW7 150 -0.76 -0.42 0.99 0.08 Vitellogenin fused with superoxide dismutase (fragment)
E9GX17 7 0.12 -0.90 -1.32 -1.45 Putative uncharacterized protein NADH DEHYDROGENASE [UBIQUINONE] 1 ALPHA SUBCOMPLEX SUBUNIT 6 (PTHR12964:SF0)
E9GXS2 18 0.25 -0.70 -0.97 -0.78 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S3 (PTHR11760:SF9)
E9GXW8 12 0.73 0.73 0.89 0.74 Putative uncharacterized protein CYTOCHROME C OXIDASE SUBUNIT 5A, MITOCHONDRIAL (PTHR14200:SF11)
E9GXZ9 8 0.12 -0.40 -2.02 -2.38 Putative uncharacterized protein SULFIDE:QUINONE OXIDOREDUCTASE, MITOCHONDRIAL (PTHR10632:SF2)
E9GYD9 11 0.29 1.07 1.21 2.08 Putative uncharacterized protein ELECTRON TRANSFER FLAVOPROTEIN SUBUNIT ALPHA, MITOCHONDRIAL (PTHR10909:SF91)
E9GZ69 12 -0.27 -0.65 -0.96 -0.91 Putative uncharacterized protein DOLICHYL-DIPHOSPHOOLIGOSACCHARIDE--PROTEIN GLYCOSYLTRANSFERASE SUBUNIT 1 (PTHR21049:SF0)
E9GZ78 8 0.58 0.40 0.33 1.05 Proteasome subunit beta type PROTEASOME SUBUNIT BETA TYPE (PTHR11599:SF4)
E9H082 34 0.20 -0.96 Putative uncharacterized protein VITELLOGENIN-2 (PTHR23345:SF1)
E9H0V8 12 0.11 -0.57 -0.76 -1.07 Putative uncharacterized protein GLYCOSYLTRANSFERASE 25 FAMILY MEMBER (PTHR10730:SF2)
E9H0Z6 13 -0.57 -1.17 -1.55 -1.30 Putative uncharacterized protein NADH DEHYDROGENASE [UBIQUINONE] IRON-SULFUR PROTEIN 2, MITOCHONDRIAL (PTHR11993:SF10)
E9H1K6 19 0.22 0.71 0.66 0.85 Putative uncharacterized protein DIHYDROLIPOYLLYSINE-RESIDUE ACETYLTRANSFERASE COMPONENT OF PYRUVATE DEHYDROGENASE COMPLEX, MITOCHONDRIAL (PTHR23151:SF9)
E9H1S8 12 0.75 1.29 -0.02 0.92 Putative uncharacterized protein HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A0 (PTHR24012:SF339)
E9H1V2 12 -0.76 -1.01 -1.92 -1.65 Putative glycogen synthase GLYCOGEN [STARCH] SYNTHASE-RELATED (PTHR10176:SF0)
E9H1Y1 9 -0.57 -0.93 -0.96 -1.07 Putative uncharacterized protein AT04468P-RELATED (PTHR11523:SF22)
E9H1Z1 4 -1.11 -2.32 -1.18 -0.08 Putative uncharacterized protein VERY-LONG-CHAIN 3-OXOOACYL-COA REDUCTASE LET-767-RELATED (PTHR24316:SF68)
E9H215 9 0.12 0.86 0.91 1.19 Putative uncharacterized protein MUSCLE-SPECIFIC PROTEIN 20 (PTHR18959:SF23)
E9H230 3 -0.65 -2.29 -3.71 Putative uncharacterized protein NADH DEHYDROGENASE [UBIQUINONE] 1 BETA SUBCOMPLEX SUBUNIT 5, MITOCHONDRIAL (PTHR13178:SF0)
E9H2T2 20 0.05 0.73 0.79 0.81 Putative uncharacterized protein SUBFAMILY NOT NAMED (PTHR11851:SF105)
E9H2T3 18 0.22 -0.02 -1.19 -1.03 Putative uncharacterized protein EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT D (PTHR12399:SF0)
E9H2U7 6 0.44 0.38 0.15 1.10 Profilin PROFILIN (PTHR11604:SF0)
E9H393 11 0.40 0.10 -0.85 -0.90 ABC protein, subfamily ABCF ATP-BINDING CASSETTE SUB-FAMILY F MEMBER 1 (PTHR19211:SF14)
E9H3T0 11 2.04 0.42 -1.29 0.75 Putative uncharacterized protein NUCLEOLIN 1-RELATED (PTHR24012:SF330)
E9H4B8 14 0.11 -0.27 -0.31 -0.85 Putative uncharacterized protein FRAGILE X MENTAL RETARDATION SYNDROME-RELATED PROTEIN 1 (PTHR10603:SF7)
E9H4K0 5 -1.32 -2.40 -0.49 -0.60 Putative uncharacterized protein FI18627P1 (PTHR11782:SF30)
E9H6I9 13 0.64 1.23 0.82 0.93 Putative uncharacterized protein CALPONIN-LIKE PROTEIN CHD64 (PTHR18959:SF39)
E9H6N4 15 -0.49 -1.79 -2.25 -1.78 Putative uncharacterized protein 26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 3 (PTHR10758:SF2)
E9H6U8 21 -0.65 -0.74 -0.89 -1.03 Putative uncharacterized protein CALCIUM-BINDING MITOCHONDRIAL CARRIER PROTEIN ARALAR1 (PTHR24089:SF13)
E9H707 15 -0.05 -0.03 0.78 1.16 Putative uncharacterized protein LONG-CHAIN SPECIFIC ACYL-COA DEHYDROGENASE, MITOCHONDRIAL (PTHR10909:SF196)
E9H736 3 -2.21 -0.74 -0.76 -1.01 Putative uncharacterized protein DILUTE CLASS UNCONVENTIONAL MYOSIN, ISOFORM C (PTHR13140:SF191)
E9H7R2 14 0.01 -0.38 -0.99 -1.15 Putative uncharacterized protein AT24389P (PTHR11153:SF8)
E9H7X5 62 -0.65 -0.99 -1.35 -1.12 Putative uncharacterized protein TRANSLATIONAL ACTIVATOR GCN1 (PTHR23346:SF7)
E9H862 50 -0.26 -1.23 -1.07 -1.14 Putative uncharacterized protein BIFUNCTIONAL GLUTAMATE/PROLINE--TRNA LIGASE (PTHR10119:SF15)
E9H8K5 99 -1.14 -1.79 -0.68 -0.65 Putative uncharacterized protein VITELLOGENIN-2 (PTHR23345:SF1)
E9H8M2 26 -0.54 -0.58 -1.58 -1.58 Piwi/Aubergine-like protein variant 1 PIWI-LIKE PROTEIN 1 (PTHR22892:SF32)
E9H8T5 23 0.47 0.38 0.19 0.84 Aspartate aminotransferase GLUTAMATE OXALOACETATE TRANSAMINASE 1, ISOFORM B (PTHR11879:SF5)
E9H9F6 23 0.19 -0.84 -0.93 -1.32 Putative uncharacterized protein MOESIN/EZRIN/RADIXIN HOMOLOG 1 (PTHR23281:SF18)
E9H9P6 14 0.04 -0.63 -1.20 -1.03 Putative uncharacterized protein PROTEIN ANON-37CS (PTHR10742:SF250)
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Supplementary table 4 (continued) 
 
 
Supplementary table 5. (see original manuscript) Results of NCBI-BLAST homology search 
against the UniProtKB/Swiss-Prot database (processed with Blast2GO) for the 189 significantly 
regulated proteins. 
 
Supplementary table 6. (see original manuscript) List of the proteins showing a significant 
enrichment of their Gene Ontology (GO) categories in Biological Process (BP) or Molecular Function 
(MF) classes compared to the whole D. pulex genome. Only the significant categories are shown here 
as GO annotations. These proteins were used for the Figures 3A and 3B, and the supplementary 
Figures S3 and S4. 
 
UniProt ID Peptides Log ratio C1/DMSO 2d
Log ratio 
C2/DMSO 2d
Log ratio 
C1/DMSO 7d
Log ratio 
C2/DMSO 7d Protein name PANTHER Family/Subfamily
E9H9X9 19 -0.08 -0.77 -1.73 -1.25 Nucleolar protein-like protein 5A NUCLEOLAR PROTEIN 56 (PTHR10894:SF0)
E9HA01 21 0.27 -0.43 -1.55 -1.27 Putative uncharacterized protein SUBFAMILY NOT NAMED (PTHR11590:SF40)
E9HA96 14 0.61 1.38 0.65 0.79 Malate dehydrogenase MALATE DEHYDROGENASE, CYTOPLASMIC (PTHR23382:SF3)
E9HAP5 9 0.16 0.29 0.68 1.37 Proteasome subunit alpha type PROTEASOME SUBUNIT ALPHA TYPE-6 (PTHR11599:SF11)
E9HC70 7 0.42 0.57 0.79 0.71 Putative uncharacterized protein ACETYL-COA ACETYLTRANSFERASE, MITOCHONDRIAL (PTHR18919:SF79)
E9HCE1 3 -2.09 -3.25 -2.80 -3.11 Putative uncharacterized protein PROTEIN F56B3.6 (PTHR12300:SF22)
E9HCT5 19 -0.54 -1.16 -2.13 -1.83 Putative uncharacterized protein VALYL-TRNA SYNTHETASE, ISOFORM A (PTHR11946:SF5)
E9HD09 5 -0.26 0.04 -0.02 1.50 Putative uncharacterized protein FERRITIN (PTHR11431:SF4)
E9HF12 23 -0.48 -1.38 -1.69 -1.34 Putative uncharacterized protein LEUCINE--TRNA LIGASE, CYTOPLASMIC (PTHR11946:SF51)
E9HFQ5 5 -1.93 -1.29 -2.31 Ubiquitin carboxyl-terminal hydrolase SUBFAMILY NOT NAMED (PTHR24006:SF421)
E9HG20 18 0.26 0.51 0.71 1.26 Adenylosuccinate synthetase ADENYLOSUCCINATE SYNTHETASE (PTHR11846:SF0)
E9HGQ3 6 0.53 -0.12 -1.06 -1.19 Putative uncharacterized protein PDZ AND LIM DOMAIN PROTEIN ZASP (PTHR24214:SF29)
E9HGR4 3 1.23 1.06 -0.95 -1.25 Putative uncharacterized protein LYSINE-SPECIFIC DEMETHYLASE LID (PTHR10694:SF8)
E9HGT3 15 -0.63 -0.76 -1.59 -0.75 Putative uncharacterized protein EPOXIDE HYDROLASE 1 (PTHR21661:SF10)
E9HGV5 21 -0.21 -0.74 -0.70 -1.03 DNA topoisomerase 2 DNA TOPOISOMERASE 2 (PTHR10169:SF38)
E9HGX0 20 0.93 0.91 0.95 1.63 Malate dehydrogenase MALATE DEHYDROGENASE, MITOCHONDRIAL (PTHR11540:SF16)
E9HI00 20 -0.02 -0.17 0.51 0.83 Putative uncharacterized protein (Fragment)
MEDIUM-CHAIN SPECIFIC ACYL-COA DEHYDROGENASE, MITOCHONDRIAL 
(PTHR10909:SF240)
E9HIB3 21 0.05 0.40 0.65 1.37 Putative uncharacterized protein DIPEPTIDASE B, ISOFORM A (PTHR11963:SF9)
E9HJQ1 15 -0.69 -1.18 -1.06 -1.24 Putative uncharacterized protein VITELLOGENIN-2 (PTHR23345:SF1)
E9HJT8 5 2.50 -0.29 -2.39 -1.83 Putative uncharacterized protein 40S RIBOSOMAL PROTEIN S17-RELATED (PTHR10732:SF0)
E9HLH8 13 0.67 0.25 -1.14 -0.84 Putative uncharacterized protein MATERNAL PROTEIN EXUPERANTIA (PTHR12384:SF1)
E9HM79 27 -0.24 -0.43 -0.82 -0.87 Putative uncharacterized protein EUKARYOTIC TRANSLATION INITIATION FACTOR 4G, ISOFORM B-RELATED (PTHR23253:SF9)
E9HM84 13 -0.99 -1.29 -1.92 -2.50 Putative uncharacterized protein MITOCHONDRIAL 2-OXOGLUTARATE/MALATE CARRIER PROTEIN (PTHR24089:SF86)
E9HN52 30 -0.10 -0.59 -0.56 -1.12 Putative uncharacterized protein TRIFUNCTIONAL ENZYME SUBUNIT ALPHA, MITOCHONDRIAL (PTHR23309:SF9)
E9HNC5 16 -0.12 -1.42 -1.64 -1.16 Putative uncharacterized protein ARGININE--TRNA LIGASE, CYTOPLASMIC (PTHR11956:SF1)
E9HNC7 17 -0.53 -1.27 -0.46 -1.00 Putative uncharacterized protein ATP-BINDING CASSETTE SUB-FAMILY E MEMBER 1 (PTHR19248:SF16)
E9HP73 15 0.63 -0.23 -1.47 -1.52 Putative uncharacterized protein
E9HR84 40 -1.02 -1.89 -1.81 -2.28 Putative uncharacterized protein CALCIUM-TRANSPORTING ATPASE SARCOPLASMIC/ENDOPLASMIC RETICULUM TYPE (PTHR24093:SF163)
E9HRX9 13 0.52 -0.57 -1.32 -1.79 Putative uncharacterized protein SUBFAMILY NOT NAMED (PTHR13711:SF174)
E9HTS2 10 0.35 -0.11 -0.84 -0.84 Putative uncharacterized protein 60S RIBOSOMAL PROTEIN L9 (PTHR11655:SF16)
E9HTT3 17 -4.54 0.64 -1.37 0.32 Putative uncharacterized protein CYSTATHIONINE BETA-SYNTHASE (PTHR10314:SF48)
E9HUP6 7 0.10 -0.55 0.05 -0.91 Putative uncharacterized protein CYSTATHIONINE GAMMA-LYASE (PTHR11808:SF15)
E9HX82 4 0.02 0.63 1.46 0.21 Putative uncharacterized protein
E9HZI5 19 1.28 -0.32 0.41 -0.95 Vitellogenin fused with superoxide dismutase (Fragment) SUPEROXIDE DISMUTASE [CU-ZN] (PTHR10003:SF32)
E9I5Q2 4 -0.43 -4.04 Putative uncharacterized protein (Fragment) TRANSLOCATION PROTEIN SEC62 (PTHR12443:SF9)
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Supplementary table 7. (see original manuscript) List of the 57 proteins showing a significant fold 
change between blank (M4) and solvent control (DMSO) samples with LPE test, after multiple-testing 
correction and removal of outliers. PANTHER annotations are included and both 2 and 7 days ratios 
are shown, with significant ones highlighted in grey. 
 
Supplementary figure 1. Correlation of protein intensities (in log2 scale) between all experiments at 
2 (A) and 7 (B) days. Pearson correlation factor was superior to 0.9 for all duplicates (red frame), 
showing a good reproducibility of replicate experiments. 
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Supplementary figure 2. Graphical representation of relations between proteins and significant 
Biological Process GO categories with proteins as nodes and shared annotations as edges. Edge width 
between 2 proteins was proportional to the minimum percentage of shared annotations and node color 
scaled according to log2 of protein fold change, A: 2 days – C1, B: 2 days – C2, C: 7 days – C1. 
Results for 7 days – C2 are shown in main (Figure 6.5). Only significant GO categories are displayed, 
but too general annotations, such as metabolic process, primary metabolic process and protein 
metabolic process, were not included for a better clarity of the graphs. 
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Supplementary figure 3. Graphical representation of relations between proteins and significant 
Molecular Function GO categories with proteins as nodes and shared annotations as edges. Edge width 
between 2 proteins was proportional to the minimum percentage of shared annotations and node color 
scaled according to log2 of protein fold change, A: 2 days – C1, B: 2 days – C2, C: 7 days – C1. 
Results for 7 days – C2 are shown in main Figure 6.6. Only significant GO categories are displayed, 
but too general annotations, such as catalytic activity, structural molecule activity and binding, were 
not included for a better clarity of the graphs. 
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Supplementary files. (see original manuscript) Cytoscape (version 2.8.3, www.cytoscape.org) files 
(.cys) used to create figures 6.5 and 6.6, and supplementary figures 2 and 3. GO Biological Process: 
Fig_BP_GO.cys ; GO Molecular Function: Fig_MF_GO.cys. 
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Chapter 7  
 
 
 
Synthesis and discussion 
The studies presented in this thesis focused on the toxicity of anticancer drugs on non-target organisms 
at the organism and the protein levels of the biological organisation. At the organism level, the 
primarily objective was to assess the sensitivity of D. pulex exposed to anticancer molecules. Imatinib, 
tamoxifen and two of its potent metabolites, i.e., 4OHTam and endoxifen, were used in acute and 
long-term experiments. Prospective assays were also performed to observe how daphnids reacted after 
being withdrawn from stress chemical or after being exposed to a mixture of tamoxifen and 4OHTam. 
At the protein level, the objective was to determine changes of protein expression in D. pulex after 
short (2 days) and mid time (7 days) exposures to tamoxifen. 
Further experiments are also proposed and briefly described in this last chapter to increase knowledge 
on tamoxifen mode of action and effects on daphnids. The relevance of using daphnids as model 
organisms and of using measured or predicted concentrations in ecotoxicology are also addressed in 
this discussion. Finally, these issues lead us to courses of action that may be undertaken to reduce the 
input of pharmaceuticals in the aquatic system. 
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Synthesis and discussion 
This thesis was a multidisciplinary project that involved a tripartite collaboration between scientists 
from ecotoxicology, toxico-pharmacology and proteomics. The project integrated pharmacokinetic 
and pharmacodynamic aspects along with ecotoxicological and proteomics approaches to address the 
issue of anticancer drug residues in surface water. The determination of tamoxifen, 4-hydroxy-
tamoxifen (4OHTam), endoxifen and imatinib, as key molecules to be assessed among all other 
anticancer drugs was the result of this tripartite collaboration. Several aspects were considered and 
discussed about these anticancer pharmaceuticals such as their chemical properties, human 
metabolism, disease incidence and drug consumption, relevance for non-target species and their 
potential effects at the population or at the protein levels. Compared with other xenobiotics, 
pharmaceuticals have the advantage to be one of the best investigated and characterised man-made 
chemicals. Broad pharmacological knowledge (e.g., physical chemical properties, mode of action, side 
effects, etc.) on commercialised pharmaceuticals is available in the literature. Together with 
ecotoxicological knowledge, the pharmacological data help to determine the potentially active and 
harmful molecules for the environment at low concentrations. Also, this exchange of knowledge may 
facilitate integrated risk assessment of pharmaceutical compounds to the aquatic fauna and flora. For 
instance transdisciplinary knowledge could lead to scientifically-based testing strategies for the 
detection, the identification and the quantification of chemicals during ecotoxicological risk 
assessment. 
The experiments that were performed in this thesis were mainly multigenerational and they were 
related to certain challenges. Adaptation to change and to unexpected situations was probably the most 
important ability to be developed prior and during these experiments to meet our predetermined 
objectives. For instance, we had to face different molecule properties that had lowered daphnids’ 
exposure concentrations, limitations in laboratory handling, unexpected toxic effects on daphnids, etc. 
Moreover, long-term experiments are rarely undertaken in ecotoxicology and detailed procedures are 
lacking in the literature. Therefore, the experimental test procedures needed to be designed and they 
were continuously adapted to ease handling. For instance, three main points were improved over the 
experiments that were performed with tamoxifen, its metabolites and imatinib. First, the period of 
exposure was reduced from the standard 21 days to 14 days because we observed that significant toxic 
effects on the reproduction were already observable after the third clutch when compared with 
controls. Moreover, multigenerational tests are time demanding and shortening of the period of 
exposure allowed us to increase the number of generations that were followed. Second, three 
organisms per beaker, in triplicate (= 3 beakers), were treated at each concentrations instead of one 
individual per concentration in 10 replicates (0 10 beakers), as recommended in the OECD guideline 
[1]. These three beakers per concentration instead of ten eased laboratory manipulations and provided 
nine treated organisms per concentration, which is close to the recommended number of individuals in 
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standard experiments. Third, the generation that was isolated and exposed to a similar maternal 
medium (with or without chemicals) was pipetted from a unique beaker among the replicates. In other 
words, offspring from a same beaker was pipetted to form the next generation to be treated, when ever 
possible, because individuals born at the same time will reproduce at the same time, i.e., the same day. 
This synchronised reproduction decreased the variability between the mothers exposed to the same 
chemical concentration, in terms of the total number of neonates produced. The three above 
improvements had enabled to provide relevant results about the toxicity of four molecules with 
anticancer properties. 
 
 
Ecotoxicological experiments 
The studies presented in this thesis showed that anticancer drugs induced several toxic effects on 
daphnids. Tamoxifen, 4OHTam and endoxifen interacted with reproduction, body-length and/or 
longevity, and some effects were unusual, such as morphological abnormalities on offspring, 
evisceration or erratic swim-styles. Tamoxifen and its metabolites were teratogen, since treated 
mothers produced body-deformed neonates. Tamoxifen impaired physiological processes in D. pulex 
and offspring at environmentally relevant concentrations, and this chemical was the most toxic 
compound among the anticancer drugs tested, followed by 4OHTam, endoxifen and imatinib. Imatinib 
interacted only with reproduction and at high concentration. 
Daphnids from mothers exposed to tamoxifen or 4OHTam were not able to recover when removed 
from test solution and transferred to incubation medium exempted from the chemicals. Two general 
hypotheses were proposed to explain why effects were observed in untreated daphnids. Firstly, 
damages may have been transferred from treated mothers to offspring. Secondly, damages may have 
occurred during the early exposure period, when eggs and embryo were still in the maternal brood 
chamber, or later when neonates were swimming in the maternal test solution. Indeed, animals 
withdrawn from solutions containing the toxic chemical were neonates that were born in test solutions 
and then removed from within the first 24-h. During this short exposure period, the toxic chemicals 
may have interacted with biological processes on the exposed developing organisms. These two 
hypotheses may be further investigated using experiments where daphnia eggs are removed from the 
brood chamber of treated mothers [2]. Eggs from the same mother and therefore of the same age could 
be individually deposited in a multi-well plate. At different times, and thus at different developmental 
stages of the embryos, each egg could be exposed to tamoxifen or 4OHTam at a concentration that is 
known to have effects in neonates (Figure 7.1). The critical window (here the most sensitive 
embryogenesis period) could be established depending on the observed neonatal and adult effects (i.e., 
malformation or not, size impairment or not, reduced reproduction or not, etc.). 
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Figure 7.1: Daphnia eggs experiment. Each egg is exposed to toxic chemical-bearing solutions at a 
different time of the embryogenesis to determine the critical window or the potential transmission of side 
effects from treated mothers. The studied endpoints in neonates could be morphological abnormalities, 
size impairment, survival, etc. 
 
The results found in the mixture experiment (tamoxifen and 4OHTam combined) are consistent with 
the hypothesis postulating that side effects could be induced directly in the developing embryo and 
might not be transmitted by parents. Indeed, in this study, the effects were similar in adult daphnids 
that were previously exposed or not to the potentially toxic chemical at embryogenesis. Once adult, 
the reproductive performance of both groups was decreased. This result showed that tamoxifen and 
4OHTam mixture was interacting with developing organisms. Besides, the combination of tamoxifen 
and 4OHTam induced effects in offspring while no effects were observed when these chemicals were 
tested individually at the same concentration. Although a synergic potential of these chemicals in 
daphnids need to be verified in complete mixture experiments (i.e., with complete individual dose 
response curves), their combined potential cannot be excluded. This hypothesis is in accordance with 
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authors who discussed the beneficial effect of tamoxifen in patients as the result of an aggregate effect 
of tamoxifen and its metabolites 4OHTam and endoxifen [3–5]. Also, experiments with endoxifen 
used in mixture would be interesting to carry out since this metabolite seems to be involved in the 
combined potential of tamoxifen and 4OHTam in cancer patients [6]. 
 
 
 
Figure 7.2: D. pulex recovery experimental design followed by an additional experiment if epigenetic 
process is suspected. 
 
 
Several mechanisms may be involved in and responsible of the observed effects on daphnids and their 
offspring exposed to tamoxifen and its metabolites, such as endocrine system interactions, DNA 
modifications but also epigenetic regulations that caused changes in phenotype or gene expression 
without changes in DNA sequence [7–9]. At the endocrine level, chemicals may have blocked or 
induced mechanisms that had disturbed the normal development of physiological functions of 
daphnids, reducing their size or reproduction for instance. Also, epigenetic regulations were 
discovered in cells exposed to tamoxifen [10–12] and recently, Vandegehuchte et al. [13] showed that 
epigenetic dysregulations (e.g., DNA methylation) occurred in daphnids that were exposed to various 
compounds. It is possible that epigenetic inheritance was one reason explaining the adverse effects 
that were observed in the epigenetic experiment, i.e., in offspring withdrawn from the solution with 
chemical. To confirm this hypothesis, we recommend to perform recovery experiments with more than 
two generations, as suggested by Harris et al. [9]. Indeed, if the adverse effects persist into 
nonexposed generations beyond the third, a true transgenerational effect can be confirmed. Figure 7.2 
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summarizes the conceptual framework of recovery experiments with a possible extension if epigenetic 
mechanism is suspected. This experimental design could be integrated in any multigenerational 
ecotoxicity experiment or it could be run individually, as a distinct experiment. Briefly, we suggest 
following up neonates that were withdrawn from the two lowest effective concentrations because at 
higher concentrations the effects may be the result of severe internal lesions rather than subtle 
epigenetic mechanism. Neonates from the first and the second generations (F0 and F1) could be used 
because mothers of the F0 were not exposed to chemical during the embryonic stage, while mothers of 
the F1 were. This parental exposure differences may also induce differences in the outcomes, which 
would be interesting to compare. Indeed, it is known that epigenetic dysregulation with health effects 
on several generations can occur because of prenatal exposure to chemical [7]. Therefore, neonates of 
the F1 may be more sensitive and less fit than neonates of F0, and therefore less able to recover. If a 
choice has to be taken between the generations to be tested, e.g., due to work feasibilities, the second 
generation would be more appropriate than the first to avoid missing latent effects resulting from 
epigenetic process.  
However, a direct action of the chemical in the endocrine system may be another reason of the adverse 
effects that were observed in treated and recovering daphnids. In invertebrates, hormones control 
development, reproduction and other physiological aspects such as growth [14]. Tamoxifen and 
4OHTam may have interfered with hormone production, release or bioavailability, such as other 
chemicals. These chemicals may also have interacted with signal transductions or with hormone 
binding to receptors by either blocking (antagonizing) or activating (agonizing) them. In vertebrates, 
tamoxifen and 4OHTam interact with the estrogen receptors (ERs) but also with the estrogen-related 
receptor (ERRs, [15]). Because daphnids lack ER, we hypothesized that these molecules could act on 
the dappu-ERR [16]. Unfortunately, neither synthetic nor endogen ligands of ERR are known in D. 
pulex, and no experiment can be undertaken at this stage to assess potential interactions of chemicals 
with this receptor in daphnids. However, interactions with dappu-ERR should be kept in mind if 
experiments that consider other mechanisms of action do not show relevant results, e.g., experiment 
with ecdysone receptors. Indeed, disruption at the ecdysteroids receptor level is often considered to be 
responsible of adverse effects when daphnids are exposed to endocrine disruption compounds [17–20]. 
Ecdysteroids are polyhdroxylated ketosteroids that are present in crustaceans and other arthropods 
[17,21] and that are involved in important processes such as molting regulation, embryo development, 
covering organism formation (cuticle), etc [19,22,23]. Ecdysone has structural similarity with 
vertebrate estrogen [24] and tamoxifen and its metabolites bind with estrogen receptors. Therefore, 
ecdysteroids may be involved in the adverse effects that were observed in D. pulex exposed to these 
chemicals. Studies reported that ecdysteroid levels such as ecdysone synthesis in daphnids can be 
measured by radioimmunoassay after its extraction and its radiolabeling [17,25]. Such experiment 
could be performed to assess ecdysteroid levels in embryos exposed to tamoxifen or its metabolites 
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and to observe whether the morphological abnormalities that were found later in offspring resulted 
from ecdysone dysregulation. At organogenesis for instance, when daphnia glands become functional, 
embryos start to synthesize ecdysteroids that are used for egg maturation [19,25]. A decrease in these 
signalling molecules may impair healthy development of the embryo and induce morphological 
abnormalities, such as found after daphnia exposures to tamoxifen and its metabolites.  
 
Figure 7.3: Illustration of potential mitigation of tamoxifen-induced developmental abnormalities by 20-
hydroxyecdysone (20-H) during D. pulex exposure. The exposure period is 21 days and individual 
offspring is evaluated microscopically to observe any side effects (fictive data) 
 
A second study may also be undertaken to determine whether the effects of tamoxifen or its 
metabolites on daphnids are due to an ecdysteroid activity. If these chemicals interact with the 
ecdysone receptor in daphnids, adverse effects on daphnids would indeed be observed. This second 
experiment could consist of using 20-hydroxyecdysone (20-H), an ecdysone receptor ligand that was 
successfully used as co-exposure molecule during ecotoxicological experiments with endocrine 
disruptors [17–20]. For instance, a concentration that is known to induce effects (e.g., morphological 
abnormalities) is chosen for the test and increasing concentration of 20-H is co-administered (Figure 
7.3). Treated and untreated neonates (< 24-h, > 3 broods) would be reared to maturity (approximately 
six days in our laboratory conditions), and then the number of individual offspring production would 
be counted daily. These newborn individuals would be evaluated microscopically to identify any 
morphological abnormalities for instance. The experiments can stop after 21 days of exposure because 
sufficient number of neonates would have been produced and assessed. If the effects of tamoxifen are 
mitigated or totally absent by co-exposure to 20-hydroxyecdysone, this would mean that tamoxifen 
interferes with ecdysteroid control of development. 
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The above two experiments would help to understand whether the endocrine system is involved in the 
adverse responses that were observed in daphnids exposed to tamoxifen or its metabolites. Proteomics 
experiments can also be undertaken to better understand the interaction between toxic chemicals and 
the biology of treated animals. Indeed, proteomics may highlight changes at sub-organism level long 
before they are observed on whole organisms or populations. 
 
Ecotoxicoproteomics vs multigenerational experiments 
In the ecotoxicoproteomic experiment, we tried to relate phenotype effects on D. pulex with potential 
alterations at the protein level. Daphnids were exposed 2 and 7 days to tamoxifen at the predicted test 
concentrations of 0.1 (C1) and 2.4 (C2) µg/L. At these concentrations already, protein dysregulations 
were found. After multiple proteomics analyses, a total of 3940 proteins were identified and quantified 
in D. pulex using the UniProt database (www.uniprot.org). Among them, 189 proteins were 
significantly regulated and possibly related to a general stress induced by tamoxifen exposure. For 
instance, the expression of the vitellogenin fused with superoxide dismutase domain (E9GVW7) was 
overexpressed in daphnids exposed to tamoxifen. Some authors hypothesised that stress situations, 
such as exposure to chemicals, are associated with oxidative stress, which results in increased levels of 
anti-oxidative enzymes [26], such as copper/zinc superoxide dismutases. These enzymes prevent 
organisms from cell and tissue damages by catalysing the dismutation of superoxide free radicals. 
Therefore, the increase of E9GVW7 expression may be a physiological response of cells upon 
tamoxifen stress [27].  
Proteins that play a role in reproduction were down-regulated in this study, such as some of the 
vitellogenin-2 family. Vitellogenins are major precursors of the egg-yolk proteins, vitellins, which are 
sources of nutrients during embryonic development [28,29]. The decrease in expression of 
reproductive proteins may be a strategy of stressed daphnids to keep energy for their primary 
functions. Because chemical exposure is an environmental stress and because stress responses are 
energy demanding, living organisms may have developed protective strategies to preserve their 
species from extinction. For instance, Rowe et al. [27] hypothesised that upon stress, organisms shift 
their energy for reproduction and/or energy for storage to survival. Jansen et al. [26] used this 
hypothesis to explain decreased levels of vitellogenin precursor in D. magna exposed to natural and 
anthropogenic stressors. Hence, to maintain their basic metabolic rate, which is considered as a 
catabolic pathway [27], treated daphnids may have temporary reduced other cost-energy functions. 
Since basic metabolism cannot be suppressed without compromising survival, it needs to be satisfied 
before energy is used for reproduction. This hypothesis is in line with the results that were found in the 
two-generational ecotoxicity experiment performed with tamoxifen in which the reproduction of the 
first daphnia generation dropped drastically when exposed to a concentration of the same order of 
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magnitude as C2. Therefore, the protein modifications identified in our studies confirmed and 
complemented the effects that were observed in treated animals during ecotoxicological experiments 
with tamoxifen. These modified proteins were identified in daphnids exposed to a concentration that 
corresponded approximately to one order of magnitude of the environmental concentration. Although 
specific biomarkers for early detection of tamoxifen harmful effects on D. pulex were not discovered 
in this study, proteins of the vitellogenin-2 family (E9H8K5) and the ryanodine receptor (E9FTU9) 
were determined as promising potential biomarkers because their expression was already modified 
after 2 days of treatment. Further experiments that focus on these proteins are recommended to verify 
their relevance as early warning proteins. In the same vein, experiments with tamoxifen at lower 
concentrations and in other aquatic organisms are suggested to improve knowledge on tamoxifen 
potential mechanism of action in non-human species. Also, the ecotoxicoproteomics analyses that 
were performed in this thesis provided the largest dataset from D. pulex that have ever been published 
up to now. These results are available for the scientific community and they may help further 
investigations on D. pulex exposed to tamoxifen or to other anticancer or endocrine disrupting 
compounds. 
Compared to proteomics that may increase understanding of potential mechanism of action of a 
chemical, ecotoxicological tests based on long-term exposures and on several generations increase 
knowledge on potential effects at the population level. Indeed, multigenerational experiments are close 
to realist situations/exposures that are useful in future hazard assessments of chemicals in the aquatic 
environment [24]. This is in accordance with Kim et al. [30] who recently underlined that the number 
of generation is an important factor for chemical toxicity assessments. For instance, the first treated 
generation are organisms that were not previously exposed to the toxic chemical may be less sensitive 
towards such compounds [30–32]. Also, the sensitivity of the treated organisms may increase over 
generations, as stated in the two-generational experiment that was performed with tamoxifen 
metabolites.  
Based on these indications, we propose to use at least two generations of daphnids to consider and to 
compare the chemical toxicity in aquatic experiments. If effects are magnified in the second 
generation, two additional generations may be followed to ascertain the long-term toxicity of 
chemicals (Figure 7.4). For instance, the results obtained during the two-generational study that was 
performed with 4OHTam did not provide new relevant effects when compared with the four-
generational experiment. By contrast, the fourth generations of treated daphnids was adversely 
affected by tamoxifen at lower concentration than the two first generations. A case by case assessment 
is suggested to decide whether additional generations should be followed or not. 
In this thesis, this follow up was done in a separate experiment, in which tamoxifen and 4OHTam was 
assessed during four generations because previous results suggested magnified effects over 
generations. It would also have been possible to follow next generations in the same experiment, as 
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time magnified effects were suspected, instead of restarting a whole four-generational experiment. But 
a new experiment allows the results that were obtained during the first assay to be confirmed. This is 
particularly relevant when molecules with unknown effects on aquatic organisms are evaluated, as it 
was indeed the case with tamoxifen metabolites. 
 
 
Figure 7.4: Multigenerational experimental design with D. pulex. The two first generations (F0 and F1) 
are required, but the next two generations (F2 and F3) are strongly recommended if magnified effects are 
suspected in the F1. 
 
Prodrugs, metabolites and specific anticancer drugs 
In general, metabolites are poorly studied, although some of them have higher potency to induce 
effects on living organisms than their parent drug. Prodrugs are chemicals for which the metabolites 
are known to be active. After administration, these metabolites may be body-excreted in wastewaters. 
Therefore, prodrugs are interesting molecules to focus on in ecotoxicology. For instance, clopidgrel is 
an antiplatelet agent administered during several months to prevent vascular diseases, such as heart 
attacks or strokes, in people at risk [33,34]. This pharmaceutical needs in vivo enzymatic activation 
(cytochrome P450) to be converted in a potent metabolite, named as clopidogrel active metabolite 
[34,35]. A small percentage of clopidogrel dose is ultimately converted to its active metabolite (i.e., 
10%), but because the number of people with cardiovascular risk is high, particularly in industrial 
countries, the consumption may be high and so its release in wastewaters. This prodrug is indeed the 
most antiplatelet therapy prescribed in the world [36–38]. Another example is the prodrugs that are 
used in oncology. These prodrugs are attractive molecules because they provide an alternative therapy 
with low cytotoxic effects, when compared with cytotoxic anticancer drugs that are systemic 
antiproliferative agents that target dividing cells [39,40]. For instance, miproxifene phosphate, 
capecitabine, cyclophosphamide, are anticancer prodrugs that could potentially release active 
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metabolites through human excreta [40–42]. Besides, it would be interesting to assess the effects of 
other anticancer compounds with endocrine disruptive activities, such as fluvestrant. Fulvestrant is an 
oestrogen receptor antagonist with no agonist effects that is used in the treatment of hormone receptor-
positive metastatic breast cancer [43]. Approximately 80 and 90 % of this chemical is excreted in 
faeces, in the intravenous and intramuscular trials, respectively [44]). Fulvestrant and its 17-ketone 
metabolite seem to be the major excretory compound. 17-Ketone metabolite has a similar anti-
estrogenic activity as its parent drug, while all other metabolites do not have any. Besides, other TKIs 
than imatinib may be assessed and monitored in the aquatic environment because a second generation 
of “tinib” has reached the market after imatinib commercialisation, such as gefitinib, sunitinib, 
nilotinib, dasatinib, sorafenib and lapatinib. These new generations of molecules are used against 
various cancers but with a broad prevalence for chronic myelogenous leukemia and gastrointestinal 
stromal tumours. Because these molecules demonstrated a definite efficacy on survival of advanced 
cancer patients - however less impressive than for imatinib in its specific indications - a progressive 
increase in their use and in their release in the environment can be expected. 
 
Nominal vs measured concentrations 
In this thesis, the need to measure the exposure level of lipophilic molecules during ecotoxicological 
experiments was highlighted because notable differences between nominal (i.e., theoretical) and 
measured concentrations were found with tamoxifen and its metabolites at all test concentrations. We 
hypothesised that tamoxifen, 4OHTam and endoxifen adsorbed on surfaces of the glass flasks that 
were used during ecotoxicological assays. This phenomenon might have induced intra- and inter-
concentrations variability as well as systematic reduction in the expected test exposure. Therefore, it 
was necessary to find a method that was able to reflect the exposure level of the test solutions and that 
was cost and time sustainable. Subsamples of the nominal solutions were therefore analysed and the 
corresponding measured concentrations were plotted against the nominal levels. This polynomial 
regression was used to establish the so-called predicted concentrations. Our method predicted well the 
low exposure levels when these predicted concentrations were compared with those measured. 
Although it is interesting to know the concentration in acute exposure experiments, this thesis 
primarily focused on long-term experiments that are environmentally relevant. Because predicted 
concentrations were used instead of nominal, comparisons with environmental concentrations were 
possible. In the experiment that was performed with imatinib, the nominal concentrations 
corresponded to those measured and environmental comparison would be possible if this chemical is 
monitored in natural waters. Furthermore, the method that was proposed to predict tamoxifen and its 
metabolites also avoided enormous number of analyses. Based on standard guidelines [1] indeed, a 
strict follow up of the concentrations would have required sampling at solution renewal and after 48h 
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at least, which was not feasible during long-term experiments. In the two-generational experiment (21 
days of exposure) that was performed with tamoxifen metabolites for instance, such a follow up would 
have required a total of approximately 900 samples to be collected and analysed (i.e., 8 concentrations, 
at t0 and t48, in triplicate, during 2 generations). Using our predictive method, a total of only 520 
samples (318 and 202 for 4OHTam and endoxifen, respectively) were analysed for all experiments 
that were carried out in this thesis with these metabolites, which was cost and time sustainable. 
Predicted concentrations instead of nominal concentrations were therefore used in this thesis. The 
chemical lost and the variability in measured concentrations raise questions about the importance of 
assessing the test solutions in ecotoxicological studies. Indeed, in the literature review that was 
undertaken in a master project involved in this thesis [45], it was shown that results based on nominal 
concentrations are still published nowadays. In articles that were published in the journal 
Environmental Toxicology and Chemistry in 2012, we found that 45% of the test chemicals were not 
measured. This means that the conclusions on the efficiency or the toxicity of these molecules were 
based on concentrations that may not reflect real exposure levels. Also, a risk may be assessed and 
decisions may be taken based on these results. Indeed, several national and international organisations 
involved in environmental protection [46] use ecotoxicological results to make decisions. If the latters 
are based on nominal concentrations, underestimation of the chemical toxicity and of the risk of 
certain chemicals to the aquatic flora and fauna is possible [47]. 
 
From single aquatic species to ecosystem 
The choice of the test species is also crucial when hazardous assessment of a chemical is undertaken. 
D. pulex and D. magna have been described in the scientific literature since 1960 [46] and they have 
been used in acute and chronic tests for years. In major cases, there is no difference in the overall 
sensitivity of the D. pulex and the D. magna exposed to several chemicals [48]. Daphnids are also 
good animal models in ecotoxicology because of their parthenogenetic life cycle. This mode of 
reproduction eases recovery, epigenetic and proteomics experiments primarily because confounding 
genetic differences are avoided [9]. Indeed, it is easy to observe phenotype modifications that are 
induced by epigenetic changes in gene expression when there are no genetic differences between 
individuals of any one strain. Finally, D. pulex may be more and more used in ecotoxicology, not only 
because D. pulex can be used a sensitive model to toxicants [49], but also because its sequenced 
genome offers the possibility to better understand chemical toxicities and chemical mode of actions 
[50,51]. 
Nevertheless, experiments with other organisms are required to assess chemical harmfulness because 
the sensitivity between species to a same molecule can be totally different [52]. In our study, two-
generations of daphnids exposed to imatinib did not show adverse effect at environmental 
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concentrations but other species may have been sensitive at lower exposure levels. It is possible that 
daphnids were highly tolerant to this molecule or it is possible that imatinib’s mode of action was too 
specific and did not target normal daphnia cells. Indeed, imatinib is specific to certain cancer cells 
only. Nevertheless, further ecotoxicological experiments are recommended to confirm the low toxicity 
of imatinib to aquatic species, but two other species may be sufficient (e.g., on algae and fish). Indeed, 
as it is not possible to test all chemicals in each species, choices have to be made. In this sense, 
multidisciplinary collaboration between biologists, pharmaco-toxicologists and ecotoxicologists may 
help to find the best species and the most relevant drug residues, with the goal to protect major aquatic 
species. Indeed, biodiversity is a key factor for humans and environmental health and well-being. It 
ensures the supply of ecosystem services and facilitates ecosystem stability, which the basis of 
sustainable development [53,54]. Water quality assessment is thus an important part of the risk 
assessment process to minimize the occurrence, the fate and the effects of hazardous substances in 
aquatic ecosystems.  
Increased knowledge may lead scientists and non-scientists to recognise some pharmaceuticals such as 
anticancer drugs as serious threat to freshwater ecosystems. This awareness may be reinforced by their 
potential magnified release due to increasing urban and medicinal therapy developments. Indeed, new 
synthetic molecules, including pharmaceuticals are discovered at an exceptional speed. Backhaus et al. 
[53] reported as an example that more than 700 new chemicals were inscribed, in a 24-h period, into 
the Chemical Abstracts Service database of the American Chemical Society website (www.cas.org), 
which means a discovery rate of more than 30 new chemicals per hour. Such as wild organisms, 
humans are directly and indirectly exposed to thousands of molecules through breathing, skin, 
mucosal lining, food, drinking water, etc. Living organisms exposure to environmental chemicals and 
metals is ubiquitous. For instance, results of body fluid analyses showed that humans are exposed to 
several xenobiotics [55–59] and that women may be exposed during their pregnancy to 43 different 
chemicals at least, among 163 analysed chemicals from 12 different chemical classes (e.g., 
polybrominated diphenyl ethers, PBDEs; perfluorinated compounds, PFCs; organochlorine pesticides, 
phthalates, etc [60]). Therefore, the problematic of xenobiotics, including pharmaceuticals, in the 
environment is of growing concern for the general public and the scientific community. Scientists and 
non-scientist are increasingly focused on the potential impact of chemicals on ecosystems but also on 
drinking water. For instance, the Institut National de la Consommation [61] published a short 
communication about the presence of tamoxifen traces in drinking water, which underlines that this 
family of molecules can also reach water intended for human consumption. In general, 
pharmaceuticals in drinking water present a low risk for human health [62], but to the best of our 
knowledge, the risk assessment of molecule that is a pharmaceutical, an endocrine disruptor and a 
carcinogen agent, like tamoxifen, has never been addressed by experts so far. Therefore, we wonder 
how these molecules would be assessed and whether their double potential risks (i.e., endocrine 
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disruptor and carcinogen agent) would be considered. Such as in ecotoxicology however, little or 
nothing is known regarding long-term effects on human exposed to pharmaceuticals through drinking 
water. 
 
Three levels of action to reduce pharmaceutical release in waters 
The risk of pharmaceuticals to the aquatic environment and to humans cannot be excluded because: 1) 
pharmaceuticals can reach natural and drinking waters, 2) pharmaceuticals are considered as pseudo-
persistent, 3) living organisms including humans may be exposed to these active residues throughout 
their entire lifetimes, for generations [30]. For these reasons, efforts should be undertaken to reduce 
pharmaceutical exposures. The best effort would obviously be to strictly avoid the release of 
pharmaceutical molecules into aquatic systems. This action is not realistic at this stage and other 
actions at different levels may help to reduce the occurrence of these compounds in waters, and thus 
the stress they induce in living organisms. Here are presented three levels of action that could reduce 
the total input of pharmaceuticals in wastewaters and natural waters. 
Pharmaceutical industries may be considered as one level where actions can be undertaken. Indeed, 
these companies, which are considered as one of the three main sources of pharmaceutical pollution 
[63], have financial and technological resources to improve industry wastewater management, drug 
conception and sales. For instance, reconsideration of the doses may be an interesting action to reduce 
pharmaceutical residue inputs into the environment. Indeed, the standard dose is not necessarily the 
lowest dose that could be prescribed to patients, as observed by Decensi et al. [64,65]. Further studies 
on the minimum therapeutic dose may therefore lead to dose reduction. Development of 
pharmaceuticals with more specific modes of action would also help to reduce the amount of residues 
in waters [66]. In addition, increment of industrial wastewater treatment processes, particularly after 
tanks cleaning, may also be beneficial for the water cycle. 
A second level of action to reduce pharmaceutical release in waters may be health facilities and 
medicine/nursing training. Physicians and nurses familiar with the toxicology of the environment, 
aware of the water cycle and conscious of the potential exposure to pharmaceutical residues to the 
general population are professionals that could control the release of substances to the environment. 
For example, a responsible and optimal use of pharmaceuticals may ensue because concerned 
physicians may pay more attention to drug prescription and doses. Prescriptions of the right dose or 
only if the real need exists, like with antibiotics, may decrease the amount of drug consumed and 
therefore the amount of residues body-excreted into wastewaters. Also, responsible medical staff 
should avoid direct spillage of pharmaceuticals and personal care products. Among several examples, 
direct spillage of intravenous bags in wastewaters is one practise widely done in medical units. Indeed, 
intravenous infusions that are not or partially used are often poured into sink to lighten waste bags 
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(personal communication, intensive care nurses). Knowledge on the potential impact of 
pharmaceutical releases in the environment may limit these behaviours and therefore decrease the total 
amount of drug residues in wastewaters. Indeed, hospital wastewater effluents are already highly 
charged with various active residues that were excreted by patients or released after immersion into a 
bath of medical equipment such as stethoscopes, urinal, etc. A pre-treatment of hospital effluents may 
relieve urban station treatment plants that are not always able to treat all wastewaters. For instance, 
source separation of excreta is an interesting option to decrease pharmaceuticals released in hospital 
wastewater. In Germany, a 20 weeks experiment was run to avoid the release of x-ray contrast media 
in water cycle [67]. Patient excreta were separated using different concepts and two are briefly 
described here as examples. First, specific toilets for patients were “built” in the unit where the 
considered pharmaceutical was given. These toilets were separated from the toilets of other patients. 
Second, the excreta were collected using containers. Patients took the containers also to their home 
and returned them to the hospital after a certain period of time. In both cases (i.e., special toilets and 
containers), the excreta were burned and the pharmaceutical was not released into wastewaters. 
Wastewater effluents were regularly sampled and the analysed concentrations of iodine from x-ray 
contrast drug were drastically reduced during the period of the study. These two concepts could be 
applied in health facilities to avoid the release of molecules of high concern, such as tamoxifen, in the 
water cycle. 
Efforts can be undertaken at the urban sewage treatment plant level. This level of action seems to be 
the favourite, although pharmaceuticals are already in the aquatic system. Most studies primarily focus 
on sewage treatment plants as the level at which water quality improvements can be done [68,69]. 
Insufficient or inappropriate sewage treatment processes are indeed one factor, among others, that 
explain the occurrence of pharmaceuticals in natural water. This level of action is thus important, 
although end-of-pipe. Ideally, future processes should be 100% efficient, avoiding thus production of 
unknown metabolites, which seems poorly realistic nowadays. Nevertheless, new technological 
treatment processes are now able to remove some pharmaceuticals from wastewaters and with low 
metabolite production [70]. However, a combination of efforts is probably the best way to reduce 
pharmaceutical occurrence in natural and drinking waters. A better awareness on pharmaceutical 
pollution may therefore encourage globally pre-commercialization assessment of drugs in terms of 
eco-conception, biodegradation and risk management, with local actions such as relevant 
recommendations on drug prescriptions, and relevant improvements on hospital and urban wastewater 
treatment management. Thereby, this thesis fitted well with the current role of environmental 
management to protect ecosystems and their inhabitants because our results provided additional 
scientific knowledge about anticancer drugs, metabolites and multigenerational experiments. 
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To summarise, anticancer drugs and their metabolites should be considered as priority substances for 
risk assessment because: 
• their metabolites could play a role as important as parent compounds in aquatic species 
• parent compound and metabolites can induce effects when considered in mixture 
• daphnids are particularly sensitive towards anticancer drugs with endocrine disrupting 
properties because some daphnia receptors have some sequence homology with human 
receptors 
• these lipophilic molecules are difficult to assess and therefore the experimental framework has 
to be well designed 
 
We hope that the results of this thesis will contribute to further work regarding integrated risk 
assessment of anticancer drugs, which is still poorly developed at present. 
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Annexe 1 
 
Pharmaceutical residues may interfere with the endocrine system of non-target organisms at the:  
• pre-receptor level (ligand availability) by affecting the synthesis, the metabolism and the 
excretion of hormones, i.e.., altering the concentration of endogen hormones. 
• receptor level (structure of ligand binding site) by either [7]: 
o mimicking the action of a naturally-produced hormone (i.e. as agonists), such as 
estrogen or testosterone, and thereby set off similar effects. E.g., diethylstilbestrol or 
methoxyclor are estrogen receptors agonists 
o or blocking the hormone receptors (i.e. as antagonists), which prevents the effect of 
endogen hormones. E.g., diethylstilbestrol or linuron are androgen receptors 
antagonists. 
• post-receptor level by interfering with co-regulators, extracellular signal, amplified signal, 
regulation in time by messenger inactivation, convergence or divergence of the signal, 
compartmentalisation of the signal and cross-talk 
 
Figure 1: Endocrine disruptive pathways. Endocrine disruptors can interact at: the pre-receptor level 
(ligand availability), the receptor level (structure of ligand binding site), and the post-receptor level (co-
regulators). 1. Extracellular signal, 2. Amplified signal, whose response depends on the proteins that are 
expressed within the cell, 3. Regulation by messenger inactivation, 4. Convergence/divergence of the 
signal, 5. Compartmentalisation of the signal and cross-talk. Example of androgen receptors agonists: 
methyl-testosterone, androgen receptors antagonists: diethylstilboestrol, linuron, estrogen receptors 
antagonists: tamoxifen. Phthalates are inhibitors of the testosterone production. Phthalates, tributyltin 
(TBT), and 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) are inhibitors of the bioconversion 
enzyme aromatase. 
 
Annexe 2 
 
Water hardness and survival 
Before conducting any test on organisms, particularly multigenerational tests, the physiological 
behavior of D. pulex needed to be known in conditions exempted from stressors. Therefore, survival 
and reproduction were assessed under our laboratory conditions. 
 
Figure 2: D. pulex survival in different reconstituted water hardness media (95, 150 and 250 mg/l CaCO3) 
 
In 2011, D. pulex survival in Elendt M4 [4] was observed from birth to death at three different water 
hardness: 95, 150 and 250 mg/L CaCO3 (Figure 2). In March, survival experiment was performed at 
hard-reconstituted medium. Sixteen individuals were reared in Elendt medium with 250 mg/L CaCO3. 
Only one individual survived until the 33rdday and mean survival was about 21 days. This longevity 
did not correspond to D. pulex survival, which was reported as 50 days by Smith [8]. 
In August, when the water hardness was reduced to 150 mg/l, the mean decreased to 12.5 days but two 
animals lived until the 45th day. In September finally, D. pulex were cultured in a reconstituted low 
water hardness corresponding to 95 mg/L CaCO3. The mean survival increased to 46 days and one 
daphnia lived until the 75th days. These results corresponded to Smith data [8] and confirmed that D. 
pulex is species that prefers to live in low water hardness. 
The reproductive capacity of the individuals that were reared in a medium at 95 mg/l CaCO3 was also 
higher than at moderate or hard water hardness. The number of young released at each laying is 
summarized in Table 1. A total water hardness of 95 mg/l CaCO3 was therefore chosen for the 
experiments that were performed in this thesis. 
 
 
Table 1: mean neonates produced by a same healthy batch of mothers exposed to 95, 150 and 250 mg/L 
CaCO3 (n =  4, 4 and 7, respectively) 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
250 5.8 6.3 9.3 14 8.8 9.3 13 9.7 5 10 91
150 4.3 8 9.5 6 14 10 11 16 12 17 8.5 2 8 1 1 128
95 8 14 13 10 15 16 18 18 7 11 18 20 19 9.5 18 12 227
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Annexe 3 
 
Daphnia pulex medium 
Daphnia medium contains additive trace nutrients to prevent deficiency symptoms [3]. Four synthetic 
media M4, M5, M6 (which is one-tenth that of the medium M4) and M7 are accepted as standardized 
media, but M4 and M7 are recognized as suitable for long-term ecotoxicological tests. Elendt [4] 
assessed the response of Daphnia magna to a toxicant in M4 and M6, and noticed that the production 
of live young was slightly higher in M4 than in M6 meaning that the tolerance of daphnids in M6 was 
lower than in M4. Also, EDTA is known to influence on the availability of metals. Its use in medium 
M4 seems to reduce the toxicity of metals by complexation process [3]. The OECD [5] does not 
recommend the M4 and the M7, which also contains EDTA, for testing compounds containing metals. 
In this thesis, the chemicals that were tested did not contain metal, and the M4 was chosen as unique 
medium for experiments and mass-culture. In this medium, the water harndess was adapted for D. 
pulex (Figure 3). Indeed, D. pulex prefers moderate or low water hardness, i.e., 40 to 48 mg/l CaCO3 
[6] or 80 to 100 mg/l CaCO3 [7], respectively. 
 
 
Figure 3: D. pulex medium with a water hardness of 90 mg/L CaCO3  
 
Moderate water hardness
N° solution Substances
Quantity 
[mg]
Volume 
[ml]
Volume [ml] 
for 5 L
Final concentration 
[mg/l] Solution Substance
Quantity 
[mg]
Volume 
[ml]
1 NaHCO3 (Hydrogénocarbonate de Sodium) 6480.0 100 H2O 5.0 64.8 a NaBr  (Bromure de Sodium) 32.0
2 KCl (Chlorure de Potassium) 580.0 100 H2O 3.5 4.1 CuCl2·2H2O (Chlorure de Cuivre 
dihydraté) 
33.0
3 MgSO4·7H2O (Sulfate de Magnésium 
heptahydraté) 
8000.0 100 H2O 4.50 72.0 ZnCl2 (Chlorure de Zinc) 26.0
4 CaCl2·2H2O (Chlorure de Calcium 
dihydraté) 
8000.0 100 H2O 4.85 77.6 CoCl2·6H2O (Chlorure de Cobalte) 25.0
5 Na2EDTA·2H2O (EDTA disodique) 500.0 100 H2O 2.5 2.5 b KI (Iodure de Potassium) 32.5
6 FeSO4·7H2O (Sulfate de fer heptahydraté) 199.1 100 H2O 2.5 0.996 Na2SeO3 (Selenate de Sodium) 22.0
7 H3BO3 (Acide borique) 2860.0 100 H2O 0.5 2.860 c NaNO3 (Nitrate de Sodium) 55.0
8 MnCl2·4H2O (Chlorure de manganèse 
tetrahydraté) 
72.1 0.361 KH2PO4 (Dihydrogénophosphate de 
Potassium)
29.0
LiCl (Chlorure de Lithium) 61.2 0.306 K2HPO4 (Hydrogénophosphate di-
Potassium) 
37.0
RbCl (Chlorure de Rubidium) 14.2 0.071 d Cyanocobalamine (Vitamin B12) 26.7
SrCl2·6H2O (Chlorure de Strontium 
exahydraté)
30.4 0.152 (+)-Biotin (Vitamine H) 20.0
NaBr  (Bromure de Sodium) a 94 H2O 0.016 e NH4VO3 (Metavanadate 
d’Ammonium)
22.5 50.0
Na2MoO4·2H2O  (Mobildate de Sodium 
dihydraté) 
12.6 + 5ml of the 
a solution
0.063 f NaOH 2.0 500.0
CuCl2·2H2O (Chlorure de Cuivre 
dihydraté) 
a + 1ml of the 
b solution
0.017
ZnCl2 (Chlorure de Zinc) a 0.013 Must be renewed every month
CoCl2·6H2O (Chlorure de Cobalte) a 0.010 Must be renewed every 3 months
KI (Iodure de Potassium) b 0.003 Must be renewed every 6 months
Na2SeO3 (Selenate de Sodium) b 0.002
9 Na2SiO3 (Metasilicate de Sodium 
anhydrate)
85.9 95 H2O 1.000
NaNO3 (Nitrate de Sodium) c + 5ml of the 
c solution
0.028
KH2PO4 (Dihydrogénophosphate de 
Potassium)
c 0.014
K2HPO4 (Hydrogénophosphate di-
Potassium) 
c 0.018
10 Thiamin-hydrochlorid (Thiamin-(HCl) 
Vitamin B1) 
120.0 97 H2O 0.075
Cyanocobalamine (Vitamin B12) d + 3ml of the 
d solution
0.001
(+)-Biotin (Vitamine H) d 0.001
11 NH4VO3 (Metavanadate d’Ammonium) e 98 H2O 0.001
+ 2ml of the 
e solution
Milieu M4 Stock solution Daphnia medium Milieu M4 Stock solution
2.5
2.5
50.0
50.0
59.0
50.0
0.315
0.315
Annexe 4 
 
Pseudokirchneriella subcapitata culture 
The Soluval Santiago laboratory in Couvet, Switzerland, kindly provided Pseudokirchneriella 
subcapitata. This algae was cultured in the OCDE medium [1] in the following conditions: light 
intensity of 4000 lux (~60-80 µE/m2/s), cool white light (non stop), pH 8, temperature of 22 ± 1°C, 
manual stirring one or twice a day. Every week, five hundred thousand cells of P. subcapitata per ml 
were added to a fresh medium. Algae growth was exponential up to the 10th day (Figure 4). After 7 or 
8 days, i.e. when absorbance of light at a wavelength of 690 nanometers was range between 0.140 
(min) and 0.170 (max), five hundred thousand cells of P. subcapitata was re-injected into a new 
medium. The rest of the algae was centrifuged at 3000 rpm for 20 minutes. The seaweed concentrate 
was stored in the dark at 4°C up to 1 weeks, in autoclaved glass bottles. After 7-8 re-injections, a new 
P. subcapitata culture was started from algae stored in Agar. 
Daphnids were fed daily with 0.2 mg C/daphnia of P. subcapitata algae. In our culture, the P. 
subcapitata contained about 28% carbon. The amount of cells per daphnid was set at a minimum of 
2.34E+07 cell/daphnia/day (0.15 mgC / Daphnia / day).  
 
 
 
Figure 4: Pseudokirchneriella subcapitata growth (x = day number after inoculation; y = 
ln(absorbance)) 
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